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Transcription, the process of copying information encoded in DNA into RNA, to 
facilitate the expression of encoded proteins, is a central process in all living organisms.  
The expression and repression of subsets of genes allows different cell types in an 
organism to maintain diverse physiological roles and permits individual cells to respond 
to various environmental stimuli.  Transcription in prokaryotic cells is performed by a 
single macromolecular complex, RNA polymerase.  In rapidly growing cells with 
abundant resources, prokaryotic RNA polymerase is mostly located at ribosomal RNA 
(rRNA) promoters, actively transcribing the large, structured RNAs required for protein 
translation.  As resources become more scarce, RNA polymerase directly responds to 
cellular signals that lead to the repression of rRNA transcription.  This regulation has 
long been thought to be driven primarily by small molecule effectors that signal scarcity.   
 In this thesis, I will report work done on two transcription factors in prokaryotes 
that regulate RNA polymerase activity at rRNA promoters.  The Staphylococcus aureus 
(Sau) Phage G1 protein PhERI (previously ORF67), was previously described as a 
general RNA polymerase inhibitor.  PhERI expression in Sau cells inhibits cell growth, 
which could have therapeutic potential against this deadly pathogen.  
I describe the structure of PhERI bound to Sau σ A4, the region of RNA 
polymerase to which it binds.  While PhERI interacts with RNAP through σ, I show that 
RNA polymerase activity at most -10/-35 promoters is not affected. Structural, 
biochemical and genomic approaches demonstrate that PhERI interacts with σA4 near the 
-35 element of all promoters, but blocks the binding of an additional RNA polymerase 
subunit, the α-CTD, to UP-element DNA sequences.  PhERI therefore only inhibits RNA 
polymerase activity at promoters requiring UP-element activation, most notably the 
rRNA promoters.  This work not only delineates the mechanism of PhERI but also 
describes novel -10/-35 promoters in Staphlococcus aureus, defines rRNA promoters in 
this organism for the first time, and shows UP-element activation is required for rRNA 
transcription.    
 The mycobacterial protein CarD is known to interact with RNA polymerase, but 
its impact on transcription directly at promoters has not been described.  The structure of 
the Thermus Thermophilus CarD was solved in the lab, allowing a model for the 
interaction between CarD and RNA polymerase to be built.  I show that CarD stimulates 
RNA polymerase activity at rRNA promoters, but not all promoters, by directly 
stabilizing the RNA polymerase open complex on promoter DNA.  These two proteins 
both exploit unique parameters of RNA polymerase at rRNA promoters to specifically 
regulate RNA polymerase activity at these functionally important promoters.   
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 Staphylococcus aureus (Sau) is a gram-positive bacterium that causes a wide 
variety of infections of the skin as well as pneumonia, meningitis, endocarditis, and 
sepsis (Lowy, 1998).  Sau infections can range from mild to extremely serious and if left 
untreated can be lethal (Klein et al., 2007a).  Interestingly, Sau persistently colonizes the 
nasal cavity of more than 20% of the human population and intermittent colonization 
occurs in more than half of healthy individuals (Burian et al., 2010).  The switch from 
non-pathogenic to pathogenic growth requires multiple integrated signals and large-scale 
changes in gene expression (George and Muir, 2007).  The molecular determinants of 
these life-style choices are largely undetermined.   
While Sau infections are generally well controlled by antibiotics, resistance to 
penicillin was reported by the late 1940s (Benner and Morthlan.V, 1967; Tong and 
Rossmann, 1997).  As additional classes of antibiotics were discovered and introduced 
into patients, Sau continued to gain resistance.  Methicillin-resistant Sau (MRSA) arose 
by the late 1950s, leaving few treatment options for serious Sau infections (Tong et al., 
2012).  The glycopeptide drug vancomycin, which inhibits cell wall synthesis, has 
become the antibiotic of last resort for MRSA infections, although recently strains have 
arisen that are resistant to this drug as well (Howden et al., 2010; Nordmann et al., 2007).  
Because of the widespread antibiotic resistance, Sau has become an increasingly costly 
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infection to treat and mortality rates have risen drastically, particularly from hospital-
acquired infections (Klein et al., 2007a).   
New antibiotics, including linezolid and trigecycline, which target the bacterial 
ribosome, have been developed to address antibiotic resistant strains of Sau and other 
bacteria (Tong et al., 2012).  Resistance to linezolid has already been described in 
patients, and can stem from point mutations at the drug-binding site or from horizontal 
gene transfer of the chloramphenicol resistance plasmid cfr (Rossolini et al., 2010). 
Given the rapid rise of Sau resistance to past therapies, novel antibiotics are likely to be 
necessary to treat resistant Sau infections in the near future.  Additionally, the recently 
developed antibiotics against Sau inhibit cell growth by previously exploited 
mechanisms, allowing resistance to rapidly spread by horizontal gene transfer of 
previously existing gene clusters (Rossolini et al., 2010; Ruiz de Gopegui et al., 2012; 
Witte and Cuny, 2011). Unexploited targets for antimicrobial therapy could potentially 
lead to antibiotics that are less susceptible to resistance.    
 
Bacteriophages and drug discovery 
 Bacteriophages (phages) are viruses that infect bacterial cells (1925; 
Bronfenbrenner and Korb, 1925). Phage infections can be lysogenic, wherein the phage 
genome is integrated into the host cell genome and the phage is transmitted vertically 
through cell division, or lytic, with the phage rapidly hijacking the host cell machinery to 
favor replication of the phage and production of phage proteins, ultimately leading to 
lysis of the host bacterium (Echols, 1972; Oppenheim et al., 2005). Upon the initial 
injection of the phage genome of a double stranded DNA phage into the host cell, the 
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host transcriptional machinery will transcribe early phage genes (Kadesch et al., 1982; 
Rosenberg et al., 1982; Siebenlist, 1979). While some phage encode a dedicated RNA 
polymerase for subsequent transcription of phage genes (Chamberlin et al., 1970), others 
will use the host machinery throughout the phage life-cycle (Oppenheim et al., 2005).   
 As early as the 1920s, scientists recognized the therapeutic potential of phage to 
treat bacterial infections to their ability to specifically and rapidly lyse bacterial cells 
(Mills, 1956; Smith, 1924). With the discovery of potent antibiotics, using phages as 
direct therapeutic agents fell out of favor in the West but continued to be used 
therapeutically in the former Soviet Union (Bacteriophages and their Implications on 
Future Biotechnology: A Review IN PRESS).   
Phages are advantageous therapeutically because they can infect and lyse a 
specific bacterial species, whereas antibiotics tend to affect bacterial species 
indiscriminately.  However, the potential for phages to provoke an immune response in 
the patient and the inherent issues with using active biological entities in patients has 
prevented their widespread use (Kelly et al., 2011; Paul et al., 2011). Phage lytic enzymes 
are the individual proteins that facilitate the lysis of the host cell and subsequent release 
of phage particles (Fischetti, 2010; Paul et al., 2011).  Lytic enzymes alone have the 
ability to lyse bacteria in a species-specific fashion and several phage lytic enzymes are 
currently being developed for use in topical creams or for direct use in patients, 
particularly to clear colonizing Sau bacteria prior to surgery (Fischetti, 2008, 2010; 
Grandgirard et al., 2008; Koller et al., 2008; Pastagia et al., 2011).  Because lytic 
enzymes are full-length proteins, which are inherently difficult to deliver to infected cells 
and tissues, their therapeutic use may be somewhat limited.  Despite the difficulties, the 
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increasingly desperate need for novel anti-microbial agents has driven the recent 
reemergence of direct phage therapies (Kelly et al., 2011). 
While phages have been studied for their therapeutic potential, they have also 
been used since the early days of modern molecular biology as simple models to study 
systems such as transcriptional regulation (Gribskov and Burgess, 1986; Kassavetis and 
Geiduschek, 1984; Minakhin and Severinov, 2005; Oppenheim et al., 2005; Orsini et al., 
1993; Ptashne, 1992) and DNA replication (Allison et al., 1977; Black and Peng, 2006; 
Doublie et al., 1998; Ray et al., 1975; Yano and Rothman-Denes, 2011).  Because of its 
small genome and binary life-style choices between lytic and lysogenic, the phage 
lambda (λ) provides a model for how gene regulation, mediated by direct interactions 
between RNA polymerase and protein factors, is related to a developmental switch 
(Oppenheim et al., 2005). Studies on the phage M13 have revealed the molecular 
mechanisms of DNA replication in Escherichia coli (Eco) cells (Allison et al., 1977; Ray 
et al., 1975). The M13 phage genome is still used in the majority of biochemical assays 
studying the in vitro activity of prokaryotic DNA polymerase (Yeeles and Marians, 
2011).  Work using phages as model systems provided the basis for our understanding of 
some of the most central tenants of modern biology, such as the central dogma, and 
provided hypotheses that were subsequently tested and validated in more complex model 
systems.   
Phage are incredibly abundant and diverse, and the mechanisms through which 
they inhibit host cell growth may reveal currently unexploited drug targets.  Phage are 
among the most abundant life forms on planet earth, estimated to number at 1031 total 
particles (Bergh et al., 1989; Whitman et al., 1998).  Phage play critical roles in the 
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ecology, evolution (Bohannan and Lenski, 2000), and pathogenicity (Wagner and 
Waldor, 2002)  of prokaryotic cells.  The large number of phage particles also represents 
a immense and largely untapped source of biological diversity: phages that have been 
sequenced contain large numbers of putative open reading frames (ORFs) with no known 
homolog (Liu et al., 2004). Understanding how phage, in their vast diversity, arrest host 
cell growth is likely to reveal novel mechanisms of inhibition that could provide targets 
for the design of new small molecule inhibitors. 
 Recent work has mined phage genomes for proteins or peptides that inhibit cell 
growth in Sau.  Kwan et al. (2005) undertook a massive sequencing project of Sau 
phages and created a library of more than 900 putative phage ORFs in an inducible vector 
that was transformed into Sau (Kwan et al., 2005; Liu et al., 2004).  ORFs that inhibited 
cell growth were considered inhibitors of essential cell functions (Fig 1.1a).  The work 
highlighted one phage protein, phage 77 ORF104, which inhibits DNA replication 
through an interaction with dnaI (Fig1.1b).  Small molecule inhibitors of dnaI were 
shown to have the same effect on cell growth as ORF104, illustrating the potential to use 
phage genomics to identify essential cellular functions and aid in the design of small 
molecules to target these functions.  The G1 phage protein PhERI (Phage Encoded rRNA 
Inhibitor; previously ORF67) was also identified in this screen.  While ORF104 targeted 
DNA replication (Fig 1.1b), PhERI was described as a putative RNA polymerase 
(RNAP) inhibitor because its expression decreased the levels of RNA in a pulse-chase 






Figure 1.1: PhERI is a putative RNA polymerase inhibitor.  a) Screen for 
ORFs that inhibit cell growth in Sau.  ORFs were cloned into an inducible 
vector and cells were grown in the absence (upper panel) or the presence 
(lower  panel)  of  inducer  in  Sau  RN4220.   ORF104,  indicated  with  red 
arrows, shows strong inhibition of growth in Sau.  b) ORF104 inhibits DNA 
synthesis.   Cells  were  pulse  labeled  with  radiolabeled  DNA,  RNA,  and 
amino  acids  at  different  time  points  after  the  induction  of  ORF104.  
ORF104 inhibits DNA synthesis.  c) PhERI inhibits RNA synthesis.  Cells 
were  pulse  labeled  with  radiolabeled  DNA,  RNA,  and  amino  acids  at 
different time points after the induction of PhERI.  PhERI inhibits synthesis 




Structure and function of prokaryotic RNAP 
 Transcription in prokaryotes is performed by the ~400 kDa core RNAP enzyme 
(subunit composition α2ββ’ω; (Darst, 2001)). Promoter recognition and initiation require 
an additional promoter-specificity subunit, σ, which binds to the core RNAP to form the 
holoenzyme (Murakami and Darst, 2003).  Holoenzyme can interact with promoter DNA 
in a sequence specific manner through the σ factor.  The initial interactions are with 
double stranded DNA to form a closed complex.  The σ factor then facilitates melting of 
the transcription bubble around the -10 element (to form an open complex) and initiation 
of transcription.   
 Structural studies of RNAPs have been critical in our understanding of these 
complex molecular machines. Crystal structures of thermophillic RNAP enzymes 
(Murakami and Darst, 2003; Vassylyev et al., 2002; Zhang et al., 1999) and electron 
microscopy (EM) studies of the Eco RNAP (Darst et al., 1989; Finn et al., 2000; 
Polyakov et al., 1995) revealed the overall architecture of the enzyme (Fig 1.2). The 
active site, and its catalytic magnesium ion, is buried in a cleft at the interface between 
the β and β’ subunits deep within the RNAP enzyme.  The β and β’ subunits form a 
clamp around the active site (Fig 1.2a). Opposite the cleft is the RNA-exit channel, 
through which the nascently transcribed RNA will be expelled (Fig 1.2b), and the 
secondary channel, through which substrate NTPs can enter the active site (Fig 1.2a). 
Structures of RNAP crystallized with elongation-complex substrates (Gnatt et al., 2001; 
Kettenberger et al., 2004; Mustaev and Korzheva, 2001) illuminated the molecular 
architecture of RNAP enzymes as it is actively transcribing genes (Fig 1.2c).  DNA binds 
to RNAP through the open space provided by the clamp; the template strand then enters 
7
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Figure 1.2: Xray crystal structures of prokaryotic core RNAP.  a)  Surface 
map of core RNAP.  α is shown in blue, β is light green and β’ dark green, 
and ω in yellow.  This view is looking through the RNAP secondary channel 
at the active site magnesium (red sphere).  b) Surface map of core RNAP, 
colored  as  above,  showing  the  RNA-exit  channel.   c)  Structure  of  core 
RNAP, colored as above, bound to transcription elongation complex (TEC) 
substrates.   DNA (orange)  enters  the  active  site  through the  cleft  in  the 
RNAP clamp.  RNA exits RNAP through the RNA-exit channel.  	

Secondary	  channel	  	  
RNA	  exit	  channel	  	  
dsDNA	  template	  
RNA	  product	  
ac:ve	  site	  Mg2+	  
ac:ve	  site	  Mg2+	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the active site through a series of interactions with positively charged RNAP residues 
(Fig 1.2c and d). Structural studies of RNAP at different states of the transcription cycle 
highlight the conformational changes required as RNAP binds to and melts promoter 
DNA, begins to initiate RNA synthesis, and clears the promoter to enter the stable 
elongation stage of transcription.  
 
Structural studies of non-thermophilic RNAP 
 To date, all high-resolution structural data on prokaryotic RNAPs come from 
structural studies of thermophilic bacteria (Campbell et al., 2001; Darst, 2001; Murakami 
et al., 2002b; Vassylyev et al., 2002; Vassylyev et al., 2007).  Eco RNAP has been 
extensively studied using biochemical and genetic techniques, but has thus far resisted 
high-resolution structural studies despite extensive effort (Twist et al., 2011a).  
Functional differences between Eco RNAP and its thermophilic homologs have led to the 
misinterpretation of high-resolution structures (Vrentas et al., 2008). Additionally, many 
protein factors that regulate RNAP function in Eco have no homologs in thermophilic 
bacteria, and therefore cannot be studied by crystallography without issues arising from 
cross-species artifacts.  Eco RNAP is also modulated by many phage proteins, which 
have been extensively characterized by biochemical techniques (Geiduschek, 1991; 
Snyder et al., 1976; Stevens, 1977; Twist et al., 2011b), whereas RNAP from the 
thermophilic bacteria have fewer known phage-encoded regulators.  
To study the structure of RNAP from non-thermophilic organisms such as Sau 
and Eco, hybrid methods have been necessary.  Cryo-EM studies have led to density 
maps of RNAP at sub-atomic resolution (Darst et al., 1989; Finn et al., 2000; Polyakov et 
9
Figure 1.3:  Single particle cryo-EM density map (at 14Å resolution, left 
panel,) and the fit of the Eco RNAP homology model into the EM density 
(EM density map is shown as the gray envelope, and the Eco atomic model 
is shown as a ribbon and colored according to the key shown in the inset, 




al., 1995).  High-resolution structures and homology models from X-ray crystallography 
can be fit into the lower resolution EM data to provide molecular models.  Recent work 
illustrates how this method can be used to build a model of Eco RNAP to molecular 
resolution (Opalka et al., 2010) (Fig 1.3).  However, these hybrid methods do not allow 
for the study of small-molecule binding and do not easily elucidate small-scale 
conformational changes between different states in the transcription cycle. Structural 
studies on RNAP from other organisms may provide well-diffracting crystals that 
explain, in molecular detail, the functional differences and the discrepancies in small-
molecule and protein factor binding to RNAP from thermophilic and non-thermophilic 
bacteria. 
 
Promoter recognition by RNAP 
 The group 1, or primary, σ factors (σ70 in Eco, σA in Sau) are responsible for the 
bulk of transcription during log-phase growth and are essential for viability (Gruber and 
Gross, 2003). Prokaryotic housekeeping promoters generally consist of two DNA 
elements that can be recognized by σ only in the context of the RNAP holoenzyme.  
Sequences at position -10 (consensus: TATAAT) and -35 (consensus: TTGACA) relative 
to the transcription start site (+1) are directly recognized by σ domain 2 (σ2) and domain 
4 (σ4) respectively (Fig 1.4).  The spacer sequence between these two elements does not 
have a conserved sequence; however the length of the spacer (optimal spacing: 17bp) is 
critical to promoter binding and subsequent transcription (Fig 1.4) (Harley and Reynolds, 




 σA is comprised of multiple domains connected by flexible linkers (Fig 1.4) 
(Paget and Helmann, 2003).  The structures of independent domains have been solved 
(Fig 1.5a) (Campbell et al., 2002), and σ bound to RNAP has been crystallized (Fig 1.6c) 
(Murakami et al., 2002b; Vassylyev et al., 2002). Structures of σ2 (Feklistov and Darst, 
2011) and σ4 (Campbell et al., 2002) have been solved in complex with DNA 
corresponding to the -10 and -35 promoter elements respectively (Fig 1.5b).  σ4 interacts 
with the double stranded -35 element through a conserved helix-turn-helix (HTH) DNA-
binding motif that sits in the major groove of promoter DNA (Fig 1.5b) Full-length σ in 
solution is not able to bind to promoter DNA as the DNA binding determinants are not 
accessible (Callaci et al., 1999; Camarero et al., 2001). σ makes obligatory contacts with 
RNAP, including an interaction between σ4 and a region of the β-subunit, the β-flap (Fig 
1.6a and b) (Murakami et al., 2002b; Vassylyev et al., 2002). Only when σ is organized in 
the context of the RNAP holoenzyme (Fig 1.6c and d) are its DNA-binding domains are 
exposed and appropriately positioned to interact simultaneously with the -10 and -35 
elements to facilitate DNA binding and subsequent melting and initiation of transcription 
(Fig 1.6) (Campbell et al., 2002; Murakami et al., 2002a). 
 Housekeeping transcription is performed by the σ70 class of σ factors, including 
the Sau σA, which recognize -10/-35 promoters as described above (Gruber and Gross, 
2003).  Alternative σ factors can bind to RNAP and direct transcription to promoters 
containing different sequence elements as a response to environmental stimuli (Ades, 
2007; Feklistov and Darst, 2009; Testerman et al., 2002).  Furthermore, subsets of -10/-
35 promoters have additional sequence elements that facilitate for RNAP binding and 
transcription initiation.  Extended -10 promoters, with the sequence TGn immediately 
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Figure 1.5 (adjacent page): Structural analysis of σ domains and σ / DNA 
interactions.  a) Crystal structure of σ4 (left panel), σ3 (central panel) and σ2 
(right panel).  b) Structures of σ2 and σ4 interacting with the -10 and -35 
DNA  elements.   σ4  (left  panel)  interacts  with  double  stranded  DNA 
(consensus: TTGACA) though its major groove.  σ2 (right panel) interacts 
with bases of the -10 element (consensus: TATAAT) as they unwind.  c) 
Crystal  structure  of  σ4  interacting  with  the  -35  element  and  the  α-CTD 




a)	   b)	  
c)	   c)	  
Figure 1.6: Structure of RNAP holoenzyme and Rpo.  a) Structure of σ4 
(orange, the Helix-turn-helix responsible for DNA recognition is shown in 
red) interacting with the RNAP β-flap tip helix (green).  b) Structure of σ4 
and the β-flap, as above, showing the interaction between σ4 and the -35 
element of promoter DNA.  c) Structure of the RNAP holoenzyme bound to 
upstream fork  DNA,  mimicking  the  interactions  of  the  closed  promoter 
complex.  RNAP is colored green and σ is colored orange.  d) Model of the 
RNAP open promoter complex (Rpo).  RNAP is shown in green and the β-
flap is highlighted in bright green.  σ is shown in orange and the promoter 




upstream of the -10 element, do not require the interaction between the -35 element and 
σ4 (Bown et al., 1997).  These promoters are recognized through an interaction between 
the extended -10 and σ regions 2 and 3 (Barne et al., 1997; Sanderson et al., 2003).  The 
region between nucleotides -6 and the -3, known as the discriminator, is also an important 
determinant of the stability of promoter DNA bound to RNAP, and therefore of the 
strength of promoter binding, promoter stability and subsequent transcription at certain 
promoters (Feklistov et al., 2006; Haugen et al., 2008; Travers, 1984). 
 
Kinetics of RNAP initiation at prokaryotic promoters 
 While structural biology has been critical to our detailed understanding of the 
interactions between RNAP and promoter DNA, the process of transcription initiation 
proceeds through many unstable, transient intermediates that are difficult to capture by 
structural studies.  RNAP holoenzyme must first interact with DNA in its double stranded 
state though interactions well upstream of the promoter start site, including the UP-
element (see below) and the -35 element (Saecker et al., 2011).  In order to initiate 
transcription, RNAP must melt the promoter DNA so that the single-stranded template 
strand can enter the enzyme’s active site.  Kinetic and footprinting studies demonstrate 
that the transition between the closed RNAP promoter complex and the stable open 
promoter complex (Rpo) in which promoter DNA is melted and in the enzyme active site, 
proceeds via at least two short lived intermediates, and involves conformational changes 
in both RNAP and promoter DNA (Chen et al., 2010; Saecker et al., 2011). The kinetic 
steps involved in transcription initiation are outlined in Fig 1.7a. 
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Figure  1.7  (adjacent  page):  Kinetics  and  structural  changes  required  for 
promoter recognition, DNA melting, transcription initiation and promoter 
clearance.   a)  Kinetic  scheme  of  transcription  initiation.   Core  RNAP 
(RNAPc) binds to a σ factor to form holoenzyme (RNAPh) which can then 
interact  specifically with double stranded DNA elements such as the -35 
element  and  UP-element  to  form the  unstable  closed  promoter  complex 
(RNAPh-closed).  Several isomerization steps are required to form the open 
promoter complex (RNAPh-open) in which promoter DNA is melted and 
the template strand is in the RNAP active site.  NTPs can then enter the 
active  site  through  the  secondary  channel  and  produce  abortive  RNA 
products several nucleotides in length.  Once an RNA product is made of 
sufficient length to push σ region 3.2 out of the RNA-exit channel and break 
the interactions between σ2 and σ4 with promoter DNA, RNAP will clear the 
promoter and enter the stable, processive, elongation phase.  b) Overview of 
structural  changes  required  for  transcription  initiation,  adapted  from 
(Murakami and Darst, 2003).	
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 Once Rpo is formed, RNA production can begin at the active center by the 
diffusion of nucleotide tri-phosphates (NTPs) through the secondary channel.  However, 
the stable interactions between σ and DNA, and the fact that σ region 3.2 (σ3.2) is 
blocking the RNA path to the RNA-exit channel, lead to the production of short 
transcripts only a few bases long (Munson and Reznikoff, 1981; Sen et al., 1998). RNAP 
remains bound to promoter DNA and produces abortive transcripts until an RNA product 
is made that is long enough to push σ3.2 out of the exit channel and break RNAP contacts 
with σ and promoter DNA (Fig 1.7b) (Murakami and Darst, 2003).  The force required to 
escape from abortive initiation is provided by “scrunching,” as RNAP pulls downstream 
DNA into the active site, but remains bound to promoter DNA, producing a stressed 
intermediate (Revyakin et al., 2006).  Once RNAP has escaped the promoter, it forms a 
transcription elongation complex (TEC), which is capable of transcribing to the end of 
the gene in a highly processive manner (Mustaev and Korzheva, 2001; Nudler, 1999; 
Nudler et al., 1996).  The RNAP structural modulations required for DNA binding, 
melting, initiation and escape are outlined in Fig 1.7b.   
 
Structural biology of promoter melting and Rpo formation 
 Structures of the RNAP holoenzyme (Fig 1.6c) and σ bound to promoter DNA 
fragments (Fig 1.6b) provide a basis for molecular models of RNAP promoter 
recognition, DNA melting and transcription initiation (Darst, 2001; Murakami et al., 
2002a).  Initial interactions between promoter DNA and RNAP holoenzyme form the 
RNAP closed complex, in which σ4 is bound to the -35 promoter element but the DNA is 
double stranded (Saecker et al., 2011). A recently solved structure of σ2 bound to single 
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stranded -10 element promoter DNA fragments (Fig 1.8) informs the mechanism of DNA 
melting by the RNAP holoenzyme. σ2 contains pockets that specifically recognize the 
highly conserved A at position -11 (Fig 1.8a) and the T at -7 (Fig 1.8b) as they flip out of 
the DNA double helix. This structure not only demonstrates the molecular mechanism for 
sequence specific recognition at the -10 element but shows unambiguously that RNAP 
holoezyme can only recognize single-stranded DNA bases as they flip out of the double 
stranded helix, effectively coupling DNA melting and sequence-specific DNA 
recognition (Feklistov and Darst, 2011). DNA melting ultimately forms a roughly 11-
base single stranded transcription bubble (Siebenlist, 1979) that places promoter DNA 
inside a protein enclosed, positively-charged channel leading to the RNAP active center.  
 
Ribosomal RNA promoters exhibit unique kinetics that are exploited for tight 
regulation 
 During exponential growth, prokaryotic cells expend significant energetic 
resources producing the enzymatic machinery required for robust translation.   The 
majority of transcription in growing cells is at ribosomal RNA (rRNA) promoters (rrn 
promoters) (Gourse et al., 1996).  However, as cells approach saturation and resources 
become scarce, rRNA production is dramatically reduced and the transcriptional profile is 
rapidly altered.  A series of direct and indirect signals are responsible for the regulation of 
transcription at rrn promoters. These combined signals affect the switch between rapidly 
dividing cells with ample resources and cells at stationary phase with limited resources, 
termed the stringent response (Chatterji and Ojha, 2001; Traxler et al., 2008). 
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a)	   b)	  
-­‐11A	   -­‐7T	  
Figure 1.8:  Structure of  σ2  bound to single stranded oligos with the -10 
element  sequence.   a)  The  conserved  -11  A  base  (tAtaat)  is  tightly 
recognized by a protein pocket in σ.  b)  The conserved -7T base (tataaT) is 
tightly  recognized  by  a  protein  pocket  in  σ.   The  less  conserved  bases 
(TaTAAt) remain stacked in a helical-like conformation and are recognized 




 The stringent response is well studied in Eco.  As cells reach saturating levels, the 
intracellular concentration of NTPs and amino acids, the substrates for transcription and 
translation respectively, decrease.  Amino acid starvation activates a ribosomal associated 
protein, relA (Friesen et al., 1976), which converts GTP into the stress-signal ppGpp, also 
known as magic spot (Paul et al., 2004; Traxler et al., 2008).  ppGpp has direct effects on 
RNAP activity, although the nature of its interaction with RNAP is still debated (Jishage 
et al., 2002; Laurie et al., 2003; Perederina et al., 2004; Vrentas et al., 2008). 
 rrn promoters are targeted by ppGpp activity through a decrease in the stability of 
open promoter complexes (Barker et al., 2001a; Barker et al., 2001b; Gourse et al., 1998).  
Most -10/-35 promoters tested are not rate-limited by the stability of the OPC; once OPCs 
form, they are generally a stable intermediate (Saecker et al., 2011).  rrn promoters, 
however, have characteristically unstable OPCs due to G/C-rich sequences in the 
discriminator elements (Pemberton et al., 2000), and can therefore be effectively 
regulated by stabilization or destabilization of this intermediate in the transcription cycle 
(Barker et al., 2001b).   
 In Eco, the protein DksA potentiates the effect of ppGpp on rrn promoters (Paul et 
al., 2004; Perederina et al., 2004). DksA binds directly to RNAP and decreases activity at 
rrn promoters in vitro and DksA mutants lose the ability to regulate rRNA expression as 
the cells approach stationary phase (Paul et al., 2004).  The structure of DksA reveals that 
the protein is an extended coiled-coil with a small globular domain (Fig 1.9a).  Structural 
homology to the cleavage factor GreA (Fig 1.9b) suggests that DksA binds directly to the 
RNAP secondary channel and the coiled-coil may place DksA residues near the RNAP 
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Figure 1.9: Structure of DksA a) Crystal structure of Dksa.  DksA consists 
of  a  small  globular  domain  and  a  long,  helical  coiled-coil.   b)  Crystal 
structure of Eco GreA, highlighting the structural homology with DksA.  c) 
Model  of  DksA bound to the RNAP secondary channel.   The co-crystal 
structure of Thermus thermophilus RNAP and the GreA Tth homolog Gfh1 
was used to align the helical coil of DksA (blue) with the co-crystalized 
Gfh1 to produce a model of DksA bound in the secondary channel.  Pdb 
codes: Dksa: 1TJL; GreA: 1GRJ; Tth RNAP/Gfh1: 3AOH.  	





active site (Fig 1.9c) (Perederina et al., 2004).  In vitro, DksA and ppGpp act 
synergistically to inhibit RNAP activity at rrn promoters (Paul et al., 2004).   
 Recent work highlighted the differences between rrn promoters and rRNA 
regulation in gram-negative bacteria, such as Eco, and the gram-positive model organism 
Bacillus subtilus (Bsub) (Krasny and Gourse, 2004). Kransy and Gourse found no DksA 
homolog in Bsub, although RelA is conserved.  In Bsub, RNAP is not regulated directly 
through an interaction with ppGpp.  Rather, Bsub rrn promoters are sensitive to the 
concentration of initiating nucleotide, GTP, and therefore relA may function to reduce the 
intracellular GTP concentration and thereby inhibit synthesis of rRNAs (Krasny and 
Gourse, 2004), whereas in Eco ppGpp interacts directly with RNAP to modulate its 
activity.   
These organisms clearly evolved different mechanisms to control the stringent 
response (Fig 1.10).  Because rrn promoters have been studied in relatively few 
organisms, including Eco, Bsub and Thermus thermophilus (Tth) (Vrentas et al., 2008), it 
is difficult to evaluate whether these regulatory mechanisms are conserved or whether 
different bacterial families have evolved as yet unexplored mechanisms of controlling the 
stringent response.  Sau, similar to Bsub, has no DksA homolog but has a clear RelA 
homolog.  However, rRNA promoters and their regulation in this organism are entirely 
uncharacterized.   
 
UP-Element function  
 In addition to the regulation described above, it was initially noted that mutations 
upstream of the -35 element in an Eco rrn promoter had a remarkable effect on RNAP 
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Figure 1.10: Model of rrn promoter regulation in E. coli and B. subtilis.  In 
E. coli, the RNAP α-CTD binds the UP-element and interacts with the co-
activator  Fis.   The  small  molecule  ppGpp  binds  directly  to  RNAP and 
modulates the stability of the open promoter complex, which affects RNAP 
activity at these promoters.  In B. subtilis, the α-CTD also interacts with 
promoter UP-elements, but not with a co-activator.  ppGpp does not affect 
RNAP  activity  directly,  but  likely  decreases  the  concentration  of  the 
initiating nucleotide at rrn promoters, GTP, and thereby decreases RNAP 




activity (Gaal et al., 1989).  Subsequent work showed that this effect was mediated by an 
A/T-rich DNA sequence upstream of the -35 element, termed the UP-element (Fig 1.5) 
(Estrem et al., 1998).  The RNAP core α-subunit consists of two domains.  While a dimer 
of the N-terminal domains is assembled in the core RNAP enzyme, the C-terminal 
domains (CTD) are linked to RNAP only by flexible linkers.  The α-CTD can interact 
directly with DNA and is responsible for recognizing the upstream A/T rich DNA 
sequence (Fig 1.5) (Blatter et al., 1994; Estrem et al., 1999; Gaal et al., 1996; Ross et al., 
1993).  The α-CTD/UP-element interaction is required for robust transcription from 
rRNA promoters in both Eco and Bsub (Gaal et al., 1989; Krasny and Gourse, 2004; 
Newlands et al., 1991) although the requirement in Eco is more pronounced (Fig 1.10).  
A recent study solved the X-ray crystal structure of σ4 and the α-CTD, which also interact 
with one another, bound to a -35 and UP-element containing DNA fragment (Fig 1.5c).  
UP-element activation provides an explanation for the extraordinary strength of the rrn 
promoters in vivo and is also a potential site of regulation for rRNA transcription.    
 
In vitro studies of Sau RNAP 
  Because of its medical relevance, Sau has been extensively studied.  Many 
strains, including MRSA strains, have been fully sequenced (Baba et al., 2008; Holden et 
al., 2004; Iandolo et al., 2002; Nair et al., 2011; Ohta et al., 2004) and genetic approaches 
have been used in an attempt to understand the regulatory steps in the switch between 
non-pathogenic and pathogenic growth (Felden et al., 2011; Tuchscherr et al., 2011).  
Relatively fewer studies have attempted to use a purified, in vitro transcription system to 
study gene expression in Sau (Deora and Misra, 1996; Rao et al., 1995; Reynolds and 
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Wigneshweraraj, 2011).  Most of the in vitro biochemistry has also focused on RNAP 
activity at pathogenicity promoters characterized by weak -10/-35 elements, suboptimal 
spacer length and binding sites for additional regulatory proteins (Rao et al., 1995; 
Reynolds and Wigneshweraraj, 2011).  Mechanistic studies on RNAP activity at typical   
-10/-35 promoters have yet to be published.  Because the genome of Sau is A/T-rich 
(Quail et al., 2012), promoter DNA may have different topology than in other organisms.  
The Sau RNAP is not active at all Eco promoters tested, but no sequence specificity was 
identified to explain the discrepancy in RNAP activity between these organisms (Rao et 
al., 1995). Furthermore, it is unclear how small molecules, such as ppGpp affect RNAP 
activity in Sau, and whether Sau RNAP is susceptible to inhibition by small molecules 
that bind to RNAP from other organisms.   
 
PhERI binds directly to Sau RNAP 
 ORF67 (PhERI) was initially identified as a growth inhibitor in Sau cells.  Further 
research attempted to identify the Sau binding partner of PhERI (Dehbi et al., 2008).  
PhERI was immobilized on a column and Sau cell lysates were allowed to bind.  Only 
Sau RNAP was found to bind specifically to immobilized PhERI.  To identify the RNAP 
subunit and domains to which PhERI binds, a yeast 2-hybrid approach was used.  PhERI 
binds to Sau’s group 1 σ factor, σA, and the interaction was localized to σA4 (Fig 1.11a).  
By FRET, PhERI was found to disrupt the interaction between RNAP and promoter 
DNA.  PhERI, and not a control ORF, was shown to inhibit purified Sau RNAP and Eco 
RNAP complexed with Sau σA in vitro on a -10/-35 promoter, λPL (Fig 1.11b) (Dehbi et 
al., 2008).  These results suggested that PhERI may be acting as a general anti-σ factor.   
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a)	   b)	   c)	  
d)	  
Figure 1.11: PhERI binds to Sau RNAP though an interaction with sigma 
region 4  and inhibits  RNAP function.   a)  Yeast-two-hybrid  showing the 
interaction between PhERI and Sau sigma region 4.  b) PhERI inhibits the 
hybrid  holoenzyme formed by Eco core  and Sau σA  at  the  -10/-35 λpL 
promoter.  c) ORF77, a control protein does not inhibit the Eco RNAP/Sau 
σA hybrid RNAP enzyme.  d)  PhERI, but not ORF77, inhibits Sau RNAP at 





Anti-σ factors bind to σ and modulate its activity  
 Because gene expression in prokaryotes is determined primarily at the step of 
transcription initiation (Young et al., 2002), the activity of σ factors is tightly regulated 
and can rapidly switch in response to diverse cellular stimuli (Kang et al., 1999; Raivio 
and Silhavy, 2001).  Anti-σ factors are proteins of bacterial or phage origin that bind to σ 
and modulate its activity (Brown and Hughes, 1995; Helmann, 1999; Pene and Uzan, 
2000).  Anti-σ factors can be further regulated by anti-anti-σ factors and proteolysis, and 
these various signals play an important role in diverse cellular processes including 
sporulation, the biosynthesis of flagella, and switching to alternative σ factors (Campbell 
et al., 2008).   
 The T4 phage protein AsiA is the most well-understood phage encoded anti-σ 
factor (Orsini et al., 1993).  AsiA is expressed early in T4 infection and is responsible for 
inhibiting Eco RNAP activity at Eco (Severinova et al., 1998), but not early phage, 
promoters (Orsini et al., 2004).  AsiA binds to σ704 and blocks the recognition of the -35 
element (Lambert et al., 2004).  The structure of AsiA bound to σ704 was solved by NMR 
and revealed that AsiA reorganizes the structure of σ704 such that the highly conserved 
HTH required for -35 recognition is converted into an extended helix, incapable of DNA 
binding  (Fig 1.12a) (Lambert et al., 2004).  Early phage promoters are able to 
compensate for the inability of σ704 to recognize the -35 element through the presence of 
a strong UP-element or an extended -10 element (Orsini et al., 2004). AsiA forms a 
protein-protein interaction with a second phage protein, MotA, which can then recruit the 




Figure 1.12:  Structure of anti-σ factors reveals their mechanism.  a) The 
conserved structure of σ4 with helix-turn-helix (HTH) responsible for DNA 
recognition  colored  in  red  (left  panel).   Interaction  with  AsiA  (blue) 
reorganizes the structure of σ4 (orange) so that the HTH (red) becomes an 
extended helix incapable of interacting with promoter DNA.  b) RSD blocks 
the DNA and RNAP binding surfaces of σ4.  Co-crystal structure of RSD 
(blue)  and  σ4  (orange)  with  the  HTH  responsible  for  DNA-recognition 
colored red (left panel) The interaction with Rsd sterically blocks the DNA 
binding site of σ4 (central panel) and the β-flap tip helix (green, left panel) 




therefore both an inhibitor of RNAP activity and, through its interaction with MotA, a co-
activator of phage gene expression.   
 σ switching in Eco and sporuation in Bacillus subtillis are controlled by the 
activity of bacterially encoded anti-σ factors.  The Eco protein RSD binds to σ70 through 
an interaction with region 4 and is responsible for sequestering σ70, which has the highest 
affinity of cellular σ factors for RNAP (Maeda et al., 2000), to induce alternative 
transcriptional profiles (Jishage and Ishihama, 1999).  RSD was crystallized in complex 
with σ704.  While the conformation of σ is maintained in the presence of RSD, RSD 
blocks both the DNA binding and the core binding surfaces of σ704 (Fig. 1.12b) 
(Patikoglou et al., 2007).  Bacterial and phage anti-σ factors have evolved various 
mechanisms to disrupt σ function and thereby alter RNAP activity.  Structural studies 
have been central to our understanding of the detailed molecular mechanisms through 
which these anti-σ factors bind to and modulate RNAP activity.    
 The first section of this work will detail my attempts to understand the molecular 
mechanism of PhERI. Using X-ray crystallography, I solved the structure of PhERI 
bound to Sau σA4.  The structure described the interaction between the two proteins in 
atomic detail, yet cannot alone explain the inhibitory function of this protein on RNAP 
activity.  Subsequent biochemical, genetic and bioinformatic work shows that PhERI 
specifically targets transcription from rRNA promoters by blocking UP-element 
activation by the RNAP α-CTD (PhERI: Phage Encoded rRNA Inhibitor).  PhERI is the 
first example of a transcription factor that binds to σ but that modulates RNAP activity 




Structural Studies of the  
PhERI / σA4 Complex 
 
  PhERI was identified as an inhibitor of cell growth in Sau (Liu et al., 2004).  It 
was subsequently shown to bind directly to Sau RNAP through an interaction with σA4 
and inhibit transcription in vitro (Dehbi et al., 2008).  These results suggest that PhERI 
may function as a general anti-σ factor. Structural studies on this class of proteins have 
been particularly useful in determining the details of their interactions with σ and their 
mechanisms of action (Fig. 1.12) (Campbell et al., 2008).  This chapter will describe my 
structural studies of PhERI and its interaction with σA4.  I solved X-ray crystal structures 
of PhERI bound to Sau σA4.  Unlike other anti-σ factors, PhERI does not appear to 
interact with the DNA or core binding determinants of σA4.  Additional biochemical and 
genetic data that validate the crystal structures will be presented.  The bacterial 2-hybrid 
work identifying a σA4 mutant that is deficient in PhERI binding was performed by 
Cristina Montero-Diaz, a graduate student in the lab of Ann Hocschild’s lab at Harvard 
Medical School.  
 
3.0 Å Structure of the PhERI / σA4 complex 
 PhERI is a 25kDa protein with no sequence homology to any protein of known 
function (Fig 2.1a).  Previous work had determined that PhERI does not interact with Eco 
σ70 (Dehbi et al., 2008); therefore PhERI is not toxic when expressed in Eco cells, as is 
33
Figure 2.1 (adjacent page):  Primary sequence of PhERI and Sau σA.   a) 
Primary sequence and predicted secondary structure of PhERI.  Secondary 
structure prediction was performed with PSIPRED.  Predicted β-sheets are 
indicated  with  a  yellow  arrow  and  α-helices  with  a  pink  cylinder.   b) 
Primary structure and alignment of the group 1 sigma factor from Sau, Eco 
and Taq.  Regions 2, 3 and 4, responsible for DNA recognition, are shown.  
Secondary structure in region 4 is indicated as white boxes.  Red indicates 
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often the case with anti-σ factors.  σA has been studied structurally in many contexts 
(Campbell et al., 2002; Murakami et al., 2002a; Murakami et al., 2002b; Patikoglou et al., 
2007), but Sau domain 4 has not been crystallized.  I used alignments with the Eco and 
Thermus aquaticus (Taq) group 1 σ factors (Fig 2.1a) to identify the Sau σA4. I cloned 
PhERI into a co-expression cassette, as previously described (Campbell and Darst, 2000), 
with Sau σA4 (Fig 2.2a). For protein purification, σA4 was cloned with a precision protease 
cleavable N-terminal 6(his) tag.  Initially, I tested the solubility of PhERI alone, σA4 
alone, and the two proteins together.  While PhERI alone was largely insoluble (Fig 2.2b, 
lane 8), it was solublized when expressed with σA4 (Fig 2.2b, lane 11).  This is indicative 
of a stable biochemical interaction between the two proteins. 
 The PhERI / σA4 complex was purified (Fig 2.2c) and screened for crystallization 
conditions. Large crystals formed under several conditions, and one condition (Fig 2.3a) 
(JCSG+ condition 59: 0.16 M Ca acetate, 0.08 M Na cacodylate pH 6.5, 14.4% PEG 
8000, 20% Glycerol) produced crystals that diffracted to near 3.0 Å (Fig 2.3b).  Although 
the conserved structure of σA4 has been solved and could have been used as a molecular 
replacement search model, anti-σ factors have been shown to alter the conformation of σ.  
Furthermore, σA4 is small, at ~10kD, and therefore may not have been sufficient to phase 
the structure of the complex.  We purified seleno-methionine substituted protein complex 
to determine initial phase information experimentally.  
 Native PhERI /σA4 crystals diffracted to 3.0Å and selenomethionine substituted 
protein crystals diffracted to 3.4Å with sufficient anomalous signal to locate the selenium 
sites and determine initial electron density maps after density modification (Fig 2.3c).  
Selenium sites were found with Shake-and-bake and the initial phases were determined 
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a)	  
σA4	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Figure 2.2: Cloning, expression and purification of the PhERI/σA4 complex.  
a) Co-expression cassette for PhERI/ σA4 expression in Eco cells.  PhERI 
and  σA4  are  cloned  as  a  single  operon,  both  genes  contain  a  ribosome 
binding site (RBS). σA4 is cloned with a 6(his) tag and cleavable precision 
protease  (ppx)  site  for  subsequent  purification  steps.   b)  Expression  of 
PhERI/ σA4 complex in Eco cells.  Lanes 1, 5 and 9: Preinduction.  Lanes 2, 
6 and 10: Post induction.  Lanes 3, 7 and 11: Soluble protein.  Lanes 4, 8 
and 12: Insoluble protein.  c) Purified PhERI/sigAd4 complex.  4-12% SDS-





a)	   b)	  
c)	  
Figure  2.3:   Crystallization,  data  collections  and  experimental  electron 
density maps of the JCSG59 PhERI/ σA4 crystals.  a) PhERI/ σA4 crystals.   	

b)  Diffraction  pattern.   Data  were  collected  at  X3A at  NSLS  at  the 
Brookhaven  National  Laboratory.   Native  crystals  diffracted  to  3.0Å.             
c)  Experimental  electron  density  map  showing  the  C-terminal  helix  of 




with SHARP. The crystallographic asymmetric unit contained two PhERI / σA4 
complexes were in the asymmetric unit.  Initial models were built and refined against the 
native dataset.   
 σA4 was not conformationally altered in either crystallographically independent 
complex PhERI (Fig 2.4).  PhERI appeared as a largely helical protein with strong 
electron density for its C-terminal domain (Fig 2.4).  However, the N-terminal region of 
PhERI was not well defined in the electron density.  I could build some backbone in this 
region, and it appears that the secondary structure is largely characterized by β-sheets, as 
predicted (Fig 2.1a), but the density was not strong enough to build side chains or 
determine the sequence register.  PhERI clearly does not reorganize the conformation of  
σA4, but the details of the interaction between the two proteins remained unclear due to 
the relatively low resolution and the poor quality of the electron density map in PhERI’s 
N-terminal region.  
 
2.0 Å Structure of PhERI /σA4 complex 
 A second crystal condition, ProteinComplex 38 (12% 1-propanol, 0.1M MES, pH 
6.5, 10% PEG 5000 MME) produced crystals (Fig 2.5a) that diffracted to significantly 
higher resolution.  To determine initial phases, I also crystallized seleno-methionine 
substituted protein complex.  I collected native data on this crystal form to 2.0Å (Fig. 
2.5b) and seleno-methionine substituted data to 2.2Å.  Phases were solved with SHARP 
and density modification was performed using Solomon.  A model was build into the 
electron density (Fig 2.5c) and refined against the native dataset. This crystal form had 
only one PhERI / σA4 complex in the asymmetric unit.   
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Figure 2.4:  Initial model of the PhERI / σA4 co-crystal structure.  There are 
two PhERI / σA4 complexes in the asymmetric unit.  PhERI is shown in blue 
and σA4 in orange.  The PhERI C-terminal domain, which is largely helical, 
is well defined in the density.  The N-terminal domain, which is predicted to 
be β-sheet, is poorly defined in the density. σA4 is not structurally rearranged 
though its interaction with PhERI.  	
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a)	   b)	  
c)	  
Figure  2.5:  ProteinComplex  38  PhERI  /  σA4  crystals.   a)  PhERI  /  σA4 
crystals.   b)  Diffraction  of  the  PC38  PhERI/  σA4  crystals.   Data  were 
collected at  the Advanced Photon Source.   Crystals  diffract  to 2.0Å.  c) 
Experimental electron density maps showing the final PhERI / σA4 model in 




 In this crystal form, I could build and refine both the N-terminal and the C-
terminal domain of PhERI (Fig. 2.6a).  Using the model from the PC38 structure, I was 
able to determine the sequence register and subsequently build much of the N-terminal 
domain in one protein complex in the JCSG59 structure (Fig 2.7).  The second complex 
in the asymmetric unit of the JCSG59 structure has clear density for the N-terminal 
domain, however I was unable to build any side chains, even with the sequence register 
provided by the high-resolution model (Fig. 2.6a).   
 A comparison of the 3 crystallographically distinct PhERI / σA4 complexes, two 
from the JCSG+59 crystal form and one from PC38 crystal form, shows that the PhERI / 
σA4 complex is highly similar  (Fig. 2.8).  Regions that differ between the 3 structures are 
also regions with elevated B-factors in the 2.0Å structure, indicating conformational 
flexibility within the crystal (Fig 2.8). 
 
Overall PhERI /σA4 structure  
 As noted above, PhERI does not alter the conformation of σA4 (Fig. 2.6b, rmsd of 
1.02 between Sau σA4 and the 1.8Å structure of Tth σA4).  PhERI does not share any 
structural homology to any previously solved crystal structures and does not contain a 
previously described fold.  
PhERI forms an extensive molecular interface with σA4 (Figure 2.6a) through both 
its N-terminal beta-sheet rich domain (purple, 1031.8Å2 of buried surface area) and its C-
terminal helical domain (blue, 1757.3Å2 of buried surface area), burying a total of 
2789.1Å2. The two proteins form extensive hydrogen bonds and salt bridges (Fig 2.9a) 






Figure 2.6: 2.0Å Structure of PhERI / σA4 complex.  a)The  PhERI / σA4 
complex. σA4 is shown in orange, the PhERI-NTD in purple and the PhERI-
CTD in blue.  b) σA4 is not reorganized through its interaction with PhERI.  
Structure of Sau σA4 from the PhERI / σA4 complex (orange) aligned to the 
high-resolution (1.8Å) structure of Taq σA4 (orange).  	
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Figure 2.7 (adjacent page): 3.0 Å structure of PhERI / σA4.  a) Placement of 
the poorly defined PhERI-NTD in the 3.0 Å electron density map using the 
2.0Å model.  2Fo-Fc map contoured to 1.0 sigma after initial refinement 
with σA4 and the PhERI CTD. Clear density for the β-sheets is seen, but side 
chains are not visible.  b) Final 3.0Å structure of PhERI/ σA4 showing 2 
complexes in  the asymmetric  unit.   PhERI is  shown in blue (CTD) and 






Table  2.1. Crystallographic statistics for PhERI/σA4 co-complex crystals (JCSG59). 
 
 Native Se1 
Data collection   
Space group C2 C2 
Cell dimensions     
    a, b, c (Å) 219.13, 57.03, 56.95 219.63, 56.83, 57.35 
    α, β, γ  (°) 90, 104.79, 90 90, 104.49, 90 
  Peak 
Wavelength 1.03839 0.9790 
Resolution (Å) 40-3.0 20-3.4 
Rsym or Rmerge 0.056 (.62) 0.124 (0.61) 
I / σI 36 (2.6) (2.1) 
Completeness (%) 100 (98.9) 99.8 (99.3) 
Redundancy 6.1 (6.2) 2.7 (2.7) 
   
Refinement   
Resolution (Å) 37-3.0  
No. reflections 13812  
Rwork / Rfree 0.2765/0.3317  
No. atoms   
    Protein 3332  
    Ligand/ion 0  
    Water 0  
B-factors   
    Protein 40.79  
    Water   
R.m.s deviations   
    Bond lengths (Å) 0.004  
    Bond angles (°) 0.824  






a)	   b)	  
Figure  2.8:   Comparison  of  the  3  PhERI/  σA4  structures.   a)  The  2.0Å 
structure (blue) and 3.0Å structures (Yellow and red) are aligned.  The three 
independent structures are highly similar (RMSD=).  b) 2.0Å structure of 
PhERI/σA4 colored by crystallographic B-factor.  Regions that are flexible in 
the 2.0Å structure, as indicated by relatively elevated B-factor (red) show 
flexibility between the 3 crystal forms, as shown in a.	
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Table 2.2.  Crystallographic statistics for PhERI/σA4 co-complex crystals (PC38). 
 
 Native Se1 
Data collection   
Space group P212121 P212121 
Cell dimensions     
    a, b, c (Å) 38.38, 64.72, 108.72 38.35, 64.87, 109.74 
    α, β, γ  (°) 90, 90, 90 90, 90, 90 
  Peak 
Wavelength 0.97949 0.97918 
Resolution (Å) 30-2.0 30.0-2.20 
Rsym or Rmerge 0.047 (0.879) 0.057 (0.734) 
I / σI 43 (2.75) 22 (2.6) 
Completeness (%) 98.3 (98.3)  98 (97.6) 
Redundancy 5.5 (5.2) 3.1 (3.1) 
   
Refinement   
Resolution (Å) 26.5-1.996  
No. reflections 18679  
Rwork / Rfree 0.2192/0.2506  
No. atoms   
    Protein 2085  
    Ligand/ion 0  
    Water 56  
B-factors   
    Protein 40.79  
    Water   
R.m.s deviations   
    Bond lengths (Å) 0.004  
    Bond angles (°) 0.775  
*Values in parentheses are for highest-resolution shell.  
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 The structure of σA4 has been determined in many contexts, including bound to 
DNA (Campbell et al., 2002), RNAP (Murakami et al., 2002b; Vassylyev et al., 2002), 
RNAP and DNA (Murakami et al., 2002b), and anti-σ factors (Lambert et al., 2004; 
Westblade et al., 2004). Although PhERI interacts with a large portion of σA4, the highly 
conserved helix-turn-helix (HTH) DNA-binding motif required for recognition of the -35 
element (Campbell et al., 2002), and the region responsible for binding the RNAP β-flap 
(Figure 4c) (Murakami et al., 2002b) are exposed in the presence of PhERI, and PhERI 
does not appear that it would sterically clash with either of these σA4 ligands (see Figure 
2.10).   
 
Model of PhERI bound to the RNAP holoenzyme 
To understand how PhERI may function in the context of the RNAP holoenzyme, 
I docked PhERI onto models of the RNAP-holoenzyme open promoter complex (RPo) by 
superimposing the structural core of σA4 (Fig. 2.10a) (Jain et al., 2005; Murakami et al., 
2002b). PhERI binds to an external surface of holoenzyme and appears poised to interact 
with promoter DNA both upstream and downstream of the -35 element, flanking the σA4 
HTH-recognition helix positioned in the major groove of the -35 element (Fig. 2.10). 
PhERI has a stretch of positively charged residues in its N-terminal region, which are in 
close proximity to DNA between the -35 to -40 positions (Fig 2.10c). PhERI also does 
not block the protein-protein interaction between σA4 and the RNAP α-CTD. PhERI is 
however in close proximity to promoter DNA in the region upstream of the -35 element, 










a)	   b)	  
Figure 2.9: Interaction map between PhERI and σA4.  a) Hydrogen bond and 
ionic interaction map.  Residues are listed and interactions are shown by 
lines  connecting  two  residues.   Hydrogen  bonds  are  shown  in  green, 
hydrogen bonds that are mediated by a water molecule are shown in blue 
and  ionic  interactions  are  shown  in  red.   Interactions  with  the  protein 
backbone  are  signified  by  a  line  touching  the  residue  number  while 
interactions mediated by the protein side chain are shown by lines starting 
next to the residue number.  Residues that differ between Sau and Eco are 
highlighted with an asterisk.  Residues found to be binding determinants by 
the  subsequent  2-hybrid  analysis  are  shown  with  a  red  asterisk.   b) 
Hydrophobic interaction map.  Residues are listed as in part  a and lines 












Figure 2.10: Model of PhERI bound to the RNAP open promoter complex 
(Rpo).  a) PhERI was modeled onto the RNAP (Rpo) complex by aligning 
the conserved structure of σA4 from the 2.0Å PhERI co-complex and σA4 
from the Rpo model.  RNAP is shown in green, promoter DNA in orange 
(with  the  -35  element  colored  red),  PhERI  is  colored  blue/purple  as  in 
Figure 2.6.  b) Zoomed view of the PhERI /RNAP interaction(s).  PhERI 
interacts  with an external  surface of  Rpo.   The RNAP α-CTD is  shown 
(yellow) interacting with an UP-element.  c) PhERI does not appear to block 
the DNA or core binding surfaces of σA4.  PhERI is shown as a surface 
representation colored as above.  The -35 element is colored red, and bases 
upstream of the -35 are labeled.  The β-flap is shown in pink to highlight the 
β-flap / σA4 interaction.  Positively charged residues in PhERI well poised to 




Identification of a σA mutant that does not bind PhERI 
To validate the structure, and provide a useful biochemical tool to study PhERI’s 
function, Cristina Montero-Diaz in Ann Hochschild’s lab performed a screen for a σA4 
mutant that would abolish the interaction with PhERI. PhERI does not bind to Eco σ704, 
while it does bind to Sau σA4. These domains are highly conserved between the two 
organisms (Fig 2.11a) and therefore we could construct hybrid σ4 domains and test their 
interaction with PhERI by bacterial two-hybrid.  Briefly, one of the proteins of interest is 
fused to the DNA-binding protein λcl and the other replaces the α-CTD of RNAP.  In the 
presence of a suitably strong protein-protein interaction, the λcl/RNAP complex will 
drive the transcription of a test promoter.   
Two-hybrid experiments mapped the PhERI /σA4 interaction to between Sau 
residues 309 and 335 (Fig 2.11).  The interaction was further probed by swapping 
individual residues from the Sau to the Eco sequence.  Four point mutations (D309A, 
E312A, N313K, V335Q) were required in combination to completely disrupt the PhERI / 
σA4 interaction (Fig 2.11b and c).  Mutations at these residues are not predicted to alter 
the interaction between σ and RNAP or σ and DNA. 
The σ residues identified in the 2-hybrid analysis sit at the interface between σ 
and PhERI in the co-crystal structure.  Sau σA E312 and N313 form both hydrogen 
bonding and ionic interactions with two positively charged residues in PhERI (K2 and 
K195).  The mutations E312A and N313K would not only disrupt these interactions but it 
would also introduce another positively charged residue in close proximity to the 
positively charged patch of PhERI (Fig 2.12a).  V335 sits in a hydrophobic pocket in 
PhERI; the introduction of the polar glutamine residue at this location is likely 
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Figure 2.11 (adjacent page):  Identification of a Sau σA mutant deficient in 
PhERI binding.  a) Alignment of Eco σ70, which cannot bind PhERI and Sau 
σA, which can.  b) Bacterial 2-hybrid analysis to identify the Sau residues 
that confer PhERI binding specificity.  PhERI was fused to lambda cl and 
σA4 replaced the RNAP α-CTD.  Binding of the 2 proteins was monitored 
by the expression of a test gene, LacZ.  The analysis of hybrid 1 (containing 
Sau residues 309-335) and hybrid 2 (lacking these residues) identified the 
region of σA interacting with PhERI.  The mutation of 4 individual residues 
(Sau  σA4  quadruple:  D301A,  E312A,  N313K,  V335Q)  eliminated  the 
interaction  between  SigAd4  and  PhERI  in  the  2-hybrid  experiment.  
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unfavorable (Fig. 2.12b) . The mutations selected in the screen for their importance to the 
PhERI / σA4 interaction are in agreement with the structural information provided by the 
X-ray crystal structures.   
 
Biochemical analysis of σA mutant 
To show that the σA mutant identified in the bacterial 2-hybrid screen is deficient 
in PhERI binding but not RNAP binding, I performed a native gel shift analysis.  PhERI, 
Sau RNAP, σA, and the σA quadruple mutant (4M, D309A, E312A, N313K, V335Q) 
were purified.  On a native gel there is clear evidence for an interaction between PhERI 
and Sau holoenzyme, as previously described (Fig 2.12c lanes 2 and 3).  While the σA 
mutant clearly interacts with RNAP core to form holoenzyme (Fig. 2.12c lane 4), no shift 
is evident upon the addition of PhERI (Fig. 2.12c lane 5).  Additionally, the interaction 
between σA and PhERI is clearly visualized on the same gel (Fig. 2.12c lanes 2 and 3), 
but is absent when the σA 4M is used. Because the interaction surface between the two 
proteins is essentially the same in 3 independent structures and is validated by an in vivo 
bacterial 2-hybrid mutational analysis and in vitro gel shift assay, I am confident that I 
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Figure 2.12: Structural analysis of the σA4 quadruple mutant.  a) The co-
crystal structure of PhERI (purple: NTD, blue: CTD) interacting with σA4.  
Mutations at σA position 312 and 313 would disrupt the interaction between 
E312 and PhERI K2 and K195 and add a positively charged residue likely 
to be repelled.  b) σA V335 is situated in a hydrophobic pocket in PhERI, 
where the polar Q would be unfavorable.  c) PhERI does not interact with 
the σA mutant in vitro.  Purified Sau core, σA, σA quadruple mutant (M) and 
PhERI were incubated on ice at the indicated concentrations and run on a 




PhERI structural homology  
BLAST searches for proteins with sequence homology to PhERI provided several 
homologous proteins from sequenced phage genomes.  One homolog, was encoded in the 
Sau phage Twort; four others were found in phages that infect other fermicutes but not 
Sau.  The relatively high levels of conservation between PhERI homologs argue that the 
proteins are functionally conserved (Fig 2.13).   
The program Consurf can be used to map the conservation of residues onto 
protein structures.  This analysis shows clearly that nearly all of the universally conserved 
residues in all the PhERI homologs are in the hydrophobic core of the protein, indicating 
that the overall fold of the homologs is  similar. The most highly conserved region of 
PhERI maps to the interaction surface with σA4 (Fig 2.14), while the rest of PhERI’s 
surface shows relatively low levels of sequence conservation. Because the region 
responsible for the direct interaction with σA4 is highly conserved, these homologous 
proteins are likely to be functionally related as well as structurally related. 
A PhERI homolog was identified in an additional Sau specific phage, Twort.  To 
test whether Twort ORF65 bound to Sau σA I cloned and purified the protein. Twort 
ORF65 also forms an interaction, as visualized on a native gel, with Sau σA (Fig. 2.14c).  
Interestingly, using the mutant σA that was identified as deficient in PhERI binding also 
eliminated the interaction with Twort ORF65 (Fig 2.14c).  This shows that not only does 
Twort ORF65 also bind to σA but that it likely interacts by the same molecular 
determinants as the G1 protein PhERI.  The two proteins are also sufficiently conserved 
to produce a structural model of ORF65 based on the structure of PhERI.  These data 
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Figure 2.13:  Alignment of PhERI homologs.  The program ConSurf was 
used  to  produce  a  structure-based  alignment.   Residues  are  colored  by 
conservation (blue = non-conserved ; red = highly conserved, see the color 
code in the inset).  The PhERI homologs are labeled by the phage genome 
in which they were identified:	

ORF67: Sau phage G1 PhERI	

ORF65: Sau phage Twort PhERI	

Lac142: Lactobacillus phage Lb338 PhERI	

EF24: Enterococcus phage phiEF24C PhERI	

A511: Listeria phage A511 PhERI	
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a)	   b)	  
c)	  
Figure 2.14:  Structural conversation of PhERI.  a) The structure of PhERI 
from the  2.0Å co-crystal  structure  with  σA4  is  shown as  a  surface  map 
colored by conservation.  The structural conservation map was made by the 
program ConSurf.  Highly conserved residues are shown in blue and poorly 
conserved residues in red.  b) Highly conserved PhERI residues map to the 
binding site of σA4. σA4 is shown in orange as a cartoon model.  Residues 
that are highly conserved (blue) cluster around the σA4 binding site.  c) The 
PhERI homolog from the Sau phage Twort interacts with σA, but not the σA 
mutant deficient in PhERI binding.  Purified proteins were incubated at the 
indicated concentrations and run on a 4-12% native PhAST gel.  	

non-­‐conserved	   conserved	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strongly suggest that the two proteins are not only structural but also functional 
homologs.   
 
PhERI is conformationally stabilized through its interaction with σA4 
 I solved the structure of PhERI complexed with Sau σA4.  To test whether PhERI 
undergoes any conformational changes upon binding σ, I attempted to crystallize PhERI 
alone.  PhERI was purified and extensively screened for crystallization conditions.  
However, I found no evidence for PhERI crystallization under any conditions. 
 Proteins with conformational flexibility are difficult to study by X-ray 
crystallography because they are less likely to form the normally repeating units required 
for crystal packing.  We used limited proteolysis as a tool to examine the conformational 
stability of PhERI alone and with its binding partner. Stably folded proteins are more 
resistant to digestion by proteases as many of their cleavage sites are buried within the 
core of the protein.  PhERI alone is readily degraded by trypsin, indicative of a poorly 
folded protein (Fig 2.15a).  However, when incubated with σA or σA4, PhERI becomes 
significantly more resistant to degradation (compare Fig 2.15a lane 4 and 2.15b lane 10).  
Because we solved the crystal structure of PhERI bound to σA4 we know that a stable and 
well-folded complex is formed between the two proteins.  However, it appears that 
PhERI may be largely unstructured or exhibit high levels of conformational flexibility 
when not bound to σ.   
 
60
Figure  2.15  (adjacent  page):   PhERI  is  structurally  stabilized  by  its 
interaction with σA4.  Limited proteolysis of PhERI alone (a) and PhERI in 
complex with σA4 (b).  The complex was formed on ice in 1x proteolysis 
buffer at 5uM and incubated at 30°C with protein:protease concentrations of 
1:0,  1000:1,  100:1,  50:1,  10:1,  5:1.   After  20  minutes,  reactions  were 
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 Structural techniques have been incredibly insightful in determining the molecular 
mechanisms of anti-σ factors (Fig 1.12).  The group 1 σ factors are well studied both 
structurally and biochemically (Figs 1.3, 1.4, 1.7 and 1.12).  The residues that interact 
with DNA and RNAP are known (Fig 1.4), and anti-σ factors typically block or disrupt 
these required σ functions.   
 The co-crystal structures I solved of PhERI bound to σA4 provide the molecular 
details of the interaction between the two proteins (Figs 2.6 and 2.9). The three structures 
are similar (Fig 2.8), and are in agreement with 2-hybrid and biochemical data on the 
interaction between the two proteins (Fig 2.11 and 2.12).   I believe the structural analysis 
of PhERI binding to σA4 accurately describes the nature of the protein-protein interaction.   
 However, the mechanism through which PhERI inhibits Sau RNAP is not 
immediately apparent from the co-crystal structure.  PhERI does not alter the 
conformation of σA4 nor does it appear to sterically block the residues required for DNA 
recognition or core RNAP binding (Fig 2.6 and 2.10). Previous work, suggesting that 
PhERI disrupts -35 element recognition by RNAP (Dehbi et al., 2008), is not supported 
by our structural data.   
 PhERI also does not appear to have any structural homology to previously studied 
anti-σ factors or any previously described protein fold.  Because PhERI joins RNAP 
through an interaction with σA4, and mutants in this region ablate PhERI binding to 
RNAP, PhERI is located well upstream of the transcription bubble, and more than 60Å 
from the RNAP active center.  σA4 recognition of the -35 element occurs at an early stage 
in transcription initiation, when promoter DNA is fully double stranded.  PhERI, because 
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it interacts with σ4 was logically hypothesized to affect transcription by blocking σA4 
activity. Our structural data do not preclude PhERI acting by blocking DNA binding, or 
indeed being in a different conformation in the context of the full holoenzyme or open 
promoter complex than it is when bound to σA4 alone as visualized in the structure.  
However, the structure does not support the previous hypothesis that PhERI blocks the -
35 element DNA recognition (Dehbi et al., 2008). Biochemical and transcriptome data 
that I will present in chapters 3-5 conclusively show that PhERI indeed does not block     
-35 element recognition by RNAP holoenzyme. 
 The structural analysis described in this chapter provided valuable information 
detailing the interaction of PhERI with Sau RNAP.  However, in this case, the molecular 
details of the interaction between PhERI and RNAP is not sufficient to propose a 
mechanism of inhibition for this protein factor.  Subsequent chapters will describe the 
biochemical, genetic and genomic tools we used to characterize the activity of PhERI at 





PhERI Inhibits rRNA Transcription in vitro 
 
 The crystal structure of the PhERI / Sau σA4 complex, described in the previous 
chapter, provides a structural model for the interaction between PhERI and Sau RNAP.  
However, unlike previously studied anti-σ factors, PhERI does not appear to block the 
functional surfaces of σA4 (Figs 2.6 and 2.10). The previous hypothesis that PhERI 
inhibited -35 element recognition (Dehbi et al., 2008)  is not supported by the co-crystal 
structure, but no alternative hypotheses are immediate apparent from the structural data 
alone.  
 RNAP activity has been studied using biochemical and genetic tools in model 
organisms for decades (Craig et al., 1998; deHaseth et al., 1998; Hinkle and Chamberlin, 
1972a, b; Severinov and Darst, 1997; Siegele et al., 1988). Eco RNAP has been 
extensively studied at various host and phage promoters (Kumar et al., 1993; Lemke et 
al., 2011; Nechaev and Severinov, 1999; Pemberton et al., 2000; Saecker et al., 2002).  
The genetic tools available in Eco have made mutant polymerases readily available; 
many of these mutants are characterized for their ability to perform the various kinetic 
steps in the transcription cycle (Artsimovitch et al., 2003; Bartlett et al., 1998; Gardella et 
al., 1989; Severinov and Darst, 1997; Sun et al., 2004).  The ability to use Eco RNAP to 
study PhERI function would allow us to rapidly test which kinetic steps (i.e. -35 
recognition, open promoter complex stability, UP-element binding, closed to open 
complex isomerization) and which promoters (-35 element dependent versus -35 element 
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independent) are affected by this phage protein. The initial biochemical studies on PhERI 
used a hybrid RNAP holoenzyme comprising Eco core RNAP and Sau σA (Dehbi et al., 
2008). 
Transcription in Sau has not been extensively studied in vitro (Deora and Misra, 
1996; Rao et al., 1995; Reynolds and Wigneshweraraj, 2011).  While the Sau RNAP and 
σA have been identified and purified (Deora and Misra, 1996), few promoters have been 
tested and none have been studied in detail at various kinetic steps by footprinting.  The 
most well studied promoters are involved in the switch from non-pathogenic to 
pathogenic growth, are characterized by weak -10/-35 elements, have non-optimal spacer 
length, and are known to be controlled by additional transcriptional activators and 
repressors (Agr P1 and P2, Fig 3.1a) (Deora and Misra, 1996; Rao et al., 1995; Reynolds 
and Wigneshweraraj, 2011).   
 In this chapter, I show that PhERI does not bind to or inhibit the previously 
studied Eco/Sau hybrid RNA holoenzyme.  To study the mechanism of PhERI, I 
developed a fully native Sau in vitro transcription system and identified -10/-35 
promoters in the Sau genome.  I show that PhERI inhibits RNAP activity in a promoter-
specific manner: PhERI is a potent inhibitor of transcription from the Sau rRNA 
promoters (rrnA and rrnB), but not all -10/-35 promoters in vitro, which is incompatible 
with a mechanism wherein PhERI blocks -35 recognition.  Because the primary 
functional regions of σA4 are not sterically blocked in the crystal structure of the PhERI /  
σA4 complex and not all -10/-35 promoters are inhibited in vitro, PhERI must modulate a 
step other than -35 recognition or alter the interaction of RNAP with promoter DNA 
without directly affecting the activity of the σ factor. rRNA transcription is known to 
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affect the rate of cell division in prokaryotes; we hypothesize that PhERI inhibits Sau 
growth directly through inhibiting RNAP activity at the rrn promoters. 
 
PhERI does not inhibit the hybrid Eco/Sau RNAP holoenzyme 
I initially attempted to replicate the results of Dehbi et al. (2008) by testing 
PhERI’s activity using Sau σA / Eco core RNAP on the well characterized -10/-35 λpL 
promoter.  Previous results showed that PhERI, but not a control phage protein, inhibits 
the hybrid RNAP at this promoter (Dehbi et al., 2008).  In contrast, I show that PhERI, 
even at 100-fold molar excess, does not inhibit the hybrid RNAP holoenzyme at this 
same promoter (Fig 3.1b). Dehbi et al. only tested one PhERI concentration (2µM, with 
RNAP at 25nM), and showed only one time point after the initiation of transcription.  
Additionally, Dehbi et al. titrate Sau σA (100-500nM) above Eco core RNAP levels 
(25nM); while RNAP activity should saturate as 100% of core RNAP is bound by σA, 
transcription levels do not (Dehbi et al., 2008).   
Due to these inconsistent results, I decided to compare the ability of PhERI to 
bind to Sau holoenzyme and the hybrid Eco/Sau holoenzyme by native gel shift (Fig 
3.1c).  While PhERI clearly shifts Sau holoenzyme (Fig 3.1c lanes 2 and 3), I see no 
evidence for a shift when the hybrid Eco / Sau enzyme is used (Fig 3.1c lane 6 and lane 
4). Because I show that PhERI does not inhibit the hybrid Eco / Sau RNAP holoenzmye 
(Fig 3.1b), or even appear to interact with the hybrid holo (Fig. 3.1c), and because the 
biochemical results reported by Dehbi et al. were experimentally flawed, I decided to test 
the function of PhERI in a native Sau in vitro transcription system. 
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Figure 3.1 (adjacent  page):  PhERI does not  inhibit  the Sau σA/Eco core 
hybrid holoenzyme on the λpL promoter. a) Sequence of the λpL promoter.  
The -10 and -35 element are highlighted in red.  b) PhERI does not inhibit 
the hybrid Eco core/Sau σA holoenzyme at  the λpL promoter.  PhERI,  at 
1μM or 5μM, was bound to Sau σA (100nM) and Eco core RNAP (50nM).  
Promoter DNA (50nM) was added and the reaction was incubated in 1x 
transcription buffer at 37°C.  Reactions were initiated with NTPs (200μM 
GTP,CTP, and UTP, 50μM ATP and 0.1μl P32 ATP), stopped with 2x stop 
buffer at the times indicated and visualized on a 12% Urea-PAGE gel by 
autoradiography.  c)  PhERI  forms  a  stable  interaction  with  the  Sau 
holoenzyme (lane 2 and lane 3), but not with the Eco core/Sau σA hybrid 
holoenzyme (lane 5 and lane 6). The proteins, at the indicated concentration, 
were incubated on ice for 10 minutes and run on a 4-12% native Phast gel.  	
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Sau RNAP has been purified for biochemical analysis by native protein 
purification (Deora and Misra, 1996; Rao et al., 1995), overexpression of tagged subunits 
(Dehbi et al., 2008) and affinity purification using RNAP antibiodies (Reynolds and 
Wigneshweraraj, 2011).  Using overexpressed subunits leads to an excess of the tagged 
domain of RNAP, and non-stoichiometric RNAPs have been shown to produce erroneous 
biochemical results (Vrentas et al., 2008).  I therefore purifed native, untagged Sau 
RNAP from NCTC8325 cells, essentially as described previously (Fig 3.2; see Materials 
and Methods) (Deora and Misra, 1996).  
I initially sought to replicate the in vivo result that PhERI inhibits RNAP activity 
(Dehbi et al., 2008).  To this end, I used Sau genomic DNA as a template for 
transcription in vitro to test PhERI at all Sau promoters, similar to the experiment 
showing inhibitory activity in vivo.  Standard transcription assays were performed, 
radiolabeling the RNA product with P32, with genomic DNA (gDNA) as the template. To 
show the validity of this approach, I tested the inhibitory activity of the well-
characterized anti-σ factor AsiA using Eco RNAP holoenzyme and Eco gDNA as the 
template.  As expected, AsiA was a potent inhibitor of RNAP activity in this assay (Fig 
3.3a).  Because Sau RNAP was active in only in low concentrations of NaCl, I tested 
different buffer and salt conditions to optimize the transcription assay for Sau RNAP (Fig 
3.3b).  For subsequent experiments I used 0.1M NaCl, which was well tolerated by Sau 
RNAP, and proteins were stored in 0.2M sodium glutamate to avoid adding additional 
NaCl to the reactions with the protein buffers.    
 PhERI inhibits promoter-specific Sau RNAP-holoenzyme transcription from Sau 








a)	   b)	  
Figure  3.2:  Purification  of  Sau  core  RNAP.   a)  Schematic  of  native, 
untagged Sau RNAP purification.  b) 4-12% SDS-PAGE gel of Sau RNAP 
after the final purification step.  Individual subunits are labeled.	
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Figure 3.3 (adjacent page): PhERI inhibits transcription from Sau RNAP but 
not  Eco  RNAP.  a)  The  T4  anti-phage  protein  AsiA inhibits  Eco  RNAP 
holoenzyme  activity  using  Eco  gDNA  as  a  template.   b)   High 
concentrations of NaCl inhibit Sau RNAP.  c) PhERI inhibits transcription 
from Sau genomic DNA.  Reactions contained σA (100nM), PhERI at the 
indicated concentrations and core RNAP (50 nM), 50ng gDNA in 1x Sau 
transcription buffer.  Reactions  were  initiated  with  200μM GTP,CTP,  and 
UTP, 50μM ATP and 0.1μl P32 ATP, stopped after 5 minutes, pipetted onto 
DE81 paper,  washed and quantified. Reactions were performed with Sau 
holoenzyme (red bars), Eco RNAP core complexed with Sau σA (blue bars), 
Eco  holoenzyme  (yellow  bars)  and  Sau  holoenzyme  containing  the  σA 

















+	   +	   +	   +	   +	   +	  
-­‐	   +	   +	   +	   +	   +	  








































































the hybrid holoenzyme formed by Eco RNAP/ Sau σA (Fig. 3.3c, blue bars), consistent 
with our in vitro results (Fig. 3.1b). Inhibition of Sau RNAP-holoenzyme by PhERI was 
dependent on the Sau σA / PhERI interaction, since RNAP containing the mutant Sau σA 
that abolished the PhERI interaction (but was normal in other respects, Fig. 2.11 and 
2.12) was not inhibited (Fig. 3.3c, green bars). PhERI inhibition therefore requires a 
native Sau in vitro transcription system. 
 
PhERI does not inhibit Sau -10/-35 promoters 
 While it is reassuring that PhERI has the same effect in vitro as in vivo, to study 
its mechanism we must identify individual promoters that are inhibited by this protein.  
Transcription from gDNA will not allow mechanistic assays as this experiment tests an 
ensemble of promoters with different binding affinities for RNAP and different kinetics 
of promoter recognition and transcriptional initiation. 
 Many early mechanistic studies of RNAP from Eco used phage promoters as 
template DNA (Letalaer and Jeanteur, 1971; Roberts, 1969; Rosenberg et al., 1982; 
Severinov and Goldfarb, 1994; Siebenlist, 1979; Siebenlist and Gilbert, 1980).  In many 
phage, early phage promoters bind RNAP with high affinity and show robust activity to 
compete with host promoters for RNAP occupancy early in the phage infection.  The 
phage T7 promoter T7A1 and the λ phage promoters pL and pR have been particularly 
useful for in vitro studies because of their stable intermediates and high levels of RNAP 
activity (Kadesch et al., 1982; Rosenberg et al., 1982).   
Recent work sequenced the genome of many Sau phages (Kwan et al., 2005).  In 
particular, I examined the genome of the Sau phage G1, which encodes PhERI.  Due to 
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the short intergenic regions and the similarity of the phage promoters to the consensus 
sequence, I easily identified many strong phage promoters (Fig 3.4). The G1 promoters 
identified are all near to consensus and have ideal spacer length (17bp); most additionally 
have an extended -10 element and an A/T rich sequence upstream of the -35 element.  
These strong promoters are likely to be selected to compete for Sau RNAP upon the 
initial injection of the phage genome into the host cell.  The coding region for PhERI is 
located downstream of one of these strong promoters (G1-pPhERI, Fig 3.5a).  Therefore 
PhERI is almost certainly an early phage gene, transcribed by Sau RNAP upon initial 
phage infection. 
 To examine PhERI’s function, I tested its activity at the phage promoter that 
drives its expression, G1pPhERI (Fig 3.5b).  While RNAP has robust activity at this 
promoter, transcription is not affected by the presence of PhERI (Fig 3.5b).  If PhERI is 
altering the interaction between σA4 and the -35 element, the phage promoters may not be 
informative as the majority have an extended -10 element and may therefore not require σ 
recognition of the -35 element.   
 To find -10/-35 promoters that may be affected by PhERI, I searched the Sau 
genome.  While Sau virulence related promoters have been studied previously (Reynolds 
and Wigneshweraraj, 2011), I decided to search for promoters with more characteristic 
promoter elements that may be constitutively active in rapidly dividing cells.  Early 
phage gene products often inhibit the host DNA replication (Datta et al., 2005; Yano and 
Rothman-Denes, 2011); inhibiting replication not only stops the cells from dividing but 






236   aaaagtttaagaaacctaTTGACAttaggtttcttttattaTATACTaagagtataag!
174 aaaaagttggtctttttttaTTGACAatttataatatctaTGaTACACTatataagaatt!
20  aaataaagtaaagaatataaTTGACAaatataaaaaactaTGtTATAATaaataagtaaa!
35      ttctcttctttttttaTTGACAaggtttaaaatataTGgTATAGTattattaagtt!
41   tagaactagaataaaagtaTTGACAaattaaaactaataaatTATAATaaaggtataac!
293 aaaaagttggtctttttttaTTGACActttaaaatttataTGtTATTATaaatataataa!
67    ttttttaaaatataccacTTGACAttttatatgttaggTGgTATAATtattttataaa!






    nnnnnnnnnnnnnnnnnnnnTTGACAnnnnnnnnnnnnnnTGnTATAATnnnnnnnnnnn!consensus	  
Figure 3.4: Promoters identified in the G1 Phage genome.  ORF number is 
listed on the right and the putative promoter is listed.  -35, -10 and extended 
-10 elements are highlighted in red.  	
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Figure 3.5 (adjacent page): PhERI does not inhibit Sau RNAP at -10/-35 
promoters for DNA replication and repair factors.  a) Sequence of promoters 
used in subsequent experiments.  -35 and -10 elements are highlighted in 
red.  b) PhERI does not inhibit transcription from its own promoter.  PhERI 
was  incubated  with  σA  (100nm),  Sau  core  RNAP  (50nM)  and  linear 
promoter  DNA (50μM) in  1x  Sau  transcription  buffer.   Reactions  were 
initiated  by  the  addition  of  NTPs  as  described  above,  stopped  with  2x 
formamide  buffer,  and  visualized  on  a  12%  Urea-PAGE  gel  by 
autoradiography.  Bands  were  quantified  in  ImageQuant  and  the  percent 
activity, relative to holoenzyme, is listed below each lane.  c) PhERI does 
not  inhibit  RNAP  activity  at  the  dnaA,  aag,  and  polIII  promoters.  
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transcription and replication of the phage genome.  I therefore looked for promoters 
upstream of genes required for DNA replication. 
 Identifying promoters in sequenced genomes is not a straightforward 
computational problem.  Many promoters are highly divergent from the -10/-35 
consensus sequences.  Furthermore, Sau is A/T-rich, which creates many false positives 
for the -10 element (sequence: TATAAT). To facilitate the search for promoter 
sequences, we built a perl-based script to identify putative promoters.  The program uses 
the likelihood of base identity at promoter positions in previously described promoters to 
score every 6 bases in a particular sequence (Fig 3.6) (short sequences are quickly 
searched, but the program can handle an entire prokaryotic genome in a matter of 
minutes).  The initial search can be for either the -10 or the -35 sequence, and the 
threshold can be set by the user.  Once a 6-base sequence has a score above the threshold, 
the program moves 15 bases downstream of a -35 sequence or 15 bases upstream of a -10 
sequence and searches for the other promoter element.  Spacers between 15 and 20 bases 
are allowed, and potential promoter sequences are output to a logfile.  This program was 
built by a talented programmer, Michael Mosley, in collaboration with the author.  While 
the author defined the parameters of the search algorithm, the details of the programming 
are out of the area of his expertise.   
 Using a combination of the Perl program described above and manual searches in 
the genome, I identified putative promoters upstream of three components of the DNA 
replication/repair machinery: dnaA, DNA polymerase III, and aag, a DNA repair factor 




Figure  3.6:  Bioinformatic  tool  used  to  identify  putative  promoters.   a) 
Promoters  were  scored  using  an  algorithm  that  used  the  likelihood  of 
nucleotides at each promoter position.  b) Example of promoter scoring.  A 
consensus -10 element (TATAAT) sequence (1) was changed, base by base 




does not affect transcription (Fig 3.5c).  PhERI has a small effect at very high 
concentrations on the already weak polIII promoter.   
PhERI does not inhibit the G1 phage promoter pPhERI or the dnaA, aag or polIII 
promoters.  Because these promoters, particularly the dnaA and aag promoters, almost 
certainly require an interaction with the -35 element (i.e. they have no extended -10 
element), PhERI is unlikely to block the interaction between σA4 and the -35 element.  
This is in agreement with the structural analysis presented in the previous chapter. 
  
PhERI inhibits RNAP at rRNA promoters 
 While PhERI appears to have no effect on the individual promoters I tested, it 
does inhibit RNAP activity in vitro when genomic DNA is used as the template (Fig 
3.3c).  The majority of transcription in log-growing prokaryotic cells is from the rRNA 
promoters (Gourse et al., 1996).  We therefore hypothesized the PhERI may be inhibiting 
transcription from these promoters.  The rRNA promoters in Sau have not been identified 
or studied previously, but the sequenced genome contains 5 rRNA operons, each 
containing the genes for the 16s, 23s and 5s rRNAs (Fig 3.7a).  I searched for the 
promoters that would drive the expression of these operons.  Two rRNA operons 
contained at least one easily identifiable promoter sequence within 200 bases of the 
sequence of the first structured RNA (Fig 3.7b).   
 Sau RNAP is active at the putative rrn promoters in vitro (Fig 3.7c), and 
furthermore PhERI inhibits this activity (Fig 3.7 c). While PhERI has no activity, even at 
high molar excess, at previously studied promoters, at the rrn promoters roughly 
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Figure 3.7: PhERI inhibits Sau RNAP at the rrn promoters.  a) Schematic of 
the rrnA operon highlighting the 16s, 23s and 5s rRNA genes.  b) Sequence 
of the rrn promoters tested in subsequent experiments.  -35 and -10 elements 
are highlighted in red.  c).  PhERI inhibits Sau RNAP at the rrn promoters.  
PhERI (at  the listed concentration) was incubated with σA (100nm), Sau 
core  RNAP  (50nM)  and  linear  promoter  DNA  (50nM)  in  1x  Sau 
transcription buffer.  Reactions were initiated by the addition of NTPs as 
described above,  stopped with 2x formamide buffer,  and visualized on a 
12%  Urea-PAGE  gel  by  autoradiography.  Bands  were  quantified  in 
ImageQuant and the percent activity, relative to holoenzyme, is listed below 




equimolar concentration of PhERI is sufficient to produce strong inhibition (0.1µM 
PhERI and 0.1µM σA).   
These results demonstrate that PhERI is not a general inhibitor of RNAP activity 
but rather is a specific inhibitor only at certain promoters.  Because PhERI does not 
inhibit RNAP activity at several -10/-35 promoters, it is unlikely to block the activities of 
σA4 (DNA and core binding) required for RNAP activity most promoters.  Therefore, 
PhERI must be modulating some other parameter specific to rrn and perhaps other Sau 
promoters.  In subsequent chapters I will show that these results are reproducible in vivo 
and search for additional Sau promoters inhibited by PhERI.  These studies will lead to a 




RNA-seq Reveals PhERI  
Sensitive Promoters in vivo 
 
 The structural and biochemical studies of PhERI, and its activity at various 
promoters, have demonstrated that it is unlikely to act as a general anti-σ factor.  While 
PhERI interacts with σA4 and forms a stable complex with the Sau RNAP holoenzyme 
(Fig 2.12), it fails to inhibit most promoters in vitro (Fig 3.5). Nonetheless, PhERI is a 
potent inhibitor of RNAP activity at the rrn promoters (Fig 3.7), which transcribe the 
structural rRNAs required for ribosomal biogenesis.  How PhERI is able to target specific 
promoters, while having no apparent effect on others, is unclear.   
 To address PhERI’s mechanism of inhibition at rrn promoters I used a genomic 
approach to simultaneously test the activity of PhERI on a large number and variety of 
Sau promoters.  While in vitro analysis allows us to probe a small number of promoters 
in great detail, having a large number of PhERI-sensitive promoters may allow us to 
compare sequence features common to these promoters and make hypotheses about how 
PhERI inhibits RNAP activity.  Studies examining the differential expression of genes by 
transcription factors and small molecules in Sau have successfully used gene-chip 
technologies to find differentially regulated genes (Hubscher et al., 2007; O'Neill et al., 
2009; Truong-Bolduc et al., 2011). 
 In this chapter, I will describe my in vivo studies of the differential expression of 
genes by PhERI.  I designed a PhERI expression vector that allows the inducible 
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expression of PhERI in Sau cells.  I first show that PhERI inhibits rRNA synthesis in 
vivo, confirming our in vitro results.  I will then describe a high-throughput RNA-seq 
analysis of cells expressing PhERI.  These studies confirm that PhERI is not a general 
inhibitor of RNAP activity, and provide a library of PhERI-sensitive promoters that will 
be used in the next chapter to elucidate the mechanism of PhERI inhibition.  I will also 
use the RNA-seq data to evaluate previous in vitro transcription experiments in Sau, 
determine robustly expressed mRNAs in vivo whose promoters may be useful for in vitro 
analyses, and compare gene expression profiles between Sau strains.    
 
Construction of an Sau PhERI inducible vector 
  Sau has a well-developed genetic system including many vectors for expressing 
exogenous proteins (Corrigan and Foster, 2009; Dehbi et al., 2008; Truong-Bolduc et al., 
2011).  There is an electrocompetent Sau strain that is readily transformable.  This strain, 
RN4220, is quite similar to the standard, non-pathogenic lab strain NCTC8325.  The 
genomes of both strains have been sequenced and differ only by 121 single nucleotide 
polymorphisms (SNPs) and several small-scale insertions and deletions (indels) (Nair et 
al., 2011).  The indels are clustered around phage-based transposable elements.  Although 
some of the SNPs are in potentially important coding regions, including virulence and 
DNA repair factors, functional differences between the two strains are largely unreported 
(Nair et al., 2011).  
PhERI was discovered in a high-throughput screen for proteins that inhibited Sau 
cell growth (Dehbi et al., 2008; Kwan et al., 2005; Liu et al., 2004).  Because PhERI 
expression is known to be toxic in Sau cells (Liu et al., 2004), I opted to use an inducible 
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expression vector that has low levels of leaky expression (Corrigan and Foster, 2009).  
Many Sau expression plasmids drive healthy expression of the protein of interest but 
have constant low-level expression in the absence of inducer, which would greatly 
complicate our analysis.  A recently described vector showed essentially no leaky 
expression of the gene of interest; further specificity was added by inducing with 
anhydrotetracycline, which has a reduced affinity for the bacterial ribosome and an 
increased ability to drive transcription from tet-inducible vectors (Fig 4.1) (Corrigan and 
Foster, 2009).  I cloned both the phage G1 PhERI and its homolog from phage Twort, 
ORF65, into pRMC2 with Sau optimized Shine-dalgarno sequences upstream of the start 
codon.  pRMC2, pRMC2-PhERI and pRMC2-TORF65 were electroporated into RN4220 
cells and grown on plates containing chloramphenicol.  In the absence of inducer, all 
strains grew with a doubling time comparable to that of the wild type (wt) RN4220 and 
NCTC8325 strains (Fig 4.2b). 
 When grown in the presence of even low levels of inducer, pRMC2-PhERI and 
pRMC2-TwortORF65 cells exhibit no evidence of cell growth over the course of several 
hours (Fig 4b (blue curve)).  The phage Twort homolog, ORF65, clearly has the same 
function in vitro as phage G1 PhERI, as would be expected from its high level of 
sequence conservation and predicted structural similarity (Fig 4.2a). When cells were 
allowed to begin the logarithmic growth phase before the addition of inducer, pRMC2-
PhERI and pRMC2-TwortORF65 containing cells exhibited an incomplete arrest of cell 
growth (Fig 4.2 a (orange and purple curves respectively) and b (orange curve)).  While 
doubling times were significantly longer, the cells continued to divide, albeit slowly, and 
I saw no evidence for cell lysis or death.    
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Figure 4.1: pRMC2 vector used for in vivo expression of PhERI. 	

a) Schematic view of pRMC2 showing the genes and cloning sites on the 
plasmid.  b) pRMC2 has reduced leaky expression of the cloned gene.  A 
previous Sau expression vector pALC2073, shows expression of the cloned 
protein.  Lysates were applied to a membrane and an antibody specific to the 
cloned protein was used to detect protein expression.  pRMC1, of which 
pRMC2  is  a  derivative,  shows  no  evidence  of  leaky  expression  of  the 
protein.  Adapted from Corrigan and Foster, 2009.	
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Figure  4.2  (adjacent  page).   PhERI  expression  in  Sau  cells  inhibits  cell 
growth. a) PhERI and Twort ORF65 were cloned into the Sau expression 
vector pRMC2 and transformed into Sau RN4220 cells by electroporation.  
Cells containg pRMC2-PhERI or empty pRMC2 were grown in TS media 
containing chloramphenicol  (25μg/ml).     PhERI/ORF65 expression was 
induced by adding 100ng/ml anhydrotetracycline at the time indicated by 
the arrow and bacterial growth was monitored by the OD600.  b) PhERI 
does not fully inhibit cell growth.  When PhERI expression is induced at the 
beginning of the culture (as indicated by the blue arrow), no cell growth is 
evident.  However, inducing PhERI expression after cells have entered the 
exponential  growth phase  (as  indicated  by the  orange arrow and orange 
curve), cell growth is inhibited compared to normally growing cells (green, 
blue  and  red  curves)  but  not  completely.   c)  Cells  as  grown  for  the 
subsequent  RNA-seq experiments.   To purify  cellular  RNA for  genomic 
analysis, RN4220 cells containing empty pRMC2 or pRMC2-PhERI were 
grown and inducer was added at an OD600 of 0.2 (red arrow).  Cells were 
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PhERI inhibits rRNA synthesis in vivo 
  I first wanted to test whether PhERI is a direct inhibitor of RNAP activity at the 
rrn promoters in vivo.  rRNAs are the most abundantly expressed RNAs in prokaryotic 
cells and are therefore excluded from both microarray and RNA-seq analyses.  Because 
of their abundance, the 16s and 23s rRNAs can be easily visualized on a standard agarose 
or polyacrylamide gel stained with ethidium bromide (Fig 4.3a).   
 To test the impact of PhERI expression on rRNA abundance in cells, I added 
inducer to pRMC2-PhERI containing cells in early-growth phase (OD600 = 0.2) and took 
aliquots of cells at different times after induction.  Cellular RNA was purified from 2x108 
cells using the RNA-easy kit (Qiagen) adapted for high-yield purification from Sau cells.  
rRNA levels in Sau cells expressing PhERI do not significantly decrease even 
hours 4 hours after the addition of inducer (Fig 4.3a).  While mRNAs are generally short-
lived in prokaryotic cells, with a half-lives on the order of minutes, structured RNAs such 
as rRNAs are quite stable (Deutscher, 2003).  The lack of depletion of rRNAs in pRMC2-
PhERI cells could be because PhERI is not inhibiting rRNA synthesis in vivo or because 
rRNAs that have been produced prior to the expression of PhERI remain stable in Sau 
cells.   
To differentiate between these possibilities, I used metabolic labeling to 
specifically visualize nascently transcribed RNA molecules. Adding radiolabeled 
inorganic phosphate to the growth medium causes radioactivity to be incorporated into all 
cellular nucleic acids within minutes.  Because labeling is performed with P32, 
radiolabeled transcripts can be separated by electrophoresis and visualized by standard 
techniques on a phosphoimaging screen (Wade et al., 1964).  
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Figure 4.3: PhERI expression inhibits rRNA synthesis in vivo. a) PhERI 
expression does not reduce rRNA concentrations in Sau cells.  Cells were 
collected at different time points before and after the induction of PhERI 
expression.  b)  PhERI inhibits new rRNA synthesis.  Inducer was added to 
Sau RN4220 cells  containing pRMC2 or pRMC2-PhERI,  and new RNA 
synthesis labeled by subsequent the addition of P32 to the growth media. 
RNA was purified from 2x108 pRMC2 and pRMC2-PhERI cells, run on a 
6% Urea-PAGE gel,  stained  with  GelRed  to  visualize  all  RNAs b)  and 
exposed to a phosphoimaging cassette to visualize newly synthesized RNA 
c).   d)  Bulk  RNA yield  was  quantified  using  a  NanoDrop  and  newly 
synthesized  RNA  by  quantifying  the  16s  and  23s  rRNA  bands  on 




I added inducer to pRMC2 and pRMC2-PhERI cells at early log-phase (OD = 
0.2), allowed 20 minutes for PhERI to be expressed, and labeled nascently transcribed 
RNAs by addition of inorganic P32 to the growth media for 20 minutes.  2 x 108 cells 
were collected from the pRMC2 and pRMC2-PhERI strains and RNA was purified as 
described above.  Total purified RNA was run on a 6% Urea-PAGE gel and visualized 
both by ethidium bromide staining (Fig 4.3b) and by autoradiography (Fig 4.3c).  While 
the levels of RNA were unchanged between the cells expressing PhERI and those 
containing empty vector (Fig 4.3b), as visualized by the ethedium bromide staining and 
nano-drop quantification of total purified RNA (Fig 4.3d), nascent rRNA synthesis was 
significantly attenuated in the cells expressing PhERI (Fig 4.3c and e).  This indicates 
that while rRNAs are not significantly depleted in cells expressing PhERI, PhERI does 
inhibit the synthesis of new rRNAs by Sau RNAP.  This is consistent with the direct 
inhibition I showed at rrn promoters in vitro.  
 
RNA-seq analysis in Sau 
Gene chip analyses have been used extensively in Sau to test the differential 
expression of all genes in the genome under various conditions (Hubscher et al., 2007; 
O'Neill et al., 2009; Truong-Bolduc et al., 2011). While microarrays have become 
standard in Sau, I decided to use a relatively new technology: RNA-seq.  The first RNA-
seq analysis in Sau was published only after we began our analysis (Felden et al., 2011).  
In both RNA-seq and genechip analyses, RNA is purified from cells and a cDNA 
library is prepared.  Genechip technology tests the relative expression between the 
samples by annealing the library prepared from cells to DNA fragments immobilized on a 
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microchip. RNA-seq also requires a cDNA library. Once the library has been prepared, 
the samples are sequenced directly using Illumina technology.  The output from RNA-seq 
technology is short sequences that can be mapped to unique locations in the genome.  The 
number of sequences mapping to an individual location give the relative expression levels 
of that RNA in the original sample.   
In addition to the relative expression levels between samples, which are provided 
in genechip analyses, RNA-seq provides additional layers of information.  Regions with 
sufficient read coverage actually provide information about the genome sequence. SNPs 
can be mapped, both between samples and between the samples and a reference genome.  
As opposed to traditional genechip technologies, RNA-seq gives information for the 
expression levels over the entire length of the mRNA, including non-coding 5’ and 3’ 
UTRs.  RNA-seq has been used, with additional preparation steps, to map promoter start 
sites (Mendoza-Vargas et al., 2009) and to locate RNAP binding sites on a genome-wide 
scale (Churchman and Weissman, 2011).  RNA-seq technologies provide not only the 
ability to compare the expression of the same mRNA between two samples, but also 
information about the relative levels of expression of different mRNAs within samples.  
The added data provided by RNA-seq proved useful when identifying promoter 
sequences in the Sau genome and evaluating which promoters may be well suited for 
further study in vitro.  
 
Sample preparation and validation for RNA-seq analysis 
To prepare the samples for RNA-seq, I purified RNA from Sau cells, as described 
above. Cells were grown to early log phase (OD600 = 0.2) and inducer was added.  Cells 
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were then collected at OD600 = 0.4 and RNAs were immediately stabilized by adding 
BioStabilize (Fig 4.2c) (Qiagen).  Cells were then lysed as described above and RNAs 
purified by the RNeasy kit.  Cellular RNA was checked for degradation by 
electrophoresis on an agarose gel, where the intact 23s and 16s rRNA bands can be 
visualized (Fig 4.4a).  To prepare the samples for RNA-seq, rRNAs must be removed as 
they constitute the vast majority of the sample and can overwhelm the sequencing results.  
This is easily achieved in eukaryotic samples through an amplification step selecting for 
poly-A containing mRNAs.  Prokaryotic mRNAs do not contain poly-A tails; therefore 
rRNAs must be physically removed from the sample.  A recently developed kit uses 
immobilized oligos complimentary to the conserved 23s and 16s rRNA sequences to 
anneal to the large rRNAs in the sample and allow all other cellular RNAs, including the 
mRNAs, to flow through (Fig4.4b).    
After this step, cellular RNA was examined on a bioanalyser chip (Fig 4.4b), 
which separates nucleic acids by size similar to standard gel electrophoresis, but allows 
the visualization of very small amounts of DNA or RNA.  While it appeared that our 
rRNA depleted sample contained very little nucleic acid by nanodrop, there is clear 
evidence for a band on the bioanalyser chip corresponding to RNAs of roughly 200 bases 
(Fig 4.4b).  The rRNA removal kit does not remove the 5s rRNA, tRNAs or other 
abundant, but small, cellular RNA species.  This band at 200 bases likely corresponds to 
these cellular RNA species, while the mRNA in the sample correspond to the less 
abundant smear above this band.  At this point, we decided to prepare a cDNA library 
using the standard random-primed PCR technique used for mRNA enriched eukaryotic 
samples (Fig 4.4c).  The sample preparation, sequencing, sequence alignment and 
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Figure 4.4 (adjacent page):  RNA purification and sequencing strategy.  a) 
Total  cellular  RNA was  purified  from Sau  cells  expressing  PhERI,  and 
control  cells  containing empty vector.   RNA quality was assessed on an 
agarose gel by visualizing the intact 16s and 23s rRNA bands.  b) rRNA 
reduction was performed using standard procedure to  remove the highly 
abundant  16s  and  23s  rRNAs  prior  to  sequencing.   RNA quality  was 
assessed by running the samples on a BioAnalyzer.   c)  RNA-seq cDNA 
libraries were made by standard procedures and RNA quality was assessed 
by running the samples on a BioAnalyzer.  d) cDNA libraries were analyzed 
for the presence of PhERI mRNA, which should only be present in cells 
containing pRMC2-PhERI.  A PCR was performed using primers to amplify 
a 100bp fragment of PhERI from the RNA-seq library prepared from cells 
containing pRMC2 (lane 3) and pRMC2-PhERI (lane 4). e) Total PhERI 
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analysis were done in close collaboration with the Genomics Resource Center at The 
Rockefeller University.  Connie Zhao and Scott Dewell were both essential at every stage 
of the RNA-seq sample preparation and data analysis.   
Because standard cDNA library preparations are not generally performed with 
prokaryotic samples, I decided to check the mRNA levels in our cDNA library by non-
quantitative PCR.  The mRNA encoding for PhERI should only be present in the cells 
containing pRMC2-PhERI and absent in the cells containing the empty pRMC2 vector. I 
amplified an approximately 100bp fragment of PhERI from each prepared library, as well 
as from a prokaryotic expression plasmid containing the gene for PhERI.  A strong band 
was amplified only from the library prepared from cells containing pRMC2-PhERI (Fig 
4.4d lane 4), and not from control cells containing pRMC2 only (Fig 4.4d lane 3), 
confirming that the cDNA libraries do indeed contain cDNA corresponding to cellular 
mRNA and the samples differ predictably.   
 The two cDNA libraries were then sequenced directly by RNA-seq on an Illumina 
HiSeq2000 for 51 cycles using the standard protocols.  Raw data was processed using 
SCS/RTA software to yield 51bp reads and subsequently aligned to the Sau NCTC 8325 
genome using TopHat.  We aligned to the NCTC 8325 genome, as opposed to using the 
genome for the strain we used, RN4220, because the quality of genome sequence is much 
higher, it differs from RN4220 in coding regions only by 121 SNPs, it is more fully 
annotated and is available in a downloadable format suitable for subsequent analyses.  
We also performed a search for reads corresponding to PhERI mRNA.  Confirming the 
result from the PCR analysis of the cDNA libraries, only 47 total reads mapped to the 
PhERI mRNA in the cells containing pRMC2, while 17403 reads mapped to PhERI from 
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the pRMC2-PhERI library (Fig 4.5e).  The RNA-seq data provided extremely good 
coverage, in part due to the relatively small size of the Sau genome compared to 
eukaryotic samples.  Alignments reported from TopHat were processed by the Cufflinks 
software package (Trapnell et al., 2010) to determine differential expression of genes and 
transcripts between conditions. 
 
RNA-seq analysis of differential gene expression by PhERI 
 An analysis of the differences in expression between control cells and cells 
expressing PhERI confirms that very few genes are expressed at significantly different 
levels between the two samples (Fig 4.5a).  Importantly, the promoters I previously tested 
for PhERI activity in vitro (dnaA, aag, polIII) showed no significant differences between 
the two samples in vivo (Fig4.5b).  The promoters that have been studied in vitro in 
previous work (Deora and Misra, 1996; Rao et al., 1995; Reynolds and Wigneshweraraj, 
2011) also showed no difference in expression levels between cells expressing PhERI and 
control cells (Fig 4.6). Furthermore, these transcripts exhibited low levels of expression 
in log-growing cells, illustrating that while they may be important for the transcriptional 
switch to pathogenic growth, they are not useful tools to determine the mechanisms of 
transcriptional regulation under general growth conditions.   
 The Cufflinks software gives an output of all genes differentially expressed 
between samples.  The statistical analysis evaluates expression levels and data quality at 
all loci to evaluate the probability of significant differential expression.  In the analysis 
performed by Cufflinks, genes differentially regulated by 3 or more fold were found to be 
significant, when the data quality and number of reads were sufficient.  By this analysis, 
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Figure 4.5 (adjacent page): RNA-seq reveals promoters sensitive to PhERI 
inhibition  in  vivo.   a)  PhERI  expression  in  Sau  RN4220 cells  does  not 
inhibit RNA levels from 95% of promoters.  RNAs were sequenced directly 
and  visualized  by  Integrated  Genomics  Viewer  (IGV).   Position  on  the 
genome is shown on the horizontal axis and the number of RNA reads per 
million  total  reads  is  shown  on  the  vertical  axis.   Upper  panel  (green) 
represents  RNA-seq data  from pRMC2-PhERI cells  and the lower  panel 
(red)  represents  RNA-seq  data  from  control  pRMC2  cells.   b)  PhERI 
expression does not inhibit transcription from DNA replication promoters in 
vivo. RNA-seq data visualized as above from the dnaA, aag, and polIII loci.   
c) Genes negative regulated by PhERI in vivo. RNA-seq data visualized as 
above from the cold shock protein 1 (csp1), cold shock protein 2 (csp2), and 
pstp  loci.  PhERI  inhibits  transcription  in  vitro  from  promoters  that  are 
susceptible  in  vivo.   In  vitro  transcription  assays  were  performed  as 
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Figure 4.6: PhERI does not affect RNA levels at the agr promoters. RNA-
seq data showing RNA levels at the agr operon in the absence (lower panel, 




fewer than 4% of all genes were repressed by PhERI expression (Table A.1a), while a 
further 5% were upregulated by PhERI (Table A.1b).  More than 90% of transcripts were 
not differentially regulated by PhERI, confirming that most group 1 σ dependent 
promoters are not affected by PhERI.  Again, this is consistent with a model in which 
PhERI does not disrupt essential functions of σA4.  In particular, this data is inconsistent 
with a model in which PhERI blocks -35 element recognition by σA4 because this would 
lead to repression of a large fraction of the -10/-35 promoters that do not contain other 
sequence elements (such as an extended -10 element).   
 The RNA-seq analysis only reveals RNA transcript levels, it does not differentiate 
between direct and indirect regulation of gene expression, nor does it reveal whether 
differential gene expression is due to changes in promoter binding and initiation or 
mRNA stability. To evaluate whether PhERI directly affects transcription at sensitive 
promoters identified using RNA-seq, I tested hits using the Sau in vitro transcription 
system.  
mRNA processing enzymes can remove 5’ and 3’ UTRs from mRNAs in cells.  
Mapping promoter start sites requires enriching for primary transcripts that have not 
undergone processing in vivo (Mendoza-Vargas et al., 2009). For our analysis, I 
sequenced mRNAs from cells without subsequent enrichment for primary transcripts.  
Much of our RNA-seq data shows evidence of processing, with RNA-seq reads mapping 
to just upstream of the start codon for many predicted genes (Figure 4.7a).  Generally, 
there is no putative promoter element immediately upstream of these transcripts (Figure 
4.7a), arguing that the transcription start site is further upstream and the mRNA has been 
processed in vivo.  However, some mRNAs in our data show clear evidence for a long 5’ 
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Figure  4.7:   RNA-seq data  aided in  the  identification of  Sau promoters.  
While  many  genes  had  mRNAs  with  clear  evidence  of  processing  by 
cellular enzymes (RNA-seq reads beginning at or near the start codon, with 
no evidence of a promoter sequence upstream of the start codon), a subset of 
genes showed clear RNA-seq reads in a 5' UTR.  Several of these genes 
contain  a  promoter  sequence  (-35  and  -10  elements  highlighted  in  red) 
upstream  of  the  location  where  RNA reads  begin  mapping  to  the  Sau 
genome.  	





UTR (Figure 4.7b).  Additionally, many of these transcripts have strong putative 
promoters just upstream of the mapped 5’ end of the mRNA (Figure 4.7c).  This 
information is not generally provided by microarray analysis that contains only 
information about RNA expression in the coding region.  
Likely candidate genes for PhERI inhibition assays in vitro had three 
characteristics: 1) High expression in the absence of PhERI (therefore likely downstream 
of a strong promoter); 2) High level of repression upon PhERI expression and 3) RNA-
seq guided promoter identification, as described in the previous paragraph (Fig. 4.7).  
Csp1, Csp2 and PSTP were identified as repressed in vivo by the expression of 
PhERI by the above analysis.  When I tested these three promoters in vitro,  there was 
clear evidence for inhibition by PhERI (Fig 4.5c).  This inhibition was dependent on the 
interaction between PhERI and σA4 as holoenzyme containing the σA mutant deficient in 
PhERI binding was not affected.  These data demonstrate that, at least at these 3 
promoters, the depletion of cellular mRNA identified through the RNA-seq analysis is 
due to a direct inhibition of RNAP activity at the promoter.  In addition to the rrn 
promoters shown in the previous chapter to be inhibited by PhERI, these promoters 
provide additional information to make hypotheses about the promoter elements that 
drive PhERI specificity. 
 
PhERI inhibition of Sau cell growth 
 The RNA-seq data provide a comprehensive analysis of all transcripts regulated 
by the expression of PhERI.  I purified RNA from cells expressing PhERI after the 
growth inhibition had begun and therefore the factor(s) leading to cell growth arrest 
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should be evident in our data.  I show that PhERI inhibits rRNA synthesis in vivo (Fig 
4.3) through direct regulation of RNAP activity at the rrn promoters (Fig 3.6). Inhibition 
of rRNA synthesis is a key regulatory step in the switch from logarithmic growth phase 
to stationary phase.  rRNA synthesis therefore can directly regulate the rate at which 
prokaryotic cells divide (Gourse et al., 1996).  Although PhERI’s growth inhibition in 
cells is likely due to its activity at rrn promoters, it could be acting through the repression 
of gene expression of another required factor for cell division.   
 Recently published work used a combination of screening and genetic validation 
to identify a comprehensive list of required genes in Sau (Xu et al., 2010).  The analysis 
was focused on identifying novel targets for small molecule inhibitors, and known drugs 
indeed do target many of the ORFs identified.  
rRNA genes and other protein and RNA factors required for translation were 
found to be essential for normal cell growth in Sau (Xu et al., 2010), highlighting the 
important role of robust translation for logarithmic cell growth. 81 of the 308 (27%) 
genes found to be required for growth were related to translation.   
 I cross referenced all the genes shown to be downregulated by the expression of 
PhERI with the comprehensive list of all genes known to be required for cell growth in 
Sau.  Only seven mRNAs downregulated by PhERI are essential, three of which (serS 
and pheS, tRNA synthetases, and rpsE, a ribosomal protein) are required for translation.  
Another recent paper showed that the regulation of RNAP activity at the promoters for 
ribosomal proteins is similar to that of the rrn promoters (Lemke et al., 2011) indicating 




Three additional downregulated genes are involved in metabolism and 
biosynthesis: glucose 6-phosphate isomerase (pgi), required for glycolysis; accB, 
required for fatty acid biosynthesis; and glutamine synthetase (glnA).  The final gene is 
annotated as a putative mRNA degredation and processing factor, RNaseJ1/J2.  Given 
that rRNA synthesis is known to directly regulate cell division in other organisms, that 
the inhibition of rRNA synthesis is known to be a direct effect of PhERI, and that only 4 
required genes are downregulated by PhERI in vivo that do not directly affect translation, 
I conclude that PhERI blocks Sau cell division by inhibiting the rrn promoters directly.    
 
Genes Upregulated by PhERI 
 I generally focused my analysis on genes found to be downregulated in PhERI 
expressing cells.  PhERI was identified as a transcriptional inhibitor and my work focuses 
on defining the mechanism of that inhibition.  However, in the high throughput in vivo 
analysis, more genes were stimulated by PhERI’s presence than repressed.  The 
upregulation of mRNAs by PhERI could be a direct effect on RNAP activity at promoters 
or an indirect effect of the repression of transcription at other promoters.  In Eco, the 
downregulation of RNAP activity at rrn promoters frees a large concentration of RNAP; 
promoters, in particular the amino acid biosynthesis promoters, are directly sensitive to 
the concentration of free RNAP.  Therefore, when the cellular concentration of RNAP 
increases due to decreased expression of rRNAs, transcription at these promoters is 
stimulated (Barker et al., 2001a).   
 Among the genes upregulated in the presence of PhERI are three phosphate 
transporters.  My data from this chapter showing that PhERI is a direct repressor of rRNA 
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transcription in vivo relies on metabolic labeling.  Radiolabled inorganic phosphate is 
added to the media, which cells import and incorporate into their nucleic acids.  A 
decrease in phosphate transport, therefore, could explain the decrease in radioactive 
signal incorporated into the rRNAs in the cells expressing PhERI.  However, the opposite 
is the case: phosphate transporters are upregulated in cells expressing PhERI and yet the 
radioactive signal indicating nascent rRNA transcription has decreased.  This data 
supports the hypothesis that the decrease in signal for nascently transcribed rRNAs is due 
to a genuine and direct inhibition of RNAP by PhERI at the rrn promoters.   
 Inhibition of transcription at rRNA promoters is an important step in the stringent 
response as cells progress to stationary phase.  Work in Eco shows that promoters 
regulating amino acid biosynthesis are directly regulated by the increased concentration 
of RNAP due to inhibition of rRNA synthesis. Among the genes upregulated by the 
expression of PhERI are several amino acid biosynthesis genes, which are indirectly 
upregulated by rRNA repression in Eco (Table A.1b).  Recent work examined the global 
transcription changes in Sau induced by the small molecule Mupirocin, which induces the 
stringent response.  In addition to the upregulation of amino acid synthesis related genes, 
genes for cellular transport processes were also upregulated (Reiss et al., 2012).  I find 
evidence for upregulation of transport processes upon the induction of PhERI expression 
(Table A.1b). This indicates that PhERI inhibits rRNA synthesis in vivo, and therefore 
indirectly stimulates transcription at other promoters, and that regulation of the switch 
between log-growing cells and cells at stationary phase may have some conserved 
elements between Eco and Sau, including the indirect upregulation of amino acid 




Comparison of relative gene expression between Sau strains 
Unlike microarray transcriptome analysis, RNA-seq provides information about 
relative expression of different genes throughout the genome.  I used the RNA-seq data 
from all genes in the Sau genome to evaluate which genes are most highly expressed in 
log-growing cells.  Recent work has examined the genomic differences between the 
commonly used, electroporatable Sau strain RN4220 (Nair et al., 2011) and its parent 
strain NCTC8325-4 (O'Neill, 2010). NCTC8325-4 differs from the fully sequenced 
NCTC8325 by the curing of 3 phage infections (O'Neill, 2010).  To evaluate the 
transcriptional differences between NCTC8325-4 and RN4220, and to ensure that 
RN4220 carrying an empty expression vector was not misrepresentative of baseline 
transcription in NCTC8325-4, we sequenced RNA purified from NCT8325-4 cells 
containing no expression vector.  
I evaluated the levels of gene expression in NCTC8325-4 and RN4220.  Among 
the 100 most highly expressed genes, none differed significantly in expression levels 
between these two strains (Table A.2).  Similarly, among the genes with no evidence for 
RNA-seq reads, none differed between the two.  
Among the 100 most highly expressed genes in RN4220 and NCTC8325-4, the 
majority (62) were ribosomal proteins or proteins otherwise involved in translation (the 
30 most abundant mRNAs in RN4220 and NCTC8325-4 are shown in Table A.2).  This 
is in good agreement with the observation that log-growing prokaryotic cells expend most 
of their transcriptional resources on maintaining the translational machinery.  Other 
highly expressed mRNAs corresponded to genes for gylcolysis and sugar metabolism 
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(12), fatty acid biosynthesis (6), chaperones (3), transcription/transcription regulation (3), 
and redox regulation (3).  9 of the 100 most abundant mRNAs were for conserved 
proteins of unknown function.  The remaining 2 genes were a GTPase required for cell 
division and protein translocase.   
An additional 212 genes, mostly of unknown function, had no evidence for RNA-
seq reads in either NCTC8325-4 or RN4220.  Whether any of these genes are upregulated 
as cells enter stationary phase, or respond to cellular stress signals, is unknown but could 
potentially be evaluated by sequencing RNA from cells under various conditions.   
 
Analysis of Single Nucleotide Polymorphisms between RN4220 and NCTC8325-4 
The genome of RN4220 was recently sequenced (Nair et al., 2011). In the genome 
sequence of RN4220, SNPs were identified that differ from NCTC8325 and NCTC8325-
4.  The authors suggested that RN4220 may be deficient in factors required for normal 
cellular responses to stress and virulence regulation (Nair et al., 2011).  Additional work 
characterized SNPs in NCTC8325-4 relative to NCTC8325 (O'Neill et al., 2009).  
Through our RNA-seq analysis, we can identify SNPs in both the NCTC8325-4 and the  
RN4220 transcriptome, and map these SNPs to the NCTC8325 genome.  
NTCT8325-4, as analyzed by O’Neill (2010), was found to differ from the 
NCTC8325 genome at 12 locations, and RN4220 had 121 SNPs, including those 
previously identified in NTCT8325-4.  However, there is clear evidence for SNPs 
identified as unique to RN4220 in NCTC8325-4 (Figure 4.8 c-e).  Importantly, SNPs 
known to be unique to RN4220 and to cause functional differences between these two 
strains, such as the frame shift in the virulence transcriptional regulator AgrA (Figure 
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Figure  4.8  (adjacent  page):  Single  nucleotide  polymorphisms  (SNPs) 
between  RN4220  and  NCTC8325-4.   a)  A previously  identified  single 
nucleotide insertion at the c-terminus of the AgrA gene causes a frame shift 
mutation.  The blue bars indicate the single nucleotide deletion, which is 
present  only  in  RN4220  cells.   RNA-seq  data  was  visualized  by  the 
Integrated  Genomics  Viewer  (IGV).   b)  The  previously  identified  non-
synonmyous SNP in the UvrC gene is found only in RN4220 cells and not 
NCTC8325-4  cells.   c)  A SNP in  the  GroEL gene  that  was  previously 
identified in RN4220, but not NCTC8325-4, is identified in both strains.  d) 
A SNP in the EzrA gene that was previously identified in RN4220, but not 
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4.8a) and the DNA repair factor UvrC (Figure 4.8b), are found only in RN4220.  
However, the SNPs in GroEL (Figure 4.8c), RimM (Figure 4.8d), and EzrA (Figure 
4.8e), which the authors of the genome sequence of RN4220 argued may effect the 
fitness of this strain (Nair et al., 2011), were found in the ancestral NCTC8325 genome as 
well as in RN4220.  Roughly half of the additional SNPs identified as unique to RN4220 
were similarly found in NCTC8325 in our analysis, but not in the analysis done by 
O’Neill  (Table A.3a).  Subsequent to our analysis, these results were confirmed by 
resequencing the NCTC8325 genome (Berscheid et al., 2012).  These mutations (RimM, 
EzrA, MurA, and GroEL) are therefore present in the parental strain NCTC8325 and are 
not unique to either NCTC8325-4 or RN4220. Berscheid et al. further show that RN4220 
and the parental strain NTCT8325 have the same fitness levels in laboratory tests.  I 
identified five novel SNPs in NCTC8325-4 (Table A.3b) that are previously unreported. 
RNA-seq can only identify SNPs in genomic regions present in the transcriptome.  
However, many of the non-coding SNPs identified in the RN4220 genome (Nair et al., 
2011) were located in 5’ or 3’ UTRs that were covered in our transcriptome data.  I could 
therefore also identify these SNPs in our data (Figure 4.9a) and show that while some 
were unique to RN4220, others were also found in NCTC8325 (listed in table 4.3).  Other 
SNPs were located in regions that were not covered in our analysis, and I therefore 
cannot verify their presence in RN4220.   
An additional advantage of the RNA-seq method is that sequencing reads 
correspond to a single molecule of RNA purified from cells.  Therefore, not only can 
SNPs be mapped to individual locations in the genome, but heterogeneity at 
chromosomal locations is also apparent (Figure 4.9b).  At some locations where a SNP 
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Figure  4.9:  RNA-seq  reveals  SNPs  in  5’  and  3’  UTRs  as  well  as 
heterogeneity within the genomic sample.  a) RNA-seq data provided strong 
coverage of many 5’ and 3’ UTRs, allowing us to unambiguously map SNPs 
in  these  regions.   SNPs  A-2244467-G,  G-2244495-A are  shown  in  the 
NCTC8325-4  RNA-seq  data.   b)  Heterogeneity  in  the  RNA-seq  data.  
Individual  sequencing  reads  correspond  to  a  single  molecule  of  cellular 
RNA, allowing the visualization of heterogeneity at genetic loci.  Here we 
show that previously identified SNPs (292179 and 292199) in RN4220 are 
not only present in NCTC8325-4, but are a heterogeneous mix of wild type 






was reported in RN4220 but not NCTC8325-4, there is genetic variation in NCTC8325-
4; most reads contain the wild type nucleotide, but the mutation in RN4220 is also 
present.  This argues that RN4220 gained mutations that were present in NCTC8325-4 at 
low frequency either due to selective forces or, more likely, due to bottleneck effects.   
 
RNA-seq reveals differential gene expression between two Sau strains 
The authors of the RN4220 genome sequence argue that the SNPs that differ 
between the strains may cause functional differences in cellular responses to stress and to 
the switch to virulent growth (Nair et al., 2011).  Subsequent work showed that the 
RN4220 and the parental strain NCTC8325 have similar fitness levels in laboratory 
conditions (Berscheid et al., 2012). Because RN4220 is electrocompetent and capable of 
being transformed by expression plasmids, it is well suited to genetic analysis and 
laboratory studies (Schenk and Laddaga, 1992).  To examine the differences in gene 
expression between the two strains, we sequenced the transcriptome of NCTC8325-4 
cells growing in the absence of plasmid or antibiotic used for selection.  I then compared 
gene expression between NCTC8325-4 cells and RN4220 cells containing pRMC2 and 
selected by addition of chloremphencol to the growth media.  While the genomes of all 
these strains have been sequenced and examined for genomic variations (Berscheid et al., 
2012; Iandolo et al., 2002; Nair et al., 2011; O'Neill, 2010; Ohta et al., 2004), 
transcriptional differences have not been examined to our knowledge.   
35 genes were found to be differentially expressed between these two Sau strains, 
representing 1.5% of all genes (Table A.4) by the Cufflinks software described above.  
To validate the technique for transcriptome comparisons between the two strains, I 
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examined a previously described transcriptional difference. RN4220 has a mutation in the 
AgrA gene that causes a frame shift near the C-terminus of the protein (Figure 4.8a).  
This mutation is known to cause disregulation of RNAIII; cells containing the AgrA 
mutation show a delayed upregulation of RNAIII, which is a key regulator in the switch 
to virulent growth (Traber and Novick, 2006).  Only four genes are significantly 
downregulated in RN4220 compared to NCTC8325-4 cells (Figure 4.10) (Table A.4a).  
RNAIII is one of these genes, in agreement with the previous data on the mutation in 
AgrA (Traber and Novick, 2006).  These data show the power of RNA-seq compared to 
other methods for transcriptome analysis: in one set of data I can identify both the SNP in 
AgrA that alters its function and the downregulation of RNAIII that is a direct result of 
this mutation.  RNAIII is the most highly repressed gene in RN4220 compared to 
NCTC8325-4, arguing for the importance of the mutation in AgrA for regulation at this 
locus.   
The other three downregulated genes in RN4220 are an acetoactate synthase, 
which catalyzes the formation of 2-acetolactate from pyruvate during stationary phase 
and an alpha-acetolactate decarboxylase from the same operon.  The final downregulated 
gene encodes a protein of unknown function.  Interestingly, four SNPs identified in the 
RN4220 genome (A-2244467-G, G-2244495-A, and deletions of C-2244932 and T-
2244933) all cluster around this gene (2244539-2244724).  These mutations were 
identified in the RN4220 genome sequence, but I see clear evidence for their presence in 
NCTC8325 genome (Figure 4.9b). The function of this gene, and of these mutations, are 











































Figure  4.10:RNAIII  is  downregulated  in  RN4220  compared  to 
NCTC8325-4.   RNA-seq  reads  mapping  to  the  gene  for  RNAIII  from 
NCTC8325-4  (upper  panel),  RN4220-pRMC2  cells  (middle  panel)  and 
RN4220 cells  expressing PhERI (lower panel).  The previously described 
frameshift  mutation in  AgrA has been shown to delay the expression of 
RNAIII in RN4220 cells.  In one data set, we are able to visualize the SNP 





31 genes are upregulated in RN4220 carrying an expression cassette and under 
antibiotic selection compared to NCTC8325-4 cells (Table A.4b). Among these 
upregulated mRNAs, nine encode putative or confirmed ABC transporters.  This may be 
due to the addition of chloramphenicol to select for RN4220 cells containing pRMC2; 
sequencing of RNA from RN4220 cells not containing an expression vector would clarify 
if this difference is inherent to the strains or rather is a response to the addition of 
antibiotic to the growth media.  ClfB, a clumping factor, is also upregulated in RN4220.  
This could potentially compensate for the ClfA mutation previously identified in 
RN4220.    
 
Identification of a putative orphan CRISPR element in Sau 
Clustered regularly interspaced short paleidromic repeats (CRISPRs) are bacterial 
RNA elements that provide an adaptive immune response to phage infection (Marraffini 
and Sontheimer, 2010).  CRISPRs are organized in bacterial genomes with many 
interspaced repeats that create a long RNA followed by the Cas genes encoding the 
protein machinery required to process the RNA into functional units.  After processing, 
crRNAs can interact with phage or invasive DNA with sequence specificity and induce 
cleavage (Marraffini and Sontheimer, 2010).  Sau is not thought to have a functional 
CRISPR system; no genes in the Sau genome have any homology to previously identified 
Cas proteins. Genomic searches for putative CRISPR elements in the Sau NCTC8325 
genome reveal only three weak hits (Grissa et al., 2007). 
I used our RNA-seq data to determine whether RNA is being expressed at any of 
the putative CRISPR loci in Sau.  While two of the three putative CRISPR elements were 
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located in annotated ORFs, and contained no signal for an additional RNA element in our 
RNA-seq data, the third putative CRISPR was located in an intergenic region and showed 
clear evidence for RNA-seq reads (Figure 4.11).  The putative CRISPR has only one 
repeating unit and no downstream Cas genes that would be required for active crRNA 
function (Marraffini and Sontheimer, 2010).  BLAST searches for the CRISPR element 
revealed that the spacers map to several locations in the Sau genome including both 
coding and non-coding regions (Grissa et al., 2007). This element may be an orphan 
CRISPR, and that reintroduction of Cas genes into Sau may activate this putative RNA 
element.   
 
RNA-seq to screen for PhERI suppressor mutations 
RNA-seq allows gene expression and SNPs to be rapidly quantified in one dataset 
as cells respond to various stimuli.  The expression of a toxic protein, or the addition of 
drugs or antibiotics to the growth media, provides a strong selective pressure on cells to 
evade the effect of the protein or small molecule.  Recent work has illustrated how RNA-
seq can be used to identify small-molecule binding targets in eukaryotic cells (Wacker et 
al., 2012).  
To evaluate whether there are PhERI resistance mutations in our RNA-seq data, I 
searched for SNPs that were present only in RN4220 cells expressing PhERI.  In our 
data, PhERI was only induced for sufficient time to allow its expression and repression of 
Sau cell growth.  Longer expression times may allow more resistance mutations to 
accumulate.  Even with the short expression time, I identified two mutations present in 
cells expressing PhERI, whereas I identified no mutations unique to cells containing only 
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Figure 4.11:  Identification of a putative CRISPR element in Sau.  a) RNA-
seq reads mapping to an intergenic region containing a putative CRISPR 
element.  The putative CRISPR sequence is denoted by a red box.  b) View 
of  the  putative  CRISPR  element  showing  relative  expression  from 
NCTC8325-4  and  RN4220  cells.   The  putative  CRISPR  repeats  are 






empty vector.  The two mutations were both in coding regions (Figure 4.12).  One was a 
glycine to alanine mutation in the transcription elongation factor GreA (Laptenko et al., 
2003; Stebbins et al., 1995) and the other was a valine to alanine mutation in a putative 
RNaseJ protein (Figure 4.12) (Even et al., 2005; Newman et al., 2011). 
Gre factors are known to bind to RNAP and modulate its activity during 
elongation phase (Borukhov et al., 1992).  PhERI also interacts with RNAP but through 
an interaction with the Sau σ factor. It is unclear how a mutation in GreA, which has not 
been studied in Sau, may alleviate PhERI activity, but finding mutations in another 
RNAP binding protein is potentially physiologically relevant (Figure 4.13a).  PhERI does 
not significantly affect the expression levels of GreA; although GreA mRNA is roughly 
1.5 fold more abundant in cells expressing PhERI, it is not statistically significant (p = 
0.13).  
The mutation in RNAseJ may also be functionally important.  RNAseJ is a 
putative member of a family of proteins (RNAse J1/J2) required for mRNA processing 
and degradation in gram-positive organisms (Even et al., 2005). Both putative RNaseJ 
proteins in Sau are significantly downregulated by PhERI expression.  One paralog was 
found to be required for normal cell growth in Sau (Xu et al., 2010); the other paralog is 
mutated in PhERI expressing cells.  Whether this mutation (V29A) is functionally 
relevant is under investigation (Figure 4.13). A mutation increasing the activity of this 
required protein, which is downregulated by PhERI, may be particularly advantageous 
for cells growing in the presence of PhERI.   
I searched for mutations in the known binding partner of PhERI, the group 1 Sau 


































Figure  4.12:  Identification  of  SNPs  from  cells  expressing  PhERI.   a) 
Identification of 2 SNPs only present in RN4220 cells expressing PhERI 
(upper panel) but absent in RN4220 cells containing empty vector (middle 
panel)  or  NCTC8325-4  cells  (bottom  panel).   GreA (left  panel)  and  a 
putative RNAseJ1/J2 protein (right panel) both contain coding changes in 
pRMC2-PhERI cells  only.   b)  Alignment  of  the  coding change in  GreA 
(G59A) compared to  with  sequences  for  the  well  studied  GreA proteins 
from Eco and Bsub.  c)  Alignment of the coding change in the putative 
RNAseJ1/J2 protein (V29A), the other RNAseJ1/J2 paralog in Sau, and the 






Figure 4.13 (adjacent page): Structural models of the coding changes from 
PhERI expression Sau cells.  a) Crystal structure of Eco GreA.  Eco G56 
(Sau59) is highlighted in red.  b) Model of the putative Sau RNAseJ1/J2 
protein.   Model was made using modeller-v9.10 with the high-resolution 
Tth structure (pdb:3BK1) as a model. The domains are labeled (β-CASP 
domain:  yellow;  β-lactamase  domain:  blue;  C-terminal  domain:  green).  
V29 is highlighted in red.  c) Zoomed view on V29, the location of the 
mutation in PhERI expressing cells.  V29 is located in a hydrophobic pocket 
and is contacting multiple aromatic and hydrophobic residues.  d) Model of 
V29A mutation (cyan) compared to the Sau wt model (dark blue).  Multiple 
hydrophobic residues are predicted to be in alternate conformations in the 
V29A model.   e)  Structural  changes  in  the  β-lactamase  domain  upon 
binding  to  substrate.   V29  is  highlighted  in  red,  yellow  indicates  the 
structure  bound to  RNA substrate.   The  distance  between the  two beta-
strands in 12.5 in the apo enzyme, but 10.2 in the open form that is capable 
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data.  Our structural and biochemical information demonstrate that the two proteins form 
an extensive molecular interaction.  2-hybrid and biochemical data show that four 
individual mutations in combination are required in σA4 to eliminate PhERI binding. 
Mutations eliminating the interaction between PhERI and RNAP would be likely to 
completely alleviate PhERI repression of cell growth.  However, the requirement for 
multiple point mutations to eliminate the interaction and the short time that cells were 
exposed to PhERI expression possibly prevent the accumulation of mutations in rpoD.  
RNA-seq could be performed at additional times long after the expression of PhERI to 
identify additional suppressor mutations, potentially in σA.  
We demonstrate that RNA-seq is a valuable tool to examine gene expression in 
Sau.  RNA-seq provides the information that was previously accessible by microarray 
analyses in this organism plus much additional data.  I was able to identify promoters 
specifically and directly inhibited by PhERI through differential gene expression analysis 
by RNA-seq (Figure 4.5)   
High throughput sequencing provides additional information that was only 
previously accessible through using multiple, complimentary techniques.  Because 
prokaryotic genomes are generally small, and contain relatively short intergenic distances 
with limited non-coding regions, we sequence the majority of the Sau genome through 
RNA-seq analysis of the transcriptome.  We were able to identify almost all of the SNPs 
previously found in RN4220, including 23/26 that were in non-coding regions.  RNA-seq 
has become increasingly cost effective and the sample preparation has been standardized 
for eukaryotic cells. I believe similar standardization of RNA-seq for prokaryotic 
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samples, and routine transcriptome analysis using high-throughput sequencing provides a 




PhERI Inhibits RNAP at rrn Promoters 
 by Blocking UP-element Binding 
 
 The structural, biochemical and genomic analyses all show that most -10/-35 
promoters are not affected, positively or negatively, by PhERI expression.  These 
complimentary methods provide data demonstrating that PhERI does not inhibit the 
normal functions of σA4.  How, then, does PhERI inhibit Sau RNAP at certain promoters, 
and how does PhERI discriminate between promoters that will be inhibited and 
promoters that will not be affected? 
 In this chapter, I will detail our mechanistic studies to understand the function of 
PhERI.  Using the DNA sequences identified in chapters three and four, I will show that 
PhERI specifically targets Sau promoters containing an A/T-rich UP-element upstream of 
their -35 element.  While PhERI binds to RNAP holoenzyme at all promoters, it blocks α-
CTD binding to the UP-element and therefore only inhibits promoters dependent on this 
interaction for robust transcription, including the rrn promoters.  PhERI is not an anti-σ 
factor in the classical sense. PhERI is a phage encoded transcription factor that inhibits 
host RNAP in a targeted manner through a novel mechanism.  While it joins the RNAP 
holoenzyme through its interaction with σA4, it modulates RNAP activity through an 
interaction with promoter DNA and another RNAP domain. These results will be 
discussed in the context of their importance in the phage life cycle, Sau transcriptional 




PhERI does not modulate the stability of Open Promoter Complexes 
 The rrn promoters have been extensively studied in Eco.  Because of their 
important role in the switch from logarithmic growth to stationary phase, the rrn 
promoters are extensively regulated by extrinsic factors as described in Chapter 1.  While 
most promoters form stable OPCs, rrn promoters form characteristically unstable OPCs.  
The stability of OPCs is rate-limiting for these promoters, and therefore proteins and 
small molecules (DksA and ppGpp respectively) that modulate the stability of the OPC 
can dramatically affect output from rrn promoters but not other -10/-35 promoters.  DksA 
and ppGpp show a reproducible effect on OPC stability at all promoters but specifically 
affect transcription at rrn promoters due to their special properties (Barker et al., 2001b; 
Paul et al., 2004).  I hypothesized that PhERI could inhibit the rrn promoters but not most 
-10/-35 promoters by modulating the stability of the OPC; I therefore tested the OPC 
stability in the presence and absence of PhERI at the promoters that I described in 
Chapter 3. 
 PhERI has no significant effect on OPC stability on any promoter tested (Fig 5.1).  
Importantly, I find that rrn promoters in Sau are quite unstable (Fig 5.1d) compared to 
other promoters tested (Fig 5.1 b and c).  The half-lives (t1/2) of the rrnA promoter was 
only 28 and 23 seconds in the presence and absence of PhERI, respectively.  The aag 
promoter had a half-life of minutes (4.5 minutes and 3.1 minutes in the presence and 
absence of PhERI, respectively) while the phage G1-pPhERI promoter had an extremely 
stable half-life (24 minutes in the absence of PhERI and 23 minutes in the presence of 
PhERI).  If PhERI were decreasing the stability of the OPC, one could explain its narrow 
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Figure  5.1  (adjacent  page):  Figure  5.2:  PhERI  does  not  modulate  the 
stability of Open Promoter Complexes (OPCs).  a) Schematic of the OPC 
stability  assay.   Briefly,  OPCs  were  formed,  after  which  they  were 
challenged with the addition of excess the dsFullCon promoter fragment.  At 
different times after the addition of challenge, reactions were started by the 
addition of NTPs or pipetted onto a filter paper.  In either case, the signal 
represents the amount of RNAP bound to promoter after the challenge.  b) 
PhERI does not  alter  the stability  of  RNAP OPCs on the aag promoter. 
OPCs were monitored by transcriptional output and visualized on a 12% 
Urea-PAGE gel (right panel).  Bands were quantitated, normalized to time 0 
and plotted (left panel).  c) PhERI does not modulate the OPC stability of 
the G1 phage pPhERI promoter.  OPCs were monitored using P32 labeled 
linear  DNA in  a  filter  binding  assay.   d)  PhERI  does  not  modulate  the 
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spectrum of inhibition and the apparent absence of a DNA sequence unique to PhERI 
sensitive promoters.  However, it does not appear that PhERI functions by modulating 
OPC stability at Sau promoters.   
 
PhERI inhibits transcription from promoters containing an A/T-rich sequence 
upstream of the -35 element 
 Because PhERI is unlikely to block -35 element recognition, we hypothesized that 
other DNA elements may confer susceptibility to PhERI inhibition.  I aligned all 
promoters tested in vitro for direct PhERI activity by their -10 and -35 elements (Fig 5.2).  
The sensitive promoters do not share an obvious common sequence, but contain an A/T-
rich region upstream of their -35 elements (80 – 100% A/T-rich in the region expected 
for an UP-element), whereas this feature was less prominent in promoters resistant to 
PhERI inhibition (65% A/T-rich, similar to the A/T content of the entire Sau genome, 
which is ~67%; Figure 5.2).  
To test whether the region upstream of the -35 element was important for PhERI 
function, I constructed hybrid promoters that swapped the DNA immediately upstream of 
the -35 element between a PhERI-sensitive promoter, rrnA, and a PhERI-resistant 
promoter, dnaA. As observed previously, PhERI inhibited transcription from rrnA (Fig. 
5.3a, lanes 1, 2). In the absence of PhERI, the rrnA(dnaA-UP) promoter showed 
decreased activity, similar to the PhERI-inhibited rrnA (Fig. 53a lane 3), and PhERI had 
no additional effect on this hybrid promoter (Fig. 5.3b, lane 4).  
PhERI did not affect transcription from the dnaA promoter (Fig. 5.3b, lanes 5, 6). 





















Figure 5.2: Sequences of Sau promoters sensitive and resistant to inhibition 
by PhERI.  -35 and -10 and extended -10 elements are highlighted in red.  
Putative UP-elements are highlighted in green.  Hybrid promoters, which 
will  be  used  in  subsequent  experiments,  swap  the  region  immediately 





resulting dnaA(rrnA-UP) promoter became highly sensitive to PhERI (Fig. 5.3b). The 
loss of activity between rrnA and rrnA(dnaA-UP) (compare Fig. 5.3, lanes 1 and 3) 
demonstrates that the A/T-rich sequence just upstream of the rrnA -35 element 
contributes significantly to rrnA activity, as with the Eco rrn promoters (Rao et al., 1994). 
Moreover, PhERI sensitivity of a promoter appears to be determined almost totally by the 
sequence just upstream of the -35 element. These results argue that PhERI’s activity is 
mediated by a promoter feature upstream of the -35 element and implicate an A/T-rich 
sequence in this inhibitory effect.  
 
PhERI alters RNAP interactions with promoter DNA upstream of the -35 element 
 To test whether PhERI directly modulates RNAP binding to promoters with A/T 
rich elements, I used DNAseI footprinting. DNAseI cleaves at exposed minor grooves of 
the DNA double-helix with some sequence dependence.  Cleavage is particularly 
sensitive to deformations or bends in the DNA double helix that widen the minor groove 
(Fox, 1997). Because RNAP extensively bends promoter DNA, DNAseI has 
characteristic cleavage patterns on DNA in the OPC, including cleavage between the -10 
and -35 elements, and cleavage upstream of the -35 element (Severinov and Darst, 1997). 
Because Sau rrn promoters have never been tested biochemically, and UP-
element binding has not been shown in this organism, I first tested the DNAseI cleavage 
pattern of the rrnA promoter using the well characterized Eco RNAP.  I observed the 
typical DNAse cleavage patterns on this promoter (Fig 5.4b) with a hypersensitive band 
immediately upstream of the -35 element and protection upstream of the -35.  To test 
whether protection in the putative UP-element on rrnA is due to RNAP α-CTD binding, I 
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Figure 5.3 (adjacent page): An element upstream of the -35 is required for 
PhERI inhibition.  In vitro transcription assays were performed as in chapter 
3 on hybrid promoter DNA that swapped the region upstream of the -35 
element from a PhERI sensitive promoter (rrnA) and a resistant promoter 
(dnaA).  a) PhERI inhibits transcription from the rrnA promoter (lane 1 and 
2).   Replacing the upstream A/T rich region decreases the output at  this 
promoter (lane 3) similar to the effect of PhERI (lane 2).  PhERI has no 
additional  effect  on this  promoter (lane 4).   b)   PhERI has no effect  on 
transcription at the dnaA promoter (lanes 5 and 6).  When an A/T-rich region 
is placed upstream of the -35 at this promoter (lane 7), it becomes highly 
sensitive to PhERI inhibition (lane 8).  Lower panels show the average of 3 
independent  normalized  experiments  with  the  error  bars  showing  one 
standard deviation above and below the mean.  	
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Figure 5.4 (adjacent page): DNAse footprinting reveals that PhERI blocks 
protection of upstream A/T-rich DNA elements.  a) Sequence of promoters 
tested below.  -35 and -10 elements are highlighted in red, UP-element in 
green.   Position  relative  to  the  first  transcribed  base  (+1)  are  listed  at 
locations  that  are  identified  experimentally  in  the  G/A ladder.   b)   Eco 
holoenzyme and Eco holoenzyme with the α-CTD truncated were incubated 
with promoter DNA end labeled on the template strand in 1x DNase buffer.  
DNAse (0.1μg/ml) was added for 1 minute before reactions were stopped 
with 0.1M EDTA, boiled and visualized on a 6% Urea-PAGE gel.  c)   Sau 
holoenzyme  (1μM)  was  incubated  with  PhERI  (2μM)  or  buffer  in  1x 
DNAse buffer and assayed as above.  DNA regions corresponding to the -10 
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used Eco RNAP lacking the α-CTD.  In the absence of the α-CTD, the hypersensitiviy 
upstream of the -35 element is dramatically decreased and there are prominent cleavage 
events in the A/T-rich UP-element (Fig5.4 lane 3).  Thus, two DNaseI cleavage 
properties appear to be diagnostic of an α-CTD/UP-element interaction i) 
Hypersensitivity at a site just upstream of the -35 element, and ii) absence of cleavage 
events within the UP-element itself.   
Sau RNAP also confers the characteristic protection from DNAseI indicating 
OPC formation (Fig 5.4c lane 5). At the rrnA promoter, OPC formation induces strong 
hypersensitivity just upstream of the -35 element, and the UP-element itself is protected 
from cleavage (Fig 5.4c, lane 5), indicative of α-CTD/UP-element interaction. Addition 
of PhERI results in a complete loss of the sensitivty immediately upstream of the -35 
element and a loss of protection within the UP-element (Fig 5.4c, compare lanes 5 and 6), 
qualitatively similar to the effect of deleting the Eco α-CTD entirely. On the dnaA 
promoter, there is no significant protection by RNAP in the region upstream of the -35 
element (Fig 5.4d, lane 8). PhERI addition leads to protection immediately upstream of 
the -35 element (Fig 5.4d, lane 9) indicating that while PhERI does not affect 
transcription from this promoter in vitro or in vivo, it is bound to RNAP and positioned 
near the DNA in this region (Fig 5.4d).  
 To show that the A/T rich element is responsible for the protection upstream of 
the -35, I tested the DNAseI digestion pattern on the hybrid promoters described above 
(Fig 5.5). Removal of the A/T-rich sequence from the rrnA promoter leads to DNA 
cleavage events between the -40 and -52 positions and a decrease in the hypersensitivity 
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Figure 5.5: DNAseI footprinting assays performed on the hybrid promoters 








lanes 2 and 5). Moving the rrnA A/T-rich sequence upstream of the -35 position in the 
dnaA promoter confers resistance to DNAse cleavage throughout the upstream region 
and increased hypersensitivity of the cleavage event immediately upstream of the -35 
(Fig 5.5b, compare lanes 8 and 11), indicative of α-CTD binding. Addition of PhERI to 
the dnaA hybrid promoter cause a complete loss of the hypersensitivity, then protects the 
DNA immediately upstream of the -35 and induces cleavage in the A/T-rich element (Fig 
5.5b, compare lanes 11 and 12), indicating loss of α-CTD binding.  
 Together, these results show that PhERI is closely associated with DNA 
immediately upstream of the -35 element on all promoters regardless of its activity, in 
agreement with the structural model, and prevents functional binding of the RNAP α-
CTD to an upstream A/T-rich promoter element. Based on the footprinting, it appears 
that PhERI protects cleavage from roughly the -35 element to base -45 relative to the 
promoter start site. By blocking the UP-element interaction, PhERI inhibits only 
transcription from the subset of promoters requiring α-CTD binding for full activity, 
including the rrn promoters.   
 
Role of PhERI in the phage life-cycle 
 Sau phages have been studied as possible therapeutic agents against highly 
resistant infections. Much of this research has focused on the ability of phages, or their 
lytic enzymes, to clear resistant infections (Fischetti, 2010). While the genomes of many 
Sau phages have been sequenced (Kwan et al., 2005), very little is understood about the 
basic molecular mechanisms through which Sau phages initially inhibit cell growth and 
co-opt the molecular machinery to favor completion of the phage life-cycle.  
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 In the previous chapters, I showed that the G1 phage protein PhERI inhibits cell 
growth in Sau by binding to the host RNAP and targeting UP-element dependent 
promoters, including the rrn promoters. The G1 phage is nearly identical to the Sau phage 
K (Kwan et al., 2005) and PhERI shares 100% sequence identity between these phages. 
PhERI has homologs in five firmicute specific phages, including in the Sau phage Twort. 
Recent publications have tested the ability of Phage K and Twort lytic enzymes to lyse 
Sau strains (Paul et al., 2011), potentially preparing for their therapeutic application 
(Kelly et al., 2011). The work I present is the first understanding of the early stages of 
infection from any Sau lytic phage. 
 Because PhERI is expressed from a -10/-35 promoter that is highly transcribed by 
Sau RNAP in vitro (Fig. 5.6 and 3.5b), and is located downstream of strong -10/-35 
promoters in all phages that encode a PhERI homolog (Fig. 5.6), it is likely one of the 
early proteins transcribed after initial injection of the double stranded phage genome into 
the host cell.  Work on the T4 phage protein AsiA shows that phage promoters escape 
inhibition by containing an extended -10 element (TGn immediately upstream of the -10 
element) or an UP-element.  To understand how the PhERI homologs are 
transcriptionally regulated, I searched for the promoter sequences that drive PhERI 
homolog expression in the phage genomes.  
Interestingly, three of the five promoters (Staphylococcus phages G1 and Twort 
and Lactobacillus phage Lb338-1) that express PhERI homologs contain an extended -10. 
Three of these promoters do contain A/T-rich regions upstream of their -35 elements 
(100%, 93% and 89% A/T, compared to ≈67% in the Sau genome), but these promoters 

















Figure  5.6:  Promoters  that  drive  the  expression  of  PhERI  and  PhERI 
homologs in phage genomes.  The fully sequenced phage is listed on the left 
along with the species of bacteria it infects.  The -35, -10 and extended -10 




Phage A511 and Enterococcus Phage phiEF24C) that do not contain an extended -10 
element do not have an A/T-rich region upstream of their -35 elements (63% and 68% 
A/T-rich), and are therefore not likely to be targeted by PhERI inhibition.  It appears that 
PhERI containing phages evolved a mechanism through which they could inhibit host 
rRNA transcription while phage promoters themselves remained unaffected through 
various mechanisms (extended -10 elements or UP-element independence).   
Upon being transcribed and translated, PhERI binds to the host RNAP 
holoenzyme (Fig. 2.2) and suppresses production of rRNAs (Fig. 3.7 and 4.3) by 
selectively inhibiting UP-element-dependent promoters (Fig. 5.3) while allowing 
transcription from the majority of -10/-35 promoters (Fig. 3.5 and Fig 4.5a), including the 
phage G1 pPhERI promoter (Fig 3.5) and other potential phage early promoters. The 
phage ultimately will require the use of host ribosomes to translate middle and late phage 
gene products; however, because rRNA is quite stable in prokaryotic cells (Deutscher, 
2003), previously formed ribosomes are abundant in Sau cells for hours after PhERI 
expression (Figure 4.3a).  Our model for PhERI inhibition of Sau RNAP is summarized 
in Figure 5.7.   
During log-phase growth, the majority of RNAP in prokaryotic cells is occupied 
in actively transcribing rRNA.  Inhibition of rRNA transcription not only leads to arrest 
of cell division (Gourse et al., 1996), but would free a large pool of host RNAP (Barker et 
al., 2001a) that could then be recruited to the strong phage early promoters. The T4 phage 
anti-σ factor, AsiA, inhibits host RNAP by blocking -35 element recognition while an 
additional protein, MotA, binds and recruits the RNAP complex to phage promoters 
(Hinton et al., 2005). The T4 phage has additional protein factors that ADP-ribosylate the 
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Figure 5.7: Model for PhERI function.  At -10/-35 promoters, PhERI joins 
the  Sau  RNAP holoenzyme through  its  interaction  with  σA4.   However, 
PhERI  does  not  block  any  of  the  functions  of  σA4 and  does  not  inhibit 
RNAP.  At promoters that require UP-element binding, PhERI joins RNAP 
holoenzyme through its  interaction  with  σA4  and  blocks  the  UP-element 




RNAP α-CTD, leading to recruitment of RNAP to phage promoters (Tiemann et al., 
2004). Whether phages K and G1 have additional proteins that actively recruit RNAP to 
phage promoters, or whether PhERI binding can directly stimulate RNAP activity at 
phage promoters, is under investigation. As demonstrated previously, PhERI expression 
alone is sufficient to inhibit cell growth (Figure 4.2) (Dehbi et al., 2008; Liu et al., 2004).  
I show that PhERI arrests cell growth by binding to RNAP and specifically inhibiting 
only a small subset of Sau promoters, including rRNA promoters, highlighting ribosomal 
synthesis as a strong target for novel therapeutics.   
 
Sau UP-element binding and Sau promoters 
 Previous in vitro transcription work in Sau only studied highly regulated virulence 
promoters.  Here, I identify and study RNAP activity and regulation at two classes of 
promoters, -10/-35 promoters (Fig. 3.5) and UP-element dependent promoters (Fig. 3.7).  
rRNA transcription has not been previously studied in Sau.  My work identified the first 
rRNA promoters in this organism and demonstrated their activity in vitro (Fig. 3.7). 
 rRNA promoters in other organisms are dependent on UP-element binding for 
robust transcriptional activation.  Similarly, in Sau, I show rRNA promoters require UP-
element / α-CTD interaction for full transcriptional activity (Fig 5.3).  Replacing UP-
element DNA sequences with more G/C-rich sequences decreases the activity of these 
promoters in vitro (Fig 5.3a, compare lanes 1 and 3).  PhERI, which blocks UP-element 
binding by the RNAP α-CTD, inhibits rRNA transcription and a minority of other 
promoters in the Sau genome (Fig 4.5, table 4.2).  This is the first demonstration of UP-
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element activation in Sau, and further shows that as in Bsub and Eco, rRNA transcription 
in Sau is activated by the UP-element/α-CTD interaction. 
 The identification of Sau and Sau phage promoters was not trivial.  The lack of 
well-characterized Sau promoters for in vitro studies was a significant problem in the 
early stages of my work.  PhERI did not appear to inhibit Sau RNAP at the Eco and Eco 
phage promoters commonly used for in vitro analysis.  Continued work on in vitro 
transcription systems from organisms other than Eco is critical to our understanding of 
transcription throughout the prokaryotic kingdom, including in pathogenic organisms.  
The work presented in this and previous chapters demonstrates the importance of 
studying protein factors in a fully native system in vitro, using appropriate test promoters 
and RNAP. The promoter sequences I identified here, in particular the rrnA and dnaA 
promoters, appear to be valid promoters in vitro: I can swap promoter sequences between 
them with predictable results and observe RNA products of the expected size (Fig 5.3). 
These promoters show expected patterns of DNaseI digestion, indicating that they form 
normal OPCs, and again I can manipulate the promoter with predictable changes in their 
digestion patterns (Fig 5.4 and 5.5).  These promoters should facilitate subsequent studies 
on Sau RNAP activity at -10/-35 promoters and should expedite further work on protein 





Structural Studies of Sau RNAP 
 
 The work I presented in the previous chapters provides the most extensive in vitro 
analysis of transcriptional regulation in Sau to date.  I identified and studied -10/-35 
promoters, including the Sau rrn promoters for the first time, and show UP-element 
activation in Sau. These studies were significantly hindered by the paucity of biochemical 
and structural information on RNAP and promoter sequences from this organism.   
 RNAP is a known target of small molecule inhibitors.  Rifampicin, which is 
currently used to treat Mycobacterium tuberculosis infections, binds to prokaryotic 
RNAP and inhibits RNAP synthesis (Campbell et al., 2001; Ezekiel and Hutchins, 1968).  
While the structure of Rif bound to Taq RNAP has been solved (Campbell et al., 2001), it 
and other small molecules do not actually inhibit the thermophilic enzymes, making 
structural studies difficult.  Crystallizing Eco RNAP, or RNAP from another species 
inhibited by small molecules, has been a priority in the prokaryotic transcription field for 
decades (Twist et al., 2011a).   
 RNAP from different species also have varying abilities to bind and be regulated 
by protein and small molecule factors (Aiyar et al., 2002; Krasny and Gourse, 2004).  We 
show that PhERI inhibition requires a fully native Sau RNAP in vitro transcription 
system (Figs 3.1 and 3.3).  Work done in collaboration with a graduate student in Ann 
Hochschild’s lab, Cristina Montero-Diaz at Harvard, identified a σ70 mutant that interacts 
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with PhERI.  Even using this Eco RNAP that binds to PhERI, it was not inhibited by 
PhERI at the Sau rrn promoters.  Only when studied at the Eco promoter rrnB promoter, 
known to be dependent on UP-element activation in Eco, did PhERI have an inhibitory 
effect (Cristina Montero-Diaz and Ann Hochschild, personal communication).  I, and 
others, showed that Sau RNAP does not recognize all Eco promoters (Deora and Misra, 
1996; Rao et al., 1995).  Additional biochemical and structural data will help explain the 
differences in RNAP activity and regulation between species and open avenues for 
studies of proteins and small molecules that bind and modulate RNAP activity.   
 Sau is an important human pathogen and the increasing antibiotic resistance in 
this species is creating an urgent need for novel therapeutics (Klein et al., 2007b; Lowy, 
1998; Pastagia et al., 2011). RNAP is a validated drug target and high-resolution data 
from Sau would provide invaluable information to design potential therapeutics.  
 This chapter will describe my efforts to study the structure of Sau RNAP. We 
initially attempted to crystallize a three-protein complex of PhERI, σA4 and the Sau β-flap 
to understand how PhERI may interact not only with σA4 but how it may potentially alter 
the interaction between σ and RNAP core.  We grew crystals containing all 3 proteins 
that diffracted to near 4.0Å-resolution; however, due to issues with data quality and 
crystal twinning, we have yet to determine the orientation of the three proteins in the 
crystal lattice.  As part of this work, we solved a 2.5Å crystal structure of the Sau β-flap 
by molecular replacement.  While the structure is highly similar to previously solved the 
β-flap structures, the flap-tip helix, which interacts with σA4, is in a novel conformation, 
revealing the extent of the flexibility of this region.  Finally, I grew crystals that are likely 
to contain full-length Sau core RNAP. While these crystals are small, they diffracted to 
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better than 4.0Å-resolution and appeared to contain a unit cell volume compatible with 
RNAP. I have attempted to reproduce these crystals to collect data of high enough quality 
to solve the structure, but have been unable to regrow the crystals in the same condition.   
 
Structural studies of a 3-protein complex containing PhERI/σA4/RNAP β-flap 
 This work was done in close collaboration with Ann Hochschild’s lab at Harvard 
University.  The 2-hybrid studies I describe were performed by a graduate student in the 
Hochschild lab, Cristina Montero-Diaz.  The crystallography was done in collaboration 
with a summer undergraduate student in the Darst lab, Lizzy Hubin.   
 To validate the original PhERI/σA4 structure, and specifically the hypothesis that 
PhERI does not block the interaction between σA4 and the RNAP β-flap (Fig 2.x), we 
performed bridging two-hybrid experiments.  We identified a 2-hybrid interaction 
between Sau σA4 and the Sau RNAP β-flap.  In the bacterial 2-hybrid system, expression 
of an unfused protein that disrupts this interaction can be visualized by a decrease in the 
transcription of the reporter gene upon its expression.  As we expected, PhERI did not 
disrupt the interaction between σA4 and RNAP.  However, we were surprised to find that 
unfused PhERI appeared to increase the expression of the reporter gene upon its 
exogenous expression (Fig. 6.1a).  This result could indicate a direct interaction between 
PhERI and the RNAP β-flap or by an indirect effect in which PhERI stabilizes a 
conformation of σA4 that binds to the flap domain.  A direct interaction between PhERI 
and the flap would not be predicted based upon our previous structural work (Fig 6.1b), 
but could help explain why PhERI is unable to interact with the hybrid RNAP-
holoenzmye comprising Sau σA with Eco core RNAP (Figure 3.1c).  We reasoned that a 
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3-protein crystal structure could determine if PhERI can interact with the β-flap and 
therefore whether large-scale conformational shifts of PhERI, σA and RNAP may occur 
after the initial interaction between PhERI and σ.A.   
 We cloned and purified the Sau β-flap, as well as the complex of PhERI and σA4.  
The 3-protein complex was then screened for crystallization conditions.   Because the β-
flap from many organisms is known to crystallize readily, we also set up trays with the 
Sau β-flap alone.  We had previously screened for conditions in which the PhERI/σA4 
complex crystallizes (see Chapter 2).  We therefore searched for conditions that gave 
crystals with the 3-proteins together but that produced neither crystals of the β-flap or the 
PhERI/σA4 complex alone.   
 Microcrystals, needles and urchin-like crystals were produced in several 
conditions containing MgCl2 and PEG4000 that were unique to drops containing all three 
proteins (Fig. 6.2a).  2-dimensional screens consistently produced microcrystals under 
these conditions, and seeding was required to produce large single plates (Fig 6.2b).  To 
determine the protein composition of the crystals, we collected several crystals, washed 
extensively in mother liquor, and redissolved the crystals in 2x SDS loading buffer.  After 
extensive heating at 95°C, the crystal solution was run on a 4-12% SDS-PAGE Phast gel.  
We clearly see evidence for all 3 proteins in the crystals (Fig. 6.2c).   
 Crystals were cryoprotected in mother liquor plus 20% glycerol and flash frozen 
in liquid nitrogen.  The 3-protein complex crystals consistently diffracted to  ~6Å-
resolution (Fig 6.2d).  One crystal diffracted to beyond 4.0Å-resolution (Fig 6.2e).  I 
indexed this crystal and collected a full dataset (P222 a = 76.95 b = 84.50 c = 120.31; α = 




Figure 6.1: ORF67 stabilizes the interaction between σA4 and the RNAP β-
flap.  a) 2-hybrid data showing that the interaction between σA4 and the β-
flap (blue bars) is increased upon the expression of unfused ORF67 (red 
bars).  b) Structural model of ORF67, σA4 and the RNAP β-flap.  The co-
crystal structure of ORF67 and σA4 was aligned with the structure of RNAP 
holoenzyme (Vassylyev et al., 2002) to model the beta-flap domain bound to 
sigAd4.  No contacts between ORF67 and the β-flap would be predicted 












Figure 6.2:  Crystallization of the 3-protein (ORF67, σA4 and the Sau β-flap) 
complex.  a) Initial hits showed needles and microcrystals.  b)  Final crystals 
after refinement of the condition and seeding.  c) SDS-PAGE PhAST gel of 
resuspended  crystals  showing  clear  evidence  of  all  three  proteins.   d) 
Diffraction of a typical crystal on the R-AXIS source.  e) Diffraction of the 
one  crystal  that  gave  spots  to  under  4.0Å  resolution.   Diffraction  was 
evaluated on the X29 beamline at Brookhaven National Laboratories (BNL) 




diffraction anisotropy server (Strong et al., 2006) (Fig. 6.3a).  We searched for a 
molecular replacement solution in all possible point groups using both the PhERI/σA4 
complex and PhERI and σA4 separately.  Phaser found initial solutions (TFZ = 8.8) in 
point group P22121.  However, initial rigid body refinement failed to reduce the R factors 
under 0.50 and the density was difficult to evaluate.   
 Due to our difficulty refining the molecular replacement model, I tested the initial 
dataset for quality.  The data shows clear evidence for twinning (Fig 6.3b), and therefore 
the data were overmerged in the initial indexing.  The true space group for the data 
appears to be P2 (a = 72.32, b = 83.23, c = 116.5; α = γ = 90° β = 91.5°).  The 
completeness of the data was significantly reduced due to the reindexing in P2 and the 
resolution was cut at 4.0 Å to maintain an overall completeness near 80%.  Phaser still 
found molecular replacement solutions with TFZ scores above 8.0. When molecular 
replacement searches were performed with the PhERI/σA4 complex or with the proteins 
alone, PhERI and σA4 were consistently placed in the same location in the unit cell (Fig. 
6.4a).  The solutions when the proteins were searched separately were consistent with the 
co-crystal structure of the two proteins.  Density is clearly seen for the β-flap tip helix 
bound to the proper surface of σA4 (Fig. 6.4b). Phaser placed the β-flap at multiple, but 
restricted, locations in the unit cell (Fig 6.4a).  Low-resolution DEN refinements were 
further used to place the β-flap in the unit cell.   
 While there are clear blobs of density for the β-flap, the low resolution and poor 
quality of the data (anisotropic, twinned and low completeness) made placing the 
structure of the β-flap in the proper orientation extremely difficult.  To properly 
determine the relative position of the 3 proteins in the unit cell, higher quality diffraction 
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Figure 6.3:  3-protein complex crystals show high anisotropy and twinning.  
a) Anisotropy analysis of the diffraction data.  The anisotropy served was 
used to truncate data not present due to anisotropy.  b).  Twinning analysis 
using Phenix (Adams et al.,  2010).  The crystals show clear evidence of 





Figure 6.4: Molecular replacement solutions and initial density maps of the 
3-protein  complex.   a)  Molecular  replacement  solutions  showing  the 
complex of ORF67 and σA4 is placed consistently within the unit cell, but 
the β-flap is placed in multiple, but constrained locations.  b) 2Fo-Fc (blue) 
and Fo-Fc (red/green) maps showing clear density for the β-flap tip helix 




data is likely required.  Data collection in the proper space group should facilitate the 
collection of more complete data, and correcting for the twinning of the crystals appears 
to allow for proper refinement of the initial models.  Only one crystal out of dozens 
screened diffracted to better than 6.0 Å-resolution. Increasing the resolution further may 
require additional screening of many crystals.   
 
Structure of the Sau β-flap 
 For the structural studies described above, we purified large quantities of the Sau 
β-flap.  As a control, we also screened for crystallization conditions of the β-flap alone. 
The Sau RNAP, and indeed RNAP from gram-positive organisms, has not been 
extensively studied from a structural perspective.  No structures of regions of Sau RNAP 
have been published.  Our structure of the Sau σA4 (Fig 2.8) provides the first crystal 
structure of a region of Sau RNAP.  This domain is highly conserved in all organisms and 
is structurally conserved in Sau. The Sau β-flap readily crystallized in many 
conditions, one of which (Fig 6.5a) produced crystals that diffract to 2.5Å (Fig. 6.5b) (0.1 
M Sodium acetate pH 4.6, 8% (w/v) PEG 4000).  Crystals were cryoprotected by a quick-
dip in mother liquor plus 20% glycerol.  Data were indexed collected and indexed (P3121, 
a = 92.651 b= 92.651, c= 129.971; α = β = 90°, γ = 120°) at X29A at Brookhaven 
National Laboratories. We searched for molecular replacement solutions in both Phaser 
and MolRep using the Taq β-flap domain with all sidechains and the flexible flap-tip 
helix removed.  Likely solutions were found in both programs (TFZ > 8.0).  Evaluation 
of the initial electron density showed clear evidence for the β-flap tip helix that was not 





Figure 6.5:  Crystallization of the Sau β-flap.  a) β-flap protein crystals.  b) 
Diffraction pattern collected on the R-AXIS source.  Diffraction is evident 
to 2.8Å.  Diffraction was initially evaluated on an R-AXIS Xray source.  
Data for the final structure were collected on beamline X29 at Brookhaven 
Natinoal  Laboratories.   c)  2Fo-Fc maps from the molecular  replacement 
solution showing clear  evidence for  the β  flap-tip  helix  (red arrow),  not 




 The β-flap crystals contained three monomers in the asymmetric unit (Fig 6.6a).  
The three individual structures were quite similar to one another (Rmsd = 1.1 and 1.2) 
and also highly similar to previously solved structures of the β-flap from other organisms 
(Rmsd = 1.3 with the flap-tip helix excluded from the Eco β-flap).  The β-flap tip helix is 
known to be flexible (Twist et al., 2011b).  This helix is responsible for interacting with, 
and organizing σA4 such that it can properly recognize the major grove of the -35 
promoter element (Murakami et al., 2002b; Vassylyev et al., 2002) (Fig 6.1b and 6.6b).  
This helix is the target for proteins that regulate RNAP activity, including the phage 
protein gp33 that binds to the flap-tip helix (Twist et al., 2011b).   
 The flap-tip helix in our structure is in a conformation incompatible with an 
interaction with σA4 (Fig 6.6d).  This helix is maintained in its conformation due to 
extensive crystal packing contacts (Fig 6.7), both within one asymmetric unit and 
between asymmetric units.  Compared to previous structures compatible with σA4 binding 
(Fig 6.6b), the flap-tip helix is rotated 70° (Fig 6.6 d and e).  It is similarly distorted in a 
co-crystal structure with the Eco phage protein gp33 (Fig 6.7c and e).  Our structure 
shows even more distortion than when the helix is stabilized by a phage transcriptional 
regulator.  This is clear evidence of the extent of the flexibility of this helix in solution.  
While it can be maintained in a stable conformation by binding other proteins, such as σ 
or gp33, crystal packing alone can capture a functionally distorted conformation of the β-
flap.   
Our structure of the Sau β-flap provices evidence that the protein in solution 
samples a wide variety of conformations, one of which is captured and stabilized by 
interaction with σA4 or other protein factors.  The interactions required to form the RNAP 
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Figure 6.6 (adjacent page): Structure of the Sau β-flap.  a) Crystallographic 
trimer of Sau β-flap.  b) interaction between the β-flap domain (green) and 
σA4 (orange) from the Tth holoenzyme structure (Vassylyev et al., 2002).  c) 
Structure as shown in b overlayed with the structure of the Eco β-flap bound 
to the phage protein gp33 (red) (Twist et al.,  2011). The β  flap-tip helix 
bound  gp33  is  in  a  conformation  incompatible  with  σA4  binding.   c) 
Structure as in b aligned to the Sau β-flap (blue) showing the flap-tip helix 
in a further contorted conformation.  d) Overlay of the Tth β-flap in the 
conformation required for σA4 (green), the Eco β-flap bound to gp33 (red) 
and the Sau β-flap (blue).  e) Structure of the Tth β-flap in the conformation 
bound to σA4 (green) and the 3 structures of the Sau β-flap present in the 
asymmetric unit (blue).  f)  Structure of the crystallographic trimer of the 
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Figure 6.7: Packing of the Sau β-flap crystals.  a) Crystal packing of the 
trimer (cyan/pink/green).  b)  The β flap-tip helix from one asymmetric unit 





holoenzyme, including the specific contacts between the β-flap and σ4, occur as one of 
the first kinetic steps in the transcription cycle, prior to promoter specific DNA 
recognition and melting.  Regulation of this step would have dramatic effects on RNAP 
activity at a wide variety of promoters in prokaryotic cells.  This conformational 
flexibility of the β-flap is a site of regulation by proteins that not only sterically block σ 
binding but may also maintain the β-flap in a conformation incompatible with σ 
recognition (Berdygulova et al., 2012; Deighan et al., 2008; Twist et al., 2011b; Yuan et 
al., 2009).   
 
 Structural studies of the Sau RNAP core enzyme 
  The structures of proteins and biological molecules can be studied by a variety of 
techniques. Both electron microscopy (EM) and X-ray crystallography have been used to 
study the structures of prokaryotic RNAPs (Campbell et al., 2002; Murakami et al., 
2002b; Polyakov et al., 1995).  EM technologies produce structures of moderate 
resolution (Polyakov et al., 1995) and cannot be used to study RNAP at atomic resolution 
for small-molecule binding studies or the placing of individual amino acids in the density 
maps.  X-ray crystallography, which is capable of producing electron density maps giving 
atomic level detail of protein structure and allowing for unambiguous placement of 
protein residues within the density maps, is limited by our ability to grow crystals of a 
protein or complex that diffract to sufficiently high resolution.  Crystallization of a 
protein generally requires a large amount (10mgs or more) of pure protein. To date, the 
only structures of prokaryotic core and holo RNAPs that have been solved to atomic 
resolution come from thermophilic bacteria (Murakami et al., 2002b; Vassylyev et al., 
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2002).  X-ray crystal structures of RNAP from additional organisms would provide 
invaluable information about the regulation and function of this important class of 
enzymes. 
 
Sau RNAP is inhibited by a small molecule inhibitor 
 One of the driving forces behind the work to crystallize non-thermophilic RNAPs 
is that the thermophilic enzymes are not effectively inhibited by many small molecule 
drugs that target RNAP function. Many small molecules are potent inhibitors of Eco 
RNAP and therefore crystals of Eco RNAP would allow for co-crystallization studies 
with the small molecules to determine their binding sites and mechanisms of inhibition.  
Small molecule inhibitors have not been tested in vitro using Sau RNAP.  Before 
attempting to crystallize Sau RNAP for subsequent structural studies, I wanted to 
determine whether this enzyme is inhibited by small molecules that are active against Eco 
RNAP.  I tested the activity of one Rifampicin derivative, Rifalazil, on Sau RNAP 
activity at three promoters (Fig 6.8). This small molecule does not effectively inhibit the 
thermophilic enzymes but is active against Eco RNAP.  I show that it is an inhibitor of 
Sau RNAP at all three promoters (Fig 6.8), indicating that an RNAP core crystal structure 
would likely open up many avenues for soaks or co-crystalization with small molecule 
regulators and inhibitors of RNAP function.   
 
Crystalization of Sau RNAP 
For our biochemical studies, I prepared highly pure Sau RNAP (Fig. 3.2).  An 
attempt to crystallize the Sau RNAP required only a scale-up of the small scale RNAP 
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Figure  6.8:  The  Sau  RNAP  is  inhibited  by  the  antibiotic  Rifalazil.  
Transcription  assays  were  performed  using  Sau  holoenzyme  on  3  Sau 
specific promoters identified in chapters 3 and 4.  RNAP core (50nM) was 
added to Sau σA (100nM); linear promoter DNA (50nM) was added to the 
reaction in 1x Sau transcription buffer. Rifalazil, added to the reactions prior 




purification.  Because I purify untagged Sau RNAP natively from cells, a large-scale 
purification would require a large amount of biomass. Through a fermentor facility, I 
obtained 300 L cultures of Sau NCTC8325 to saturation, producing ~300g of solid 
biomass.  I purified Sau RNAP from ~150g of biomass for subsequent structural studies.  
Following the same purification protocol (Fig 3.2) (polymin P and ammonium sulfate 
precipitations followed by purification on heparin, sephadex-200 and S columns), 
producing ~5mgs of Sau RNAP.  The sample was concentrated to 12mg/ml and screened 
extensively for crystallization conditions. 
 One condition (0.1 M HEPES pH 7.5, 0.2 M MgCl2, 30% PEG400) produced 
small protein crystals after approximately 14 days (Fig 6.9a).  I managed to reproduce 
these crystals with Sau RNAP from the same purification, but was limited by the quantity 
of sample that remained.  Crystals were cryoprotected by a quick dip in the mother liquor 
with the addition of 5% glycerol and flash frozen in liquid nitrogen. Due to the small size 
of these crystals (5µM), we evaluated their diffraction on the microdiffractomoter at the 
Advanced Light Source at Argonne National Laboratories.  Of the 6 total crystals we 
screened, only one showed evidence of diffraction.  This crystal, however, clearly 
diffracted to beyond 4.0 Å-resolution (Fig 6.9b).  While the quality of the spots was 
good, due to extensive ice formation on the loop, we attempted to anneal the crystal.  
After annealing, the spots appeared streaky (Fig 6.9b).  Although the data quality after 
annealing was quite poor, we indexed the crystal and collected a dataset. 
 Crystals of protein purified natively from cells may not contain the protein of 
interest, but rather be composed of a crystallizable impurity.  RNAP, due to its large size, 





Figure 6.9:  Crystallization of Sau RNAP.  a) Putative Sau RNAP protein 
crystals.  Left image is a brightfield, right is UV absorption.  One crystal is 
indicated by a red arrow in both images.  b) Diffraction pattern of putative 
Sau RNAP crystals.  Diffraction was evaluated on the 24-ID beamline at the 




fully indicative of a crystal containing RNAP, it is a good indication that the crystal is at 
least compatible with RNAP crystal packing in the unit cell.  I was able to index the Sau 
RNAP crystals to evaluate their unit cell.  While the data is compatible with many 
different space groups (Fig 6.10), many of which consist of unit cells large enough to 
contain RNAP, an initial analysis of the statistics of indexing of the data in all the 
possible space groups identified P4 as the likely correct space group.  The unit cell in P4  
(a = 182.46, b = 182.46, c = 181.57; α = β =  γ = 90°) could accommodate one Sau RNAP 
molecule (MW ~ 350kD) with a solvent content of 70.4% (Fig 6.10).  Because of the 
poor quality of the data, attempts to scale the dataset failed and molecular replacement to 
solve the phases could not be attempted.   
Given the promising initial diffraction data, I attempted to repeat the large-scale 
Sau RNAP purification and produce additional crystals under this same condition.  I also 
tried to improve the crystals, in particular their size, by screening additives to the 
crystallization.  Subsequent studies could use micro or macro seeding to improve crystal 
size and quality.  However, I was never able to reproduce crystals under the same 
condition from subsequent large-scale RNAP purifications.  RNAP purified from 
subsequent fermetor batches proved not only to be uncrystallizeable, but also completely 
inactive biochemically.  Although the purification appeared to proceed normally, either 
the RNAP was inactived by small molecule(s) in the sample or conformationally unable 
to undergo transcription.  We hope to resolve the issues in the fermentor growth and/or 
RNAP purification to again produce large amounts of highly active RNAP suitable for 
crystallization.  Given the promising initial diffraction by the putative Sau RNAP crystal, 
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P4	  
1	  Sau	  RNAP	  (~350kD)	  
Solvent	  content:	  70.4%	  
Figure  6.10:   Indexing  of  putative  Sau  RNAP crystals.   Indexing  was 
performed  using  HKL2000,  and  the  statistics  of  indexing  were  used  to 
determine the likely space group.  χ2 values of space groups higher than P4 




we believe that Sau may be a suitable organism for high-resolution studies of mesophilic 




Structure and Function of Tth CarD 
 
 Mycobacterium tuberculosis (Mtb) is a pathogenic bacterial species and is the 
primary causative agent of tuberculosis, a serious infection of the lungs. More than 30% 
of the world’s population is currently infected with latent Mtb and Mtb reactivation in 
this subset of the population is responsible for 1.3 million deaths a year (WHO, 2009).  
Mtb infects tissues in the lung where it invades the host macrophages where it evades the 
immune response to continue to divide.   As with Sau, multi-drug resistance in Mtb 
makes infections difficult and costly to treat (Heep et al., 2000; Ramaswamy and Musser, 
1998).  Mtb cells divide only once every 15-20 hours, as opposed to Eco and Sau cells 
which divide every 20-30 minutes (Stallings and Glickman, 2011). This slow growth rate 
has made Mtb difficult to study in the laboratory, and it makes Mtb difficult to fully 
eliminate from patients.   
 Mtb’s ability to persist in patients for years and even decades depends on a 
complex cellular response to the anaerobic conditions and various stressors inherent to 
the host immune response.  The stringent response, outlined in the introduction, adjusts 
the prokaryotic growth regime from rapid growth and cell division when resources are 
abundant to the stress response required to survive when resources are scarce (Gourse et 
al., 1996; Traxler et al., 2008).  The stringent response, including the downregulation of 
rRNA synthesis, is thought to be important to the ability of Mtb to persist in the stressful 
environment of the human host (Stallings and Glickman, 2011).   
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 CarD was identified in a high throughput screen for genes upregulated by the 
DNA damage response in Mycobacterium smegmatis (Msm) (Stallings et al., 2009), a 
model organism closely related to Mtb but with a faster doubling time (and therefore 
more amenable to laboratory study).  The original work on CarD showed that it is 
essential for cellular survival, critical for the response to oxidative stress and DNA 
damage, and is a negative regulator of the transcription of ribosomal components 
(Stallings et al., 2009). CarD contains a conserved RNAP Interacting Domain (RID), 
similar to the RID that mediates the interaction between the transcription repair coupling 
factor (TRCF or Mfd) and RNAP (Stallings et al., 2009).  While the N-terminal region of 
CarD contains the RID, the C-terminal region has no apparent sequence homology to any 
other protein family.    
CarD pulls down RNAP subunits in Msm and interacts with the RNAP β subunit, 
the site of TRCF-RID interaction, by 2-hybrid assays.  Because CarD binds to RNAP and 
appears to regulate rRNA transcription, it was hypothesized to be a regulator of the 
stringent response, similar to DksA in Eco (Stallings et al., 2009) (see Chapter 1).  CarD 
is widely conserved in prokaryotic species, with homologs in Bsub, the thermophilic 
bacterium Thermus Thermophilus (Tth) and Myxococcus Xanthus (Stallings and 
Glickman, 2011; Stallings et al., 2009).  Unfortunately, no homolog exists in Eco, and 
therefore the rich genetic and biochemical tools that have been developed in Eco for 
studying RNAP regulation have not been accessible to examine CarD function.   
 CarD is essential in Mtb and Msm, which has complicated studies of its function 
(Stallings and Glickman, 2011; Stallings et al., 2009).  DksA, which regulates rRNA 
synthesis at the transition into stationary phase, is not essential in Eco (Paul et al., 2004), 
170
	  
and therefore it has been hypothesized that while CarD binds to RNAP, it may have some 
other required function relating to DNA replication and DNA damage (Stallings and 
Glickman, 2011).  Specifically, because rRNA operons are so highly expressed in log-
growing prokaryotic cells, collisions between RNAP and the DNA replisome are likely to 
occur at these loci.  Such collisions between RNAP and the replisome are generally 
bypassed by the DNA replication machinery; however, if RNAP is not removed and the 
replisome cannot clear the collision, DNA replication is disrupted and the DNA damage 
response is activated.  Because collisions of RNAP and the replisome traveling in the 
same direction are more easily bypassed that head-on collisions, it is generally assumed 
that rRNA operons are oriented in the direction of DNA replication to alleviate the 
probability of deleterious RNAP/replisome collisions (Stallings and Glickman, 2011).  
RNAP binding proteins, including TRCF and DksA, have been shown to help remove 
RNAP from stalled complexes, eliminating replisome roadblocks (Pomerantz and 
O'donnell, 2008, 2010; Tehranchi et al., 2010). 
 Mtb only has one rRNA operon from which all ribosomal RNAs must be 
transcribed (Stallings and Glickman, 2011).  In contrast, Eco contains 7, Bsub 10 
(Stallings and Glickman, 2011) and Sau 5 (Baba et al., 2008; Wada et al., 1993). Whether 
CarD is essential or not appears to be correlated with the number of rRNA operons in an 
organism: organisms with fewer rRNA operons, such as Mtb and Msm, require CarD 
while Bsub does not (Stallings and Glickman, 2011).  Whether CarD is directly 
modulating RNAP activity at promoters, and whether modulation of RNAP activity is its 
required function, remain unclear.   
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 Subsequent work showed that while CarD depletion leads to an upregulation of 
rRNA and transcription related proteins, mutating the CarD-RID to disrupt its interaction 
with RNAP leads to a decrease in RNAP activity at rRNA promoters (Stallings, CL, 
personal communication).  These seemingly disparate results may point to multiple 
important roles of CarD in cells, some relating to its interaction with RNAP and others 
perhaps independent of this interaction.   
 In this chapter, I will present our work to understand the structure and function of 
CarD directly on RNAP at promoter sequences.  The work presented here is a 
collaboration between our group and Christina Stallings at Washington University, and 
the in vivo data that I will briefly discuss come from Christina’s lab. The structure of 
CarD, as well as the modeling of CarD onto RNAP, was performed by a post-doc in the 
Darst lab, Devendra Srivastava, and Elizabeth Campbell, who was essential to the project 
throughout.  I will largely focus on my own work to describe the direct function of CarD 
on RNAP activity. 
 
Structure of Tth CarD 
 Thermophilic organisms can produce proteins with unique characteristics. 
Thermophilic enzymes tend to be optimally active at temperatures at which many 
proteins from non-thermophilic organisms denature, can be uniquely stable (Kelch and 
Agard, 2007), and are often well suited for crystallographic studies.  Because CarD has a 
homolog in Tth, Devendra initially attempted to solve the crystal structure of both Tth 
and Mtb CarD.  He also attempted to co-purify CarD and the RNAP β-1 domain to study 





























Figure 7.1:  Structure of Tth CarD.  a)  CarD contains two domains, an N-
terminal RNA polymerase Interacting Domain (RID, pink) and a C-terminal 
domain (green).  The helices and sheets are numbered as in the sequence 
alignment in Fig. 7.3.  b) CarD RID (pink) is structurally homologous to the 
previously  solved  Transcription  Repair  Coupling  Factor  (TRCF)  RID 




  The Tth CarD crystal structure (Fig. 7.1) was solved by Devendra Srivastava and 
Elizabeth Campbell.  The structure reveals that the CarD-RID is similar to the Mfd-RID 
(Fig. 7.1b), arguing that the two proteins likely interact with RNAP in a conserved 
fashion (RMSD = 1.45). While the CarD-CTD is connected to the RID by a linker, and 
therefore could be flexible with respect to the RID and the RNAP interaction, extensive 
inter-domain interactions between the RID and the CTD (Fig. 7.2) are likely to stabilize 
CarD in the structure we visualize.  Because of the relatively high conservation between 
Tth and Mtb CarD, we were able to make a structural model for the Mtb CarD based on 
the Tth data (Fig. 7.3). 
 The structure of the TRCF-RID has been solved in complex with the RNAP β1 
domain.  CarD has a structurally homologous RID and also interacts specifically with the 
β-1 domain of RNAP (Stallings et al., 2009).  Therefore, we can use the previous 
structures of a RID bound to RNAP to model CarD onto RNAP.  Because the RID 
interacts directly with the RNAP β-subunit, part of the catalytic core of the enzyme that is 
present throughout the transcription cycle, it is unclear whether CarD should be modeled 
onto structures of RNAP holoenzyme at promoter DNA or RNAP core bound to 
elongation substrates. CarD can be accommodated by both the RNAP holoenzyme open 
promoter complex (OPC) (Fig. 7.4a) and the RNAP elongation complex (Fig. 7.4b).    
 To determine at which point in the transcription cycle CarD interacts with RNAP, 
and dissect which kinetic steps to test for modulation by CarD, work in Christina 
Stalling’s lab used ChIP-Seq.  CarD was HA-tagged in Msm, growing cells were 
crosslinked, and lysates were collected and passed over a column that binds to the HA tag 
or contains an RNAP specific antibody.  After elution from the column, crosslinks were 
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Figure  7.2  (Adjacent  page):  CarD  RID  and  CTD  form  extensive 
interdomain  contacts.  a)  Interaction  map  showing  specific  interactions 
between residues on the RID and the CTD.  Ionic interactions are shown in 
red,  hydrogen  bonds  in  blue  and  hydrophobic  interactions  in  black.   b) 
Buried surface area analysis.  The surface area of the CarD-RID, CarD-CTD 
and full length CarD (upper row) were used to calculate the buried surface 






















RID	   CTD	  
Total	  surface	  area:	  	  	  4229.7	  Å2	   6116.8	  Å2	   9516.7	  Å2	  
Buried	  surface	  area:	  	  	  829.8	  Å2	  






Figure 7.3:  Structural modeling of Mtb CarD.  a) Alignment of Tth, Msm, 
and Mtb CarD with the strands and helices numbered corresponding to Fig. 
7.1.  b)  Structural model of Mtb CarD based on the structure of the Tth 
protein.  Top panel is the structure of Tth CarD shown as a cartoon and 
colored as in Fig 7.1.  Middle panel is the experimental structure of CarD 
shown  as  a  surface  representation  colored  by  electrostatic  potential 
(negative charge = red; positive charge = blue).  Bottom panel is the Mtb 
structural model based shown as a surface representation and colored by 
electrostatic potential as above.  Both the Tth and the Mtb CarDs contain a 





Figure 7.4: Model of CarD interacting with RNAP.  a)  Structural model of 
CarD bound to the RNAP open promoter complex.  CarD was modeled onto 
RNAP by alignment with the structure of the TRCF RID bound to the β-1 
lobe (Westblade et al., 2010).  σA is shown in orange, β in cyan and βʹ′ in 
pink.  CarD is represented as a ribbon structure and colored as in Figure 7.1.  
b)   Structure  of  CarD modeled  onto  a  transcription  elongation  complex 




reversed and bound DNA sequences were determined by high-throughput direct 
sequencing. While RNAP is bound to DNA throughout the length of genes and operons 
(Fig 7.5, red lines) as expected, CarD appears to interact with DNA at promoter 
sequences (Fig. 7.5 blue lines) and to correlate to regions of DNA where σ is bound (Fig 
7.5, green lines).  Based on these results, CarD appears to associate with RNAP at 
promoter sequences where σ is present.   
 
CarD stimulates RNAP activity at Tth rrn promoters 
 The results of experiments examining CarD function(s) in vivo have produced 
seemingly contradictory results.  While it is clear that CarD interacts with RNAP 
(Stallings et al., 2009), the direct effects on RNAP activity are unclear.  Because CarD 
may have multiple functions in vivo, only some of which involve RNAP binding, we 
decided to test its function on RNAP in a purified, in vitro transcription system.  The 
work from the previous chapters illustrates the importance of studying transcription 
factors in their native systems.  I tested Tth CarD using Tth core RNAP, Tth σA and Tth 
promoters. CarD appears to alter rRNA transcription in Mtb and Msm in vivo; I therefore 
assayed CarD’s activity on the Tth rRNA promoters in vitro. 
 CarD has a robust stimulatory effect on rRNA transcription in vitro (Fig. 7.6).  
Two Tth rRNA promoters have been previously studied, the 16s and 23s rRNA 
promoters (Fig. 7.6a).  CarD stimulates RNAP activity at both promoters (Fig. 7.6b).  
RNAP activity at low temperatures (42°C) required the use of a truncated version of Tth 
σA with region 1.1 deleted (σA-Δ1.1).  Region 1.1 is auto-inhibitory; in the absence of 
core RNAP, it interacts with σ4 to prevent DNA binding.  We also tested full-length σA at 
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Figure  7.5:  CarD  binds  to  transcription  initiation  complexes.   Protein 
nucleic  acid  complexes  containing  CarD-HA,  HA-TRCF,  and  HA were 
immunoprecipitated from Msm with a monoclonal antibody specific for HA.  
RNAP and σ were immunoprecipitated with monoclonal antibodies specific 
for these subunits.  Co-precipitated DNA was sequenced and the number of 
sequence reads for every base pair was normalized to the total DNA co-
precipitated  and  expressed  as  a  log2  value.   The  number  of  reads  co-
precipitated with HA alone served as the background and was subtracted 
from the other samples.  The legend in panel A is the same for all the panels, 
genes  are  designated  with  black  arrows,  and  annotated  promoters  and 





Tth	  16s	  promoter	  
Tth	  23s	  promoter	  
CAAAAAGAGTTGACTTAAAGTCAACCTATAGGATACTTACAGCCATCGAGAG !T7A1	  promoter	  
a)	  
b)	  
Figure 7.6: CarD stimulates RNAP activity at rRNA promoters but inhibits 
transcription  at  the  T7A1  promoter.  a)  Sequences  of  promoters  used  in 
subsequent  experiments.   -10 and -35 elements  are  highlighted with  red 
boxes.  b)  Open promoter complexes were formed by first incubating CarD 
(200nM)  with  RNAP holoenzyme  (50nM,  containing  σAΔN1.1),  adding 
linear template DNA (50nM) and incubating at 65°C as described in the 
methods.   Varying concentrations of CarD (0,  50,  100,  200 and 500nM) 
were added to RNAP core, and reactions initiated by the addition of NTPs. 




high temperature (65°C) and confirm that CarD stimulates RNAP activity at the two 
rRNA promoters regardless of the presence of region 1.1 (Fig. 7.7). These results are the 
first evidence that CarD has a direct effect on RNAP activity at promoters.  
 
CarD inhibits RNAP at the T7A1 promoter 
 To determine whether the effect of CarD on rRNA promoters is specific to this 
class of promoter, we also tested CarD’s activity on the -10/-35 Eco phage promoter 
T7A1, which has been extensively studied in vitro.  Interestingly, while CarD stimulates 
transcription from rRNA promoters, it inhibits RNAP activity at the T7A1 promoter (Fig. 
7.6b).   
 
CarD stabilizes Open Promoter Complexes 
 To evaluate the mechanism of CarD’s effects on RNAP activity at these 
promoters, we tested CarD’s ability to modulate the production of abortive transcripts.  
We formed OPCs and initiated transcription with only two NTPs for the 23s rRNA 
promoter to give a 4-base product and with the dinucleotide primter ApU and labeled 
CTP for T7A1 to produce a 3-base product (Fig 7.8a).  CarD stimulates the production of 
abortive products at both the 23s rRNA and the T7A1 promoter (Fig 7.8b). 
While CarD has the same effect on the production of abortive products from the 
23s rRNA promoter, it increases abortive transcription and decreases run-off transcription 
at the T7A1 promoter.  The T7A1 promoter is a phage promoter known to bind to RNAP 
with high affinity and form stable OPCs (Kadesch et al., 1982; Rosenberg et al., 1982) 
while rRNA promoters from various organisms are characterized by their unstable OPCs 
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Figure 7.7: CarD stimulates RNAP activity on rRNA promoters with Full 




GGGGGCCCTTGACAAAGGCCATGCCTCCTTGGTATCTTCCCTTTTGCGCTGC !Tth	  23s	  promoter	  
CAAAAAGAGTTGACTTAAAGTCAACCTATAGGATACTTACAGCCATCGAGAG !T7A1	  promoter	  
a)	  
b)	  
Figure 7.8: CarD stabilizes RNAP open promoter complexes (OPCs).  a) 
Sequences of promoters used in subsequent experiments.  Abortive RNA 
products produced by the nucleotides added to the reactions are colored in 
red.  b)  CarD stimulates abortive initiation at the 23s rRNA and the T7A1 
promoter.   Open  promoter  complexes  were  formed  by  first  incubating 
various concentrations of  CarD with RNAP holoenzyme (50nM),  adding 
linear template DNA (50nM) followed by incubation at 65°C as described in 
the methods. Reactions were initiated by the addition of NTPs to produce 
short RNA products. After five minutes, reactions were stopped and run on a 




(Barker et al., 2001b; Krasny and Gourse, 2004; Paul et al., 2004).  CarD could act upon 
the same kinetic step in these two promoters and have different effects on the output due 
to the differences in the relative stabilities of the intermediates of transcription initiation.   
 We tested the stability of open promoter complexes in the presence and absence 
of CarD on the 23s and T7A1 promoters. We found that heparin actively inhibited Tth 
RNAP activity, but that the double stranded DNA fragment, FullCon, at 20 fold molar 
excess to the promoter DNA fragment (Paul et al., 2004), was able to fully compete for 
RNAP binding.  The FullCon promoter was developed by in vitro selection for high 
affinity binding to RNAP holoenzyme (Gaal et al., 2001).  To test the stability of OPCs, I 
first formed OPCs at 65°C. For the 23s rRNA promoter, we measured OPC stability 
using transcription as an output.  Briefly, after the formation of OPCs, we added FullCon 
DNA to challenge the complexes, after which we initiated with NTPs and allowed the 
reaction to proceed.  The transcriptional output is a measure of how much RPo was 
present at the time of initiation.  The half-life of the 23s rRNA promoter was quite short 
(t=10s).  CarD stabilized the half-life significantly (Fig 7.9a). 
 For the T7A1 promoter, we measured OPC stability by filter binding.  The T7A1 
promoter fragment was end-labeled with P32 and used to form OPCs at 65°C.  Once 
OPCs were formed, we challenged with unlabeled FullCon DNA.  At time points after 
the addition of the FullCon fragment, we aliquoted 10µl of the reaction onto a prewashed 
filterpaper that binds specifically to protein and not nucleic acid.  Therefore, radiolabel 
present on the filterpaper records T7A1 DNA bound to RNAP.  The half-life of the T7A1 
promoter was remarkably stable (t = 71 min) and CarD further stabilized this promoter 
(Fig. 7.8c).   
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Figure 7.9: CarD stabilizes OPCs. Open promoter complexes were formed 
by first incubating CarD (200nM) with RNAP holoenzyme (50nM), adding 
linear template DNA (50nM) followed by incubation at 65°C as described in 
detail in methods. At t=0, 1μM FullCon DNA was added as a competitor, 
and open complex stability was monitored over time by run-off transcription 
assays for  the 23S rrna promoter  and filter  binding for  T7A1. The OPC 
stability at the rRNA promoter was visualized by Urea-PAGE gel (a), bands 
were quantified and normalized to t=0 (b).  c)  T7A1 OPCs were measured 
by filter binding using radiolabeled linear promoter fragment.  Signal was 




 rRNA promoters from multiple organisms have short OPC half-lifes (Krasny and 
Gourse, 2004; Paul et al., 2004).  Proteins such as DksA, and small molecules, such as 
ppGpp, that modulate the half-life of OPCs at all promoters affect the RNAP output from 
rRNA promoters primarily due to their unique kinetic parameters (Paul et al., 2004).  
CarD also appears to modulate the stability of OPCs, but unlike DksA and ppGpp, CarD 
stabilizes OPCs. The stabilization of RPo stimulates transcription from the rRNA 
promoters, where RPo is unstable (half life of 10s versus 71 minutes at the T7A1 
promoter).  However, on the already stable T7A1 promoter, further stabilization of RPo 
may prevent RNAP promoter clearance and subsequently inhibit run-off transcription.   
 
CarD mutants stimulate rRNA transcription 
  CarD modeled onto the RNAP OPC places the CarD-CTD near promoter DNA at 
the non-template strand -10 element and downstream where the template and non-
template strand reform duplex DNA (Fig. 7.4a).  CarD contains a number of positively 
charged amino acids in this region that would be well placed to make contacts with the 
DNA backbone and potentially alter RNAPs interactions with promoter DNA.  Work in 
Christina’s lab showed that Mtb CarD alone in solution has a weak and non-specific 
interaction with DNA.  Mutation of the positively charged residues at the CTD tip, which 
potentially interact with DNA in the model, disrupted the DNA binding activity of CarD 
by gel shift (Stallings, CL, personal communication).   
 We sought to determine the ability of Tth CarD mutants in this region to activate 
transcription from the rRNA promoters.  The mutagenesis and protein purification for 
this project was performed by a technician in the Darst lab, Katherine Leon.  None of the 
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mutants predicted to interact with DNA, which block DNA binding of CarD in solution, 
have any effect on CarD activity (Fig 7.10a and b).   
 Because there are several positively charged residues in this region, and because 
RNAP binding recruits CarD to the site of its potential interaction with DNA, single 
mutations that affect binding to DNA in solution may have a reduced effect on CarD 
activity in the context of RNAP.  To show that the CarD-CTD is required for CarD’s 
activity, we tested the CarD-RID alone.  The CarD-RID is unable to stimulate RNAP 
activity at the rRNA promoters, even at large molar excess (Fig 7.10c), arguing that the 
CarD-CTD is critical for its activity at promoters. 
 However, the CarD-RID alone may have a reduced affinity for binding to RNAP.  
The complex of CarD bound to the RNAP β1 domain was relatively unstable during 
purification.  To determine whether the defect in transcriptional activation of the CarD-
RID was due to an inability to interact with RNAP, I probed the interaction in vitro.  Tth 
RNAP is (10)his tagged, but Tth CarD and σA both have their affinity tags cleaved 
through the purification process. I used Ni-bead pull downs to test the ability of CarD and 
the CarD-RID to bind to immobilized Tth RNAP holoenzyme.  While CarD clearly 
interacts with RNAP holoenzyme (Fig. 7.11a, lanes 7 and 8), we see no evidence of the 
CarD-RID bound to RNAP (Fig 7.11b, lanes 7 and 8).   
The Ni-bead pulldowns were performed at relatively low protein concentrations.  
Based on previous reports and the data I present here, we believe that CarD interacts with 
RNAP through its RID, which therefore must be capable of binding to β-1 lobe of RNAP 
both in vivo (Stallings et al., 2009) and in vitro.  I therefore performed native gel shifts at 
both low and high protein concentration to determine whether the CarD-RID/RNAP 
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Figure 7.10 (Adjacent page):  CarD C-terminal mutants do not affect CarD 
stimulation of RNAP activity at the 23s rRNA promoter.  a) Transcription 
assays were performed as above with 200nM wild type (wt) CarD and the 
CarD CTD mutants  listed.   b)   Transcription  assays  were  performed  as 
above  with  wt  CarD  and  the  CarD  mutants  listed  at  increasing 
concentrations.  c) The CarD-RID alone does not stimulate RNAP activity at 
the 23s rRNA promoter.  Wt CarD and the CarD RID were added at the 
indicated concentrations to transcription assays performed as above.  	
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lane:	   1	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   3	   4	   5	   6	   7	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Figure 7.11:  The CarD-RID does not interact with Tth RNAP by Ni-bead 
pulldowns.   His-tagged  Tth  RNAP (2uM)  was  incubated  with  untagged 
σAΔN1.1 (5uM) and untagged CarD or CarD-RID (10uM).  The mixture 
was then bound to Ni-agarose resin, washed extensively with wash buffer 
(10mM Tris HCl pH 8.0, 250mM Na Cl, 25mM Imidazole) and eluted with 
500mM Imidazole.  Aliquots from the load, wash and elution steps were run 




interaction is low affinity and therefore requires high protein concentrations.  While the 
gel shift performed at low concentration confirms the Ni-bead pulldown experiments (i.e. 
no apparent binding of the CarD-RID to RNAP; Fig. 7.12a, compare lanes 4 and 5), at 
high concentration we see clear evidence for a CarD-RID/RNAP interaction (Fig 7.12b, 
lane 3, red arrow).  These data argue that the CarD-RID interacts with RNAP, but with a 
lower affinity than full length CarD.  Therefore, the absence of apparent stimulation of 
RNAP activity by the CarD-RID at the rRNA promoters could be explained by either 
poor binding or the mechanistic importance of the CarD-CTD.  We are currently planning 
experiments to test these possibilities.   
 
CarD and PhERI target unique characteristics of rRNA promoters 
 rRNA promoters are uniquely tuned to be both abundantly expressed in log-
growing cells and to be regulated by a variety of small molecules and protein factors as 
cells progress into stationary phase.  Early work on rRNA regulation in prokaryotes 
focused on the importance of small molecules (Barker et al., 2001a; Barker et al., 2001b; 
Gourse et al., 1998).  ppGpp, a modified nucleotide formed under stress conditions by the 
ribosome associated protein RelA, directly modulates the activity of RNAP at rRNA 
promoters (Barker et al., 2001b).  These promoters are also uniquely sensitive to the 
concentration of initiating nucleotide (Krasny and Gourse, 2004).  As cellular pools of 
NTPs decrease during starvation, rRNA promoters are inhibited without the aid of any 
additional signals or protein factors.  The kinetics of rRNA promoters, in particular the 
characteristic instability of their open promoter complexes, allows them to respond to 
such cellular signals (Barker et al., 2001a; Barker et al., 2001b; Krasny and Gourse, 
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Figure 7.12: The CarD-RID only interacts with Tth RNAP at high protein 
concentration.  a) Native-PhastGel analysis of CarD and CarD-RID binding 
to Tth RNAP at low concentration.  Proteins were incubated at the listed 
concentration and electrophoresed on a 4-12% native Phast gel.  While a 
shift  is  evidence  for  the  CarD/RNAP holoenzyme  complex,  no  shift  is 
apparent  upon  binding  of  the  CarD-RID.   b)  CarD  and  CarD-RID 
interaction  with  Tth  RNAP  holoeznyme  at  high  protein  concentration 
visualized  on  a  native  Phast  gel.   Proteins  were  incubated  at  the  listed 
concentration  and  visualized  as  above.   A band  is  visible  indicating  an 




2004).  rRNA promoters in various organisms also require UP-element binding and in 
Eco are further regulated by an additional activator, Fis (Krasny and Gourse, 2004; 
McLeod et al., 2002).  In Bsub, the signals that regulate rRNA transcription are different 
than in Eco.  Small molecules, in particular NTP concentration, feature prominently in 
the regulation (Krasny and Gourse, 2004).   
  The hypothesis that rRNA regulation is driven exclusively by small molecules 
was disproved in Eco by the discovery of the stringent response regulator DksA and 
activator Fis (Paul et al., 2004; Perederina et al., 2004).  In the absence of DksA, Eco 
cells are unable to properly downregulate the expression of rRNAs upon entering 
stationary phase (Paul et al., 2004).  DksA, which is structurally related to the Gre factors 
(Perederina et al., 2004), binds to the RNAP secondary channel, and decreases the 
stability of OPCs, thereby decreasing transcriptional output from rRNA promoters, which 
are rate-limited by this step.  ppGpp also decreases the stability of OPCs, and ppGpp and 
DksA have a synergistic effect on the inhibition of RNAP activity at rRNA promoters in 
Eco (Paul et al., 2004).  rRNA regulation in Eco therefore depends on both protein factors 
and small molecule signals to ensure the appropriate response to stress or starvation.  No 
DksA homologs have been found in many organisms, including the gram-positive 
organisms Bsub (Krasny and Gourse, 2004) and Sau.  There is also no evidence for a 
DksA homolog in thermophilic bacteria, hindering structural studies of DksA bound to 
RNAP holoenzyme and RPo.   
 The G1 phage protein PhERI and Tth/Mtb CarD both exploit the unique 
characteristics of rRNA promoters to have a profound impact on rRNA transcription.  
PhERI is the first protein factor that joins RNAP through an interaction with the global 
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transcription regulator σ but regulates RNAP activity though modulation of another 
RNAP domain, the α-CTD.  PhERI, by blocking productive α-CTD binding to UP-
elements, inhibits rRNA transcription, and thereby halts normal logarithmic cell growth 
(Chapters 1 – 5).  The majority of Sau promoters, having no dependence on UP-element 
binding, are not inhibited by PhERI.  PhERI thus exploits one unique characteristic of 
rRNA transcription previously described in other organisms: UP-element activation. 
 CarD, like DksA, modulates the stability of RPo, but rather than destabilizing 
RPo to decrease output from rRNA promoters, CarD increases the stability of RPo and 
stimulates RNAP activity at rRNA promoters (Fig. 7.8).   Whether this is CarD’s only, or 
even primary, function in vivo remains the subject of active research.  However, CarD’s 
effect on rRNA transcription in vitro demonstrates that it is a direct modulator of RNAP 
at rRNA promoters. 
 Neither Tth, Mtb or Sau have DksA homologs. Originally it appeared that CarD 
may be a functional homolog of DksA because it can compliment a DksA knockout in 
Eco cells (Stallings et al., 2009).  However, we show that CarD acts by stabilizing RPo, 
while DksA destabilizes RPo.   
 rRNA expression is one of the most important transcriptional switches in 
prokaryotic cells.  RNAP activity at rRNA promoters is regulated by small molecules that 
modulate RNAP activity (Gourse et al., 1998; Krasny and Gourse, 2004).  These 
promoters are finely tuned to be able to both have robust RNAP activity in log-growing 
cells but respond rapidly to changing cellular conditions.  While regulation may come 
from various small molecule signals of cell stress or starvation, proteins have co-opted 
the unique kinetic parameters of rRNA promoters to also facilitate the regulation of 
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RNAP activity.  We describe the prokaryotic protein CarD and the phage protein PhERI 
that both target rRNA transcription through unique parameters of rrn promoters: RPo 
stability and UP-element binding respectively.  While only three proteins in all 
prokaryotic organisms have been shown to directly target rRNA transcription 
specifically, two of which are described in this thesis, we believe the uniqueness of rRNA 
promoters can be a prime target for regulation not only be small molecules but also by 




Identification of the plastid RNA polymerase  
in Plasmodium falciparum 
 
Malaria, an infection by parasites from the family Plasmdoium, affects 300 
million and causes over one million deaths per year (2010; Kar and Kar, 2010; Murray et 
al., 2012).  Plasmodium falciparum (Pf) causes the majority of malaria cases throughout 
sub-Saharan Africa (2010; Kar and Kar, 2010).  Pf has a complex life-cycle that involves 
infection both of human and mosquito hosts; humans are infected when bitten by a Pf 
carrying mosquito (Cox, 2010).  In the initial stages of the infection, Pf parasites divide in 
the liver before being released into the blood where they infect red blood cells (RBCs), 
causing high fever, nausea, headaches, and other symptoms of infection (Trampuz et al., 
2003).   
Malaria is difficult to treat due to the lack of diagnostic tools and high levels of 
resistance to small-molecule therapeutics (Wernsdorfer and Noedl, 2003).  Malaria is 
traditionally diagnosed by visualizing blood smears on a microscope, technologies that 
are not widely available in developing countries (Tangpukdee et al., 2009; 
Wongsrichanalai et al., 2007).  Small-molecule interventions to malaria infection have 
suffered from widespread resistance (Wellems, 2002).  Because malaria generally affects 
those in developing countries, research and drug development on this important disease 
have lacked funding until recently (Murray et al., 2012).  Many traditional antimicrobials 
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are not effective against Plasmodium parasites due to their eukaryotic nature. Treatment 
is further complicated by the lack of accessibility to regular and quality healthcare in 
regions with endemic infections (Murray et al., 2012).   
Quinine, a small molecule isolated from the bark of Cinchona tree, and 
chloroquine were the first active anti-malarial agents.   However resistance rapidly arose 
to these treatments (Chaturvedi et al., 2010; Wernsdorfer, 1994).  Army research (a 
response, largely, to the malarial burden of US soldiers in the war in Vietnam) in the 
United States developed the quinine derivative mefloquine (Miller and Su, 2011) as a 
next-generation malarial drug.  Work in China identified artemisinin, derived from a 
medicinal plant (Miller and Su, 2011).  The use of mefloquine has been generally low 
due to its side effects and the emergence of resistance (Wernsdorfer, 1994).  Currently, 
artemisinin, and its derivatives, are the drug of choice for severe malaria infections 
(Miller and Su, 2011), although resistance to artemisinin has been described (Dondorp et 
al., 2009).   
Pf and related parasites harbor an organelle, termed the apiocoplast or plastid, 
descended from an endosymbiotic event with a cyanobacterium (Walter and McFadden, 
2005) (Fig. 8.1a).  The plastid has been shown to be required for Pf viability by chemical 
and genetic means (Nair and Striepen, 2011), but its essential function is not fully 
established (Roos et al., 1999).  It has been hypothesized that the plastid is required for 
biosynthetic pathway(s), and isolates reactions that produce reactive byproducts away 
from cellular proteins and nucleic acids.  Recent work shows that the inactivation of the 
plastid can be fully rescued by the addition of isopentenyl pyrophosphate (IPP).  Pf 
parasites can be grown indefinitely in the presence of antibiotics that block plastid 
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Figure  8.1:  Schematic  of  apicoplast  structure.   a)  Schematic  view  of 
Toxoplasma gondii, a parasite closely related to Pf.  Cellular organelles are 
labeled; the plastid is shown in green.  b) Rif inhibits the plastidic RNAP.  
Rifampicin  was  added  to  parasites  in  culture  and  RNAs  visualized  by 
northern blot.   rRNA and a nuclear  gene,  MSA, are not  affected by Rif 
addition,  but  the  plastid  encoded  rpoB/C  mRNA  is  repressed  by  Rif 
addition.  Adapted from (McConkey et al., 1997). 	

a)	   b)	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function if they are supplemented with IPP (Yeh and DeRisi, 2011).  This work argues 
that the only required function of the plastid in blood stage parasite growth is the 
biosynthesis of IPP.  However, it is unknown if the plastid has any other required roles at 
different stages of the Pf life cycle, either in the human or the mosquito host.    
Like the mitochondrion or chloroplast, the plastid harbors its own genome 
(Saxena et al., 2010; Wilson et al., 1996).  Indeed, the identification of the plastid began 
with the isolation of its circular genome (Gardner et al., 1991).  Very few genes are 
encoded on the plastid, arguing that plastidic genes have been shuttled to the nuclear 
genome (Wilson et al., 1996).  Import into the plastid itself is controlled by a bipartitate 
N-terminal import signal (Fig 8.2) (Waller et al., 2000; Zuegge et al., 2001).  Hundreds of 
nuclear genes are annotated as likely plastidic proteins, and many have been shown to 
localize to the plastid by co-localization studies (Nair and Striepen, 2011).  The plastidic 
genome contains genes for translational and transcriptional machinery, including rRNAs 
and tRNAs.  The large (β and β’) subunits of a prokaryotic like RNAP are also encoded 
on the plastidic plasmid (Wilson et al., 1996). 
RNA polymerase is a validated drug target being inhibited by the small molecule 
Rifampicin (Rif) (Hartmann et al., 1967; Hinkle et al., 1972b).  Rif binds near the RNAP 
active site and blocks the path of nascently transcribed RNA (Campbell et al., 2001).  Rif 
and Rif derivatives inhibit RNAP Sau (Fig 6.8), Eco and Mtb (Zenkin et al., 2005).  Rif 
has been tested as an anti-malarial agent in patients, alone and in combination with other 
antibiotics.  Rif showed moderate antimalarial activity in patients but is less effective 
than other therapies and therefore is not used clinically (Pukrittayakamee et al., 1994).   
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Figure 8.2: Schematic view of plastid membranes and protein import into 
the  plastid  in  Pf.   Proteins  containing  the  bipartite  N-terminal  signal 
sequence  (green protein;  yellow/orange  targeting  sequence)  are  imported 
across  the  four  membranes  of  the  apicoplast.   An  additional  pathway 
through which proteins localize to the apicoplast is shown (red proteins).  




The RNAP subunits encoded in the plastid are most closely related to 
cyanobacterial RNAP, which has not been previously studied in vitro or in vivo.  The 
addition of Rif to Pf parasites in culture inhibits parasitic growth, and also inhibits the 
synthesis of plastidic mRNA as assessed by northern blot (Fig. 8.1b) (McConkey et al., 
1997). Whether cyanobacterial RNAP is directly inhibited by Rif, or any Rif derivatives, 
has not been established.   
The plastid is required for viability of malaria parasites and therefore may provide 
novel drug targets (Nair and Striepen, 2011; Yeh and DeRisi, 2011).  RNAP activity in 
the plastid appears to be essential for viability of the parasite (Dahl and Rosenthal, 2007; 
McConkey et al., 1997; Pukrittayakamee et al., 1994), and is a known target for small 
molecule inhibitors (Campbell et al., 2001; Ezekiel and Hutchins, 1968; Hinkle et al., 
1972a).  This chapter will detail our efforts to identify, validate and clone the plastidic 
RNAP from Pf. To evaluate the potential for small molecule development against the 
prokaryotic-like RNAP in malaria, I identified the subunits of RNAP holoenzmye (α, β, 
β’, and σ) in the plastidic and nuclear Pf genome sequences.  To show that our putative 
RNAP subunits assemble in vivo, I attempted to tag the nuclear-encoded α subunit with 
affinity and fluorescent tags.  These studies examine an interesting target for drug 
development but also attempted to study a cyanbacterial-like RNAP for the first time.   
This project was done in close collaboration with Kirk Deitsch at Weill Cornell 
Medical College.  Kirk allowed me, and several of my summer students to culture and 
transfect Pf parasites in his lab.  The pull-downs and mass spectrometry experiments 
were planned in collaboration with the laboratory or Brian Chait here at The Rockefeller 




Identification of the RNAP α-subunit 
 The β and β’ subunits of RNAP are encoded in the plastidic genome, but every 
known bacterial RNAP also requires two copies of the α subunit for basic function and a 
σ subunit for initiation.  α and σ are not identifiable in the plastidic genome.  Therefore, 
if a functional RNAP assembles in the plastid, the α and σ subunits must be imported 
from the nuclear genome.  Bioinformatic tools are available to predict whether nuclear 
genes are likely to be imported into the plastid.  Blast searches in the Pf genome using the 
Eco α RNAP protein sequence identify a putative α RNAP subunit in the nuclear 
genome.  The gene (XP_001349803.1) is annotated as an RNAP subunit (Fig 8.3).  When 
evaluated for import into the plastid by the PATS server (Waller et al., 2000; Zuegge et 
al., 2001), this protein has a score of 0.989 (with a score of 1 being the most likely to be 
imported into the plastid), indicating a likely plastid import signal.  The predicted 
secondary structure of the Pf α and Eco α are listed in Fig 8.4a. 
 The α subunit of RNAP from other organisms has been amenable to 
crystallographic studies.  To attempt to crystallize this protein, a summer student in the 
Darst Lab, Leigh Harris, attempted to clone, express and purify Pf α constructs (Fig 
8.4b).  All constructs, except a small C-terminal fragment, were insoluble when 
expressed in Eco, even with the addition of solubilizing tags.  This C-terminal fragment 
was purified (Fig. 8.5b) and screened extensively for crystallization conditions, but no 
crystallization conditions were identified. 
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Figure 8.3: Domain conservation in the putative Pf α and Pf σ.  a) Pf α was 
blasted against the Eco genome and the rpoA/RNAP α fold was identified.  
b) ) Pf σ was blasted against the Eco genome and the rpoD/RNAP σ fold 
was  identified.   The  N-terminus  of  this  protein  has  no  known  fold  or 





Figure  8.4:  Schematic  view  of  the  putative  Pf  α  RNAP  subunit.   a) 
Comparison of the secondary structure predictions (sheet: blue; helix: red) 
for Pf α  to the known secondary structure of Eco α.   b) Pf α  constructs 





Figure 8.5 (adjacent page): Expression and purification of Pf α  and Pf α 
fragments.  a) Expression and solubility gel of full length Pf α (pJO.15) and 
an α truncation (pJO.08).  Both proteins are present in the insoluble fraction 
(lane D).  b) Purification of a C-terminal fragment of Pf α.   Protein was 
visualized on a 4-12% SDS-PAGE gel after the gel purification step and 







Identification of nuclear σ subunit 
 BLAST searches with Eco σ70 identified no σ homologs in Pf.  σ factors are 
required for promoter recognition and DNA melting, and it is unlikely that a functional 
cyanobacterial RNAP could exist without a σ subunit.  While group 1 σ factors are well 
conserved throughout bacterial species, differences between Eco and cyanobacterial 
RNAP sequences could explain the apparent lack of BLAST search hits.  When BLAST 
searches were performed with cyanobacterial σ factors, a Pf homolog was identified in 
the nuclear genome (Fig 8.3b).  Like the putative α-subunit, the putative σ factor (gene: 
XP_966194.1)  is likely to be imported into the plastid (PATS score: 0.991).  This protein 
is annotated as being of unknown function. 
 BLAST searches for the RNAP ω subunit from various organisms, including Eco 
and several sequenced cyanobacteria, yielded no obvious homologous protein in Pf.  
Cyanobacteria have a clear ω homolog.  This protein is small (<90 amino acids) and is 
not required for RNAP catalytic activity.  Whether Pf contains an ω homolog that could 
not be identified in our analysis is unclear.   
 
Validation of putative plastidic RNAP: pA pull-down 
 The β and β’ subunits of the cyanobacterial-like RNAP, encoded in the plastid, 
are almost certainly incorporated into a cyanbacterial-like transcriptional apparatus.  
However, the α and σ subunits we identified in the nucleus may not be properly imported 
into the plastid, despite their high PATS score values, and may not be the functional 
RNAP subunits.  We also failed to identify an ω subunit in silico although it may be 
present, but highly divergent in sequence, in the Pf genome.  To show that the complex 
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we identified in silico forms a complex in vivo, we attempted to purify the putative 
plastid-RNAP complex (pRNAP) by affinity tagging subunits in vivo followed by 
purification and mass-spectrometry.  Genetic tools are not available to make mutants in 
plastidic proteins in Pf.  Genetically altering nuclear genes is not trivial in this organism, 
but has been done previously (Deitsch et al., 2001; Epp et al., 2008).   
 To grow Pf in the laboratory requires cell culture conditions wherein the parasite 
can infect human RBCs.  Therefore, growing large-scale cultures requires using large 
volumes of RBCs and is technically difficult.  In vivo protein-tagging for identification of 
complexes requires a large amount of biomass to perform the purification steps.  Only 
one study has previously used mass spectrometry to identify in vivo assembled protein 
complexes in Pf, and large (2-3L) fermentor batches of RBCs were required for starting 
materials (Takebe et al., 2007).   
 For subsequent purification and mass spectrometry analyses, I decided to tag the 
putative nuclear encoded α subunit.  The σ subunit binds to core RNAP only at 
promoters, and therefore may not be an ideal target for pull-down experiments, whereas 
α is incorporated into RNAP at all steps in the transcription cycle.  I therefore cloned the 
nuclear α-subunit with a C-terminal protein-A (pA) tag.  Previous pull-down experiments 
in Pf used a PTP tag (Takebe et al., 2007), which I also cloned onto the C-terminus of the 
α-subunit.  While the endogenous, untagged α subunit was not removed from the Pf 
genome, we reasoned that it would not complicate our analyses. 
 These constructs were transfected into wild type Pf lab strain C3 by standard 
procedures (Epp et al., 2008).  Both produced potentially transfected parasite lines after 
two months of selection for the plasmid.  To ensure that the Pf lines were indeed 
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transfected and expressing our tagged RNAP α subunit constructs, I recovered plasmid 
DNA from the transfected lines, as well as purified mRNA and evaluated protein levels 
by western blot.  Plasmid DNA was recovered from transfected lines matching the 
constructs we expect.  RT PCR was used to identify mRNA corresponding to the gene of 
interest.  I used primers annealing to the tag for this purpose: endogenous RNAP α would 
be amplified by primers annealing just to the gene.  I see clear evidence for mRNA 
expressing out tagged constructs (Fig 8.6a and b).  Finally, I performed western blots 
using an antibody specific to the pA tag.  As a positive control, I tested a yeast strain 
previously shown to express pA tagged Nup130; the negative control was C3v86, the 
wild type Pf strain used for the initial transfection.   
 By western blot, we see clear evidence for pA tagged protein in the pA-tagged α 
transfected cell line (Fig 8.6b).  However, there is no distinct band at the correct 
molecular weight, as is the case for Nup130.  This is likely evidence of protein 
processing and/or degradation.  Proteins are known to be processed as they are 
transported across the plastidic membranes (Fig. 8.2), however we would still expect to 
see one predominant band somewhat under the size of the theoretical mass (74 kDa).  
Whether the degradation apparent in the western blot is occurring in the cells or after we 
lyse the cells and prepare the sample is unclear.   
 At this point, satisfied that pA tagged protein is being expressed in our transfected 
Pf lines, we decided to proceed with pA pull-downs and subsequent analysis.  Samples 
were sent to the Ben Mamoun lab at Yale for large-scale growth in their fermentor 
facility.  However, we were never able to achieve enough sample to proceed beyond this 
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Figure 8.6:  Expression of pA tagged Pf α in C3 Pf parasites.  a) Schematic 
of PCR used to identify tagged Pf α.  The Pf α gene is shown in black with 
the N-terminal signal sequence and the C-terminal pA tag highlighted in red.  
Primers used for PCR are shown as blue arrows.  The second reverse primer 
anneals to a sequence in the pA tag and therefore can differentiate between 
endogenous and exogenously expressed Pf α.  b) Non-quantitate RT-PCR of 
control cells (lane 1) and cells expressing pA tagged Pf α (lanes 2 and 3).  c) 
Western  blot  with  anti-pA antibody.   pA tagged  Nup130 was  used  as  a 
positive control, C3v86 which does not express a pA tagged protein was 
used as a negative control.  pJO.07 corresponds to C3 parasites containing 
the pA tagged Pf α subunit.  	

a)	  
b)	   c)	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step.  The Ben Mamoun lab was unable to grow the required sample for our pull-down 
experiments due to logistical issues. 
 
Validation of putative plastidic RNAP: Rif pull-outs 
 Due to the inherent difficulty of transfecting Pf parasites, the time required and 
the possibility that our exogenously expressed, tagged protein was being degraded in 
vivo, we decided to use chemical means to pull-out unusual RNAPs.  Rifampicin binds to 
RNAP from many organism with high affinity and slow Koff rates (Feklistov et al., 2008).  
We reasoned that Rif, bound to a resin, could interact with RNAPs and facilitate the 
purification of RNAP from organisms that are not genetically tractable.  Rif binds near 
the active site of RNAP, deep inside the cleft formed by the β and β’ subunits (Fig. 8.7) 
(Campbell et al., 2001).  We therefore reasoned that Rif would have to be attached to the 
resin via a long, flexible linker, allowing it to reach its RNAP binding site.  This work 
was done in collaboration with a fantastic chemist, Arkady Mustaev, and a talented 
summer student in the Darst lab, Fatmata Bah.   
 Arkady Mustaev chemically synthesized agarose resins bound to Rif via linkers of 
increasing length (17 C-C bonds, 42 C-C bonds and 52 C-C bonds).  The distance from 
the surface of RNAP to the Rif binding site is approximately 45 Å (Fig 8.7b).  I initially 
used purified Eco RNAP to show that it bound specifically to Rif-conjugated resins.  To 
remove protein from the resin, I used Guanidinium to denature all proteins; adding excess 
Rif was insufficient to remove bound RNAP from the column (likely due to the 
extremely slow Koff of Rif bound to RNAP).  Gels were silver stained to allow 
visualization of small amounts of protein.  RNAP binds specifically to resin conjugated to 
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Figure 8.7: Structure of Rif bound the RNAP.  a) Surface representation of 
Taq RNAP (green) bound to Rif (red).  Rif binds deep within the cleft of 
RNAP adjascent to the active site.  b) Zoom of Rif (red) binding pocket 
showing shortest path  (yellow) to the surface of RNAP.  The distance was 







Figure 8.8: Rif pull-outs of Eco RNAP.  a) Rif was conjugated to agarose 
beads with a  17 carbon-carbon bond containing linker.   Eco RNAP was 
incubated with the beads, followed by thorough washing with 1x binding 
buffer.  Bound protein was eluted using 6M guanidinium.  Aliquots from 
each  sample  were  visualized  on  a  4-12%  SDS-PAGE  gel  with  silver 
staining.   b)  Rif  conjugated  to  agarose  beads  using  a  42  carbon-carbon 
linker.  Pull-outs were performed as in part a.  c)  Rif conjugated to agarose 













































Rif with 42 or 52 C-C linkers, but not with the 17 C-C linker, which we predict would be 
too short to reach the Rif binding site on RNAP (Fig 8.8).   
 Next I attempted to specifically purify RNAP from Eco lysate using the same 
techniques.  While purified RNAP appeared to bind to the Rif-conjugated resins, we see 
no RNAP enrichment in the elution fractions from Eco lysates (Fig 8.9).  While some 
bands appear that are approximately the right size for RNAP in elution fractions from the 
42 C-C and 52 C-C conjugated resins these results proved difficult to reproduce 
systematically.   
 
Validation of putative plastidic RNAP: mCherry tagged α 
 Because pull-downs using pA tagged RNAP and pull-outs using chemical ligands 
proved difficult, we decided to attempt to tag the α subunit with a fluorescent tag that 
would allow direct visualization by standard microscopic techniques.  This work was 
done with the help of a talented undergraduate, Ronnie Almonte.  We cloned the RNAP 
α subunit with mCherry, a monomeric RFP, fused to the C-terminus of the protein.  We 
then attempted to transfect wild type Pf parasite lines and a parasite line with a plastid-
localized protein fused to GFP for co-localization studies.  However, after two attempts at 
transfection, we were never able to attain a single parasite line containing our gene of 
interest.   
 
Conclusions and future directions 
 The identification of the plastidic RNAP in Pf proved technically challenging at 
almost every point.  Even relatively simple techniques, such as molecular cloning, are 
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Figure 8.9: Purification of RNAP from Eco lysate.  a) Eco lysate was loaded 
onto Rif conjugated beads with a 17 carbon-carbon linker.  Purification was 
performed as in Figure 8.  b) Eco lysate was loaded onto Rif conjugated 
beads with a  42 carbon-carbon linker.   Purification was performed as in 
Figure 8.  c) Eco lysate was loaded onto Rif conjugated beads with a 52 












































difficult in Pf.  The genome content in Pf is nearly 90% A/T rich and Pf proteins are often 
characterized by long, unstructured regions, making them notoriously difficult to study or 
purify using model organisms such as Eco.  DNA synthesis is increasingly cost effective 
and may be particularly useful when attempting to clone Pf genes due to their wildly 
abnormal codon usage in Eco.  Using codon optimized DNA could potentially make the 
expression and purification of the Pf plastidic RNAP domains and complexes feasible in 
Eco.   
 The Pf plastidic RNAP is related to the cyanobacterial enzymes.  In these 
organisms, some of which have been fully sequenced, RNAP genes are annotated and 
likely to form functional complexes.  Studying RNAP from cyanobacteria may provide 
insights into the Pf enzyme and, even if conclusions on the Pf enzyme would be limited, 
would certainly be interesting from an evolutionary standpoint.  As in Sau, promoters and 
regulatory factors are completely uncharacterized in the cyanobacteria.   
 Recent work has characterized the putative replicative DNA polymerase in the Pf 
plastid.  Work on this enzyme is facilitated by the fact that a single protein encodes both 
helicase and DNA polymerase activities and is clearly imported into the Pf plastid.  
Identification of the active RNAP required for transcription in the plastid would provide a 
rich biochemical system for evaluating gene expression in this organelle.  Furthermore, 
given a purified in vitro system, testing or designing small-molecule inhibitors of RNAP 
activity would be relatively trivial.  This research would provide a framework for 
understanding transcription in the Pf plastid, and allow for the development of small-




Materials and Methods 
 
Protein Expression and Purification  
 The PhERI / σA4 (Sau σA residues 297-368) complex was cloned into a single 
operon as described (Patikoglou et al., 2007).  Both proteins were cloned to be expressed 
from a single mRNA transcribed by T7 RNA polymerase using pET vectors or the 
modified pET vector pSKB2, and to have a ribosome binding site.  σA4 was cloned with a 
cleaveable 6(his) tag whereas PhERI contains no affinity tag (see figure 2.2). The 
complex was expressed in Eco BL21(DE3) cells with 1mM IPTG at 37°C for 3h and 
purified using Ni-affinity chromatography using 1x protein purification buffer (20mM 
Tris HCl pH 8.0, 0.5M NaCl, 5% glycerol, 0.5mM β-ME). The his(6) tag was 
subsequently cleaved from σA4 by incubation overnight with precision protease and the 
complex was further purified by substractive Ni-affinity and size exclusion 
chromatography in 10mM Tris HCl, 0.5M NaCl, 1mM DTT. PhERI and σA4 formed a 
stable, stoichiometric complex throughout the purification. We dialyzed the complex into 
crystallization buffer (10mM Tris-HCl pH 8.0, 0.5M NaCl) and screened for 
crystallization conditions.  
 PhERI was cloned into pET29a using NdeI and XhoI, removing the native stop 
codon, to produce a C-terminally His-tagged protein. PhERI was expressed in 
BL21(DE3) cells with 0.5mM IPTG overnight at 18°C and purified using standard Ni-
affinity chromatography in 1x protein buffer.   
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 Sau σA was cloned into PSKB2, a modified pET vector, using NheI and HindIII. 
The His-tagged protein was expressed in BL21(DE3)plysS cells at 25°C for 5 hours. The 
protein was purified using Ni-affinity chromatography, dialysed into low salt buffer 
(20mM Tris HCl pH 8.0, 0.1M NaCl, 1mM DTT, 5% glycerol), and subsequently 
purified on a Q-sepharose column using a linear salt gradient (0.1M – 0.6M). Eco core 
was removed by a final purification step using size-exclusion chromatography in 20mM 
Tris HCl pH 8.0, 0.25M NaCl, 5% glycerol, 1mM DTT (SD75). The σA-mutant was 
made by megaprimed-PCR, cloned into the same expression vector and purified by the 
same protocol. σA and PhERI for subsequent use in biochemical experiments were stored 
in Sau protein storage buffer (10mM Tris HCl pH 8.0, 150mM NaGlutamate, 15% 
glycerol and 1mM DTT). 
 
Crystallization of the PhERI / σA4 4 complex 
 Crystals of the PhERI / σA4 complex were grown under two different conditions at 
22°C: JSCG59 (0.16M CaAcetate, 0.08M NaCacodylate, 15% (w/v) PEG8000 and 20% 
glycerol) and PC38 (0.1M MES pH 6.5, 10% (w/v) PEG5000 MME, and 20% 1-
propanol). Sitting and hanging drops were used and crystals were formed using a 1:1 
ratio of protein complex (10mg/ml) and reservoir solution. JCSG59 crystals were flash 
frozen in their mother liquid while PC38 crystals were cryoprotected briefly in 15% 
glycerol before being frozen. Selenomethionine substituted protein was purified and 
crystallized under the same conditions. Data were collected at the X3A beamline at the 
Brookhaven National Laboratories and 24-ID at the Advanced Photon Source. The native 
PC38 crystals diffracted to under 2.0Å. The data was processed using HKL2000 
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(Otwinowski and Minor, 1997), selenomethionine sites were found using Shake-and-
Bake (Weeks et al., 2002), SAD phases calculated using SHARP (de La Fortelle et al., 
1997) and initial density modification performed with Resolve (Terwilliger, 2000). Coot 
(Emsley and Cowtan, 2004) was used for model building and the structures were refined 
using Phenix (Adams et al., 2010). The high-resolution model was used late in the 
refinement process for the JCSG59 structure to aid in the placement of poorly defined 
density.  
 
Calculation of buried surface area and protein contacts 
 Buried surface area was calculated using the CCP4 (Bailey, 1994; Potterton et al., 
2003) based program AREAIMOL by measuring the total surface area of PhERI and σA4 
individually, and then measuring the total surface area of the complex.   
 To evaluate the contacts between the two proteins, we used the CCP4 (Bailey, 
1994; Potterton et al., 2003) based program Contact. Putative contacts were then 
evaluated in the structural data using PyMol.  Hydrogen bonds, or water mediated 
hydrogen bonds, were accepted if they were within 4Å.   
 
Purification of Sau RNAP 
  Sau RNAP was purified natively from cells essentially as described (Deora and 
Misra, 1996). Briefly, Sau  NCTC8325-4 cells were grown to an O.D. of 1.0, collected by 
centrifugation, washed in a high salt buffer, and resuspended in grinding buffer (TGED 
(10mM Tris HCl pH 8.0, 5% glycerol, 0.1mM EDTA and 1mM DTT) + 0.2M NaCl). 
Cells were lysed by French-Press and the cleared lysate was precipitated with 
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polethyleneimine at 0.6% (v/v). After centrifugation, the pellets were washed with TGED 
+ 0.45 M NaCl, RNAP was eluted with TGED + 1.0M and precipitated with 35% (w/v) 
ammonium sulfate. The pelleted protein was resuspended in TGED and diluted to a 
conductivity equal to TGED + 0.1M NaCl. Protein was purified sequentially by a 
herparin column using a linear salt gradient and gel filtration column. An S-sepharose 
column was required as a final step to remove holoenzyme from core RNAP. RNAP was 
stored at -20°C in Sau protein storage buffer (10mM TrisHCl pH 8.0, 0.15M NaGlu, 30% 
glycerol, 1mM DTT).  Protein purity was analyzed at each step in the purification by 
running protein samples on a 4-12% SDS-PAGE gel. 
 
Native gel eletrophoresis 
 Proteins were incubated for 10 minutes on ice at the indicated concentrations in 
1x protein buffer (10mM Tris HCl pH 8.0, 150mM Sodium Glutamate, 1mM DTT) 
supplemented with 10% glycerol to facilitate subsequent gel loading.  After incubation, 
samples were loaded onto a 4-12% PhastGel using native buffer strips (GE Healthcare).  
Gel migration was monitored by adding 0.05% bromphenol blue to the loading buffer.  
Gels were stained with coomassie blue. 
 
Limited proteolysis 
 PhERI or σA4, or the reconstituted complex of the two proteins were incubated at 
5µM in 10µl in 1x proteolysis buffer (100 mM Tris HCl, pH 8.0 and 20 mM CaCl2) on 
ice for 10 minutes.  Reactions were brought to 30°C before the addition of trypsin at the 
following molar ratios (protein:protease): 1:0, 1000:1, 100:1, 50:1, 10:1, 5:1.  Reactions 
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were allowed to proceed for 30 minutes and stopped with the addition of 1µl of 100mM 
PMSF.  10µl SDS loading buffer was added and samples boiled for 5 minutes at 95°C 
before being run on a 4-12% SDS-PAGE gel (Invitrogen).   
 
Preparation of DNA template for in vitro transcription assays 
 Promoter DNA fragments were made by PCR.  Briefly, DNA oligos annealing to 
more than 100 bases upstream of the promoter and roughly 100 bases downstream were 
ordered.  PCR was then used to amplify the promoter fragment directly from the Sau or 
Phage G1 genome.  Promoter fragments were at least 250 bases in length; shorter 
promoter fragments, or DNA oligos corresponding to promoter fragments of 100-150 
bases, produced no activity in vitro.  PCR products were then purified on a 1.5% agarose 
gel and electroeluted into a 15kD dialysis tubing before subsequent phenol:chloroform 
extraction and ethanol precipitation.  Promoter fragments were then resuspended in 
10mM Tris pH 9.0 at 1µM final concentration.   
 
In vitro transcription assays 
 Proteins used in in vitro transcription assays were diluted into 1x protein storage 
buffer. σA (100nM) was preincubated with PhERI (or buffer) for 10 minutes on ice, 
followed by the addition of Sau core RNAP (50nM). After 10 minutes, DNA (50ng of 
genomic DNA or 50nM of purified promoter DNA) was added and the reaction brought 
to 20µl in 1x Sau transcription buffer (40mM Tris-acetate pH 7.9, 10mM MgCl2, 1mM 
EDTA, 50ug/ml BSA, 100mM NaCl and 1mM DTT). Reactions were incubated for 10 
minutes at 37°C to form open promoter complexes and then initiated with NTPs (200uM 
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GTP, CTP, UTP, 50uM ATP, 0.1ul alpha-P32ATP). After 5 minutes reactions were 
stopped with 2x formamide buffer (98% formamide, 5mM EDTA) and run on a 12% 
Urea PAGE gel. Products were visualized on a phosphoimging screen and where 
applicable quantified using ImageQuant.  
For the assays using genomic DNA as the transcription template, reactions were 
stopped with 20mM EDTA and 0.5% SDS, pipetted onto Whatman DE81 paper, washed 
5 times with Sodium Phosphate (50g/L), rinsed with water, dried and visualized on a 
phosphoimaging screen.  
 
Sau promoter identification 
 Sau promoters were identified through the use of a bioinformatic tool and 
manually by searching in the annotated Sau genome using the program Artemis 
(Rutherford et al., 2000).  Briefly, the DNA sequence upstream of genes of known 
function (i.e. DNA polIII or dnaA) was manually searched for promoter-like sequences 
(TTGACA/TATAAT).  When obvious promoters were not apparent, a program designed 
by Michael Mosely was used.  The PromoterScore program is a Perl based script that 
searches genomic sequences for putative -10 or -35 elements.  The user can select a score 
threshold above which a sequence is considered a putative -10 or -35 element.  The 
scoring is based on the observed likelihood of bases at each position in the -10 and -35 
elements.  Once a sequence has reached the score threshold for the initial search, the 
program moves 15 bases downstream of a putative -35 or 15 bases upstream of a -10 and 
searches for the other sequence element, again using a threshold for putative sequence 
elements defined by the user.  Putative promoters are output to a text file.     
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Strains and plasmids 
RN4220 was obtained from Peter Moyle in Tom Muirs lab.  pRMC2 and 
NCTC8325-4 were a generous gift from Ramesh Wigneshweraraj at Imperial College 
London.   
 
PhERI expression in vivo 
 PhERI was cloned into the Sau expression vector pRMC2 (Corrigan and Foster, 
2009) using primers containing a consensus Shine-Dalgarno sequence and BglII upstream 
of the start codon and a stop codon and EcoRI site downstream. pRMC2-PhERI and 
empty pRMC2 were then transformed into Sau strain RN4220 by standard 
electroporation (Schenk and Laddaga, 1992) and transformants selected on trypticase soy 
(TS) plates containing Chloramphenicol (10ug/ml). RN4220 containing empty pRMC2 
and pRMC2-PhERI were grown in TS broth containing Chloramphenicol and transgene 
expression was induced with 100ng/ml anhydrotetracycline, which was the minimum 
required concentration for maximal cell growth inhibition by PhERI.  
 
RNA purification  
 RNA was purified from cells at mid-log phase growth (O.D.600 0.3-0.4) using the 
RNeasy kit from Qiagen. Briefly, 2x108 cells were removed from growing cultures, 
immediately added to 2 volumes of BioStabilize solution and incubated for 5 minutes at 
room temperature. Cells were then collected by centrifugation, resuspended in TE buffer 
containing 1mg/ml lysostaphin and 200ug proteinase K and incubated for 15 minutes at 
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RT. 100µl zirconia beads (0.1mm) were added and the cells lysed for 3 x 2minutes, with 
a 1-minute rest on ice, in a bead-beater at top speed. The lysate was centrifuged briefly to 
remove the beads and the remaining procedure was carried out to the manufacturer’s 
specifications. Purified RNA was quantified using a NanoDrop spectrometer.  
 
Metabolic labeling of Sau rRNA 
 In vivo labeling of nascent RNAs was carried out as described (Wade et al., 
1964). Briefly, cells containing pRMC2-PhERI or empty pRMC2 were induced with 
100ng/ml anhydrotetracycline at O.D.600 0.2, allowed to grow for 40 minutes (1 normal 
doubling time), after which 200µCi of P32 labeled orthophosphoric acid was added 
directly to the growth media. 2x108 cells were collected after 20 minutes and RNA 
purified as described above. To visualize rRNA, total RNA was run on a 6% 
polyacrylamide gel, which was stained with 1x gelred (Phenix Research) to visualize 
total RNA. The same gel was then exposed to a phosphoimaging cassette to visualize P32 
incorporation into cellular RNA.   P32 containing rRNA was quantified using 
ImageQuant. Three independent experiments were performed and relative P32 
incorporation was averaged.  Total RNA was quantified by Nanodrop and averaged over 
three independent experiments.   
 
RNA-seq: Sample preparation and Sequencing 
 Total RNA was purified as described above from Sau RN4220 cells containing 
pRMC2 and pRMC2-PhERI at OD600 = 0.4 after the addition of anhydrotetracycline 
(100ng/ml) at OD600 = 0.2.  For RNA-seq analysis, 2x108 cells were immediately added 
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to 2x volumes of BioStabilize (Qiagen) and incubated at room temperature for 10 
minutes before RNA purification.   
 For the RNA-seq analysis, mRNAs are generally enriched to exclude the majority 
of large, structured rRNAs.  RiboZero rRNA removal kit for gram-positive organisms 
(Epicenter) was used to eliminate the 16s and 23s rRNA species prior to sequencing 
analysis.  RNA quality was then checked on a BioAnalyzer (Agilent) chip prior to cDNA 
library synthesis.  cDNA libraries were prepared by standard techniques for subsequent 
Illumina sequencing using the mRNA-seq Sample Prep kit (Illumina) eliminating the step 
for mRNA amplification.  Briefly, after the rRNA reduction, RNA was fragmented and 
used as a template for a randomly primed PCR.  After the amplification, ends are repaired 
and ligated to Illumina adapters.  The cDNA library is then verified for appropriate 
fragment size (200-300bp) on a BioAnalyzer chip.    
Samples were amplified onto flowcells using an Illumina cBot and sequenced on 
an Illumina HiSeq2000 for 51 cycles per manufacturer protocols. Raw sequencing data 
was processed using the onboard SCS/RTA software yielding 51bp reads. 
 
RNA-seq: Data Analysis 
Sequencing reads were processed using TopHat (Trapnell et al., 2009), an 
alignment package designed to align sequencing reads derived from transcribed RNA. 
Briefly, the program aligns reads to a reference genome, identifying regions of coverage 
that correspond to transcribed RNA. These regions are joined and queried for potential 
junctions by attempting alignment of reads that did not initially align. Reads aligning to 
multiple locations are kept (to a maximum of 20 potential positions) to assist constructing 
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gene models for genes with repetitive or low complexity features. When aligning reads, 2 
mismatches to the reference (Ensembl S_aureus_nctc_8325.EB1.fa) were allowed.  
Alignments reported from TopHat were processed by the Cufflinks software 
package (Trapnell et al., 2010) to determine differential expression of genes and 
transcripts between conditions.  
Alignments were quantitated against the Ensembl annotation: 
(S_aureus_nctc_8325.EB1_s_aureus_nctc_8325.gtf).  
Expression values are reported as fragments-per-kilobase-of-gene-per-million-
mapped reads (FPKM).  Data were visualized using the Integrated Genomics Viewer 
(Robinson et al., 2011).   
 
Open Promoter Complex Stability Assay 
 Open promoter complexes were assayed as previously described.  Briefly PhERI 
(1µM), or empty protein buffer, was incubated with σA (100nM) for 10 minutes before 
the addition of Sau core RNAP (50nM).  The complex was incubated on ice for 10 
minutes.  For the aag and rrnA promoter, 50nM of linear DNA was added to the reaction 
in 1x Sau transcription buffer, as described.  Open promoter complexes were allowed to 
form for 20 minutes at 37°C before being challenged by the addition of 1µM double 
stranded FullCon promoter fragment.  At time points after the addition of the FullCon 
promoter fragment (Gaal et al., 2001), reactions were initiated by the addition of 200µM 
NTPs with α-P32 labeled ATP.  Reactions were stopped after 5 minutes by the addition of 
2x stop buffer and electrophoresed on a 12% Urea-PAGE gel as described above. 
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 For the G1-PhERI promoter, we assayed open promoter complexes by filter 
binding.  The linear promoter fragment was end-labeled with P32 using polynucleotide 
kinase (PNK, New England Biolabs) under standard conditions.  Open complexes were 
formed by incubation of holo +/- PhERI at the above concentrations at 37°C and 
challenged by the addition of 1µM unlabeled FullCon promoter fragment.  At time points 
after the addition of challenging DNA, 10µl aliquots were pipetted onto prewashed filter 
papers (MF-Membrane Filters, 0.45µM, Millipore), allowed to bind for 10 seconds, and 
washed with 1x wash buffer (10mM Tris pH 8.0, 0.2M NaCl).  Filter papers were dried 
and quantified on a phosphoimaging screen.  All samples were normalized to the signal at 
time = 0.    
 
Construction of hybrid promoters 
 Hybrid promoters for transcription assays and DNAse footprinting were made by 
megaprimed PCR.  Breifly, a DNA oligo containing the DNA upstream of the -35 from 
the rrnA promoter and the -35 element of the dnaA promoter was used, with an rrnA 
upstream primer, to amplify the upstream promoter region.  This was then used as a 
megaprimer using a dnaA downstream primer to amplify the full hybrid promoter.  The 
dnaA(up)-rrnA(down) promoter was made using the inverse strategy: an initial PCR 
using a primer for upstream dnaA promoter and the rrnA -35 element.  The first PCR was 
then used to megaprime using the rrnA downstream primer.  Sequences were verified by 
standard DNA sequencing.    
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DNAse I footprinting 
 DNA fragments were made by PCR and end-labeled on the template strand. The 
reverse PCR oligo (100pmol) was gel purified, P32 end labeled with polynucleotide 
kinase (PNK), and unincorporated nucleotide was removed on a sephadex G-50 spin 
column. The radiolabeled primer was then added to a standard PCR reaction using a 
blunt-end PCR enzyme and the PCR product was gel purified.  
 Reactions were performed by forming a complex between sigma (5µM) PhERI 
(5µM) and core (2µM) on ice. Labeled promoter DNA (0.1µl) and DNAseI reaction 
buffer (1x : 5mM Tris-acetate pH 7.9, 5mM KCl, 1mM MgCl2) were added and 
incubated at 37°C for 10 minutes. DNAseI (0.1µg/ml) was added for 1 minute and 
reactions stopped with 15mM EDTA. Samples were boiled for 5 minutes, separated on a 
6% UREA PAGE gel and visualized on a phosphoimager screen.  
 
β-flap : Protein Expression and Purification  
 The Sau β-flap (Sau β residues 789-916) was cloned into the modified pET vector 
pSKB2 using the restriction enzymes NdeI and BamHI to contain an N-terminal 6(his) 
tag upstream of a precision protease cleavage site.  The Sau β-flap was then transformed 
into Eco BL21(DE3) cells and induced at 37°C for 3h using 1mM IPTG.   
 Lysate from 2L of BL21(DE3) cells was lysed by French Press, cleared by 
centrifugation and loaded onto a HiTrap IMAC column (GE Healthcare).  The column 
was washed with 20mM, 40mM and 60mM Imdazole in purification buffer (20mM Tris 
HCl pH 8.0, 0.5M NaCl, 5% glycerol and 0.5mM β-ME).  Protein was eluted from the 
column in 250mM Imdazole, dialyzed overnight in the presence of precision protease 
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(50:1 protein:protease) into purification buffer, and reloaded onto a HiTrap IMAC 
column to remove uncleaved protein and tag.  The β-flap was finally purified by size 
exclusion chromatography on an SD75 gel filtration column (GE healthcare).    
 
Crystallization of β-flap/PhERI/σA4 complex  
 The PhERI/σA4 complex was purified as described above, and the Sau β-flap was 
purified separately.  The PhERI/σA4 complex was concentrated to 10mg/ml and the β-flap 
to 5mg/ml; both proteins were buffer exchanged into crystallization buffer (10mM Tris 
HCl pH 8.0 and 0.5M NaCl).  The two protein solutions were mixed (10mg/ml PhERI / 
σA4 complex; 5mg/ml Sau β-flap) on ice and incubated for 10 minutes prior to setting up 
crystallization screens.  Initial hits were further refined by 2-dimensional screening.  
Seeding from initial needles into two conditions (0.1 M MES pH 6.5, 2% (w/v) PEG 
10,000, and 0.2M Magnesium chloride, and 0.1 M HEPES pH 7.5, 2%  (w/v) PEG 4000) 
reproducibly produced large plates.  We evaluated the protein content of these crystals by 
looping several large plates, washing them 8 times in fresh mother liquor and 
resuspending them in 2x SDS-loading buffer.  After extensive boiling, the solution was 
run on an 8-25% PhastGel and stained with coomassie blue. For diffraction analysis, the 
crystals were cryoprotected in mother liquor plus 20% glyercol for both conditions before 
being flash frozen in liquid nitrogen.   
 
Data Collection and Analysis 
 The crystals of the 3-protein complex were tested for diffraction at the X29 
beamline at Brookhaven National Laboratories.  One crystal diffracted to under 4.0Å 
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resolution. Data were indexed and scaled using HKL2000 (Otwinowski and Minor, 
1997).  We searched for molecular replacement solutions using the PhERI/σA4 complex 
using both Phaser (Mccoy et al., 2007) and MolRep.  Data was analyzed for diffraction 
defects using Phenix (Adams et al., 2010) and low-resolution DEN refinements were 
attempted using CNS (Brunger et al., 1998; Schroder et al., 2010).   
 
Crystallization of the β-flap  
 The Sau β-flap alone was purified as described, dialyzed into crystallization 
buffer (10mM Tris HCl pH 8.0 and 0.5M NaCl) and screen for crystallization conditions. 
Large, high quality crystals were produced in many conditions, including 0.1 M Sodium 
acetate pH 4.6, 8% (w/v) PEG 4000.  These crystals were cryoprotected in 20% glycerol 
before being flash frozen in liquid nitrogen.  Data were collected on the X29 beamline at 
Brookhaven National Laboratories.  Data were indexed and scaled using HKL2000 
(Otwinowski and Minor, 1997) and molecular replacement solutions identified using 
Phaser (Mccoy et al., 2007).   The model building was performed using Coot (Emsley 
and Cowtan, 2004) and refined using Phenix (Adams et al., 2010).   
 
Sau Transcription Assays using Rifalazil 
 Sau transcription assays were performed exactly as described above, with the 
addition of Rifalazil at the indicated concentrations.  Briefly, open promoter complexes 
were formed by mixing Sau core with σA, adding linear promoter DNA fragments, and 
incubating at 37°C for 10 minutes.  2 minutes prior to the initiation of the reaction, 
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Rifalazil was added to the complex.  Reactions were then initiated by the addition of 
NTPs exactly as previously above.   
 
Crystallization of Sau RNAP 
 Sau RNAP was purified as described above.  After the final step in the 
purification, protein was dialyzed into 1x crystallization buffer (10mM Tris HCl pH 8.0, 
0.2M NaCl, 1mM DTT) and extensively screened for crystallization conditions.  In one 
condition (0.1 M HEPES pH 7.5, 0.2 M MgCl2, 30% PEG400), small crystals grew after 
approximately 14 days.  We evaluated the protein content of these crystals by visualizing 
them on a UV microscope (JANSi UVEX).  Sau RNAP crystals were cryoprotected by a 
quick dip in mother liquor supplemented with 5% glycerol and flash frozen in liquid 
nitrogen.  We evaluated crystal diffraction on the microdiffractomoter (beamline 24-ID-
E) at the Advanced Photon Source at Argonne National Laboratories.  The one diffracting 
crystal was indexed using HKL2000 (Otwinowski and Minor, 1997).   
 
CarD: In vitro transcription assays 
 Proteins used in in vitro transcription assays were diluted into 1x protein storage 
buffer (10mM TrisHCl pH 8.0, 0.15M NaGlu, 15% glycerol, 1mM DTT). CarD, at the 
indicated concentration, was preincubated with core RNAP (50nM) for 10 minutes on 
ice, followed by the addition of σ (Tth σA full length or σAΔN1.1, as indicated; 100nM). 
After 10 minutes, linear promoter DNA (50nM) was added and the reaction brought to 
20µl in 1x transcription buffer (40mM Tris-acetate pH 7.9, 10mM MgCl2, 1mM EDTA, 
50ug/ml BSA, 100mM NaCl and 1mM DTT). Reactions were incubated for 10 minutes 
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at 65°C to form open promoter complexes and then initiated with NTPs (200uM GTP, 
CTP, UTP, 50uM ATP, 0.1ul α-P32ATP). After 5 minutes reactions were stopped with 2x 
formamide buffer (98% formamide, 5mM EDTA) and run on a 12% Urea PAGE gel. 
Products were visualized on a phosphoimging screen and quantified using ImageQuant. 
Promoter fragments were prepared by PCR, purified on a 1.5% agarose gel, and 
electroeluted into dialysis tubing. Following phenol/chloroform extraction, DNA was 
ethanol precipitated and resuspended in 10mM TrisHCl pH 8.0 to 1µM final 
concentration. 
 
CarD: Abortive Initiation Assays 
 Abortive transcription assays were performed as above, but initiated with NTPs 
suitable to give only short products.  The 23s rRNA promoter was tested by forming open 
promoter complexes as above.  Transcription was initiated by adding the initiating 
nucleotide, GTP (200nM) and labeled CTP (50µM CTP, 0.1µl α-P32CTP) to form a 4-
base RNA product.  T7A1 was tested by forming open complexes as above and initiating 
with ApU dinucleotide primer (20µM) corresponding to the +1 and +2 nucleotides and 
radiolabeled CTP (50µM CTP, 0.1µl α-P32CTP).   
 
CarD: Open Complex Stability assays 
 Reactions were prepared as above for the in vitro transcription assays.  Briefly, 
CarD or buffer, was preincubated with core RNAP (50nM) for 10 minutes before the 
addition of σAΔN1.1 (100nM). Linear promoter DNA (50nM) was added and the 
reactions were incubated at 65°C for 10 minutes to form open complexes.  Once open 
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complexes were formed, they were challenged with the FullCon double stranded DNA 
fragment in large molar excess (1µM).  For the 23s rRNA promoter, open complexes 
were quantified by initiating transcription with NTPs at the concentrations used above at 
various times after the addition of competing DNA. 5 minutes after the addition of NTPs, 
reactions were stopped with 2x formamide buffer, run on a 12% Urea PAGE gel, 
visualized and quantified as above.   
On the T7A1 promoter, open complexes were quantified by filter binding, as 
described above.  Briefly, linear promoter DNA fragments were end-labeled with P32.  
Labeled promoter DNA (50nM) was added to RNAP holoenzyme +/- CarD.  After 
incubation at 65°C to form open complexes, a large excess (1µM) of the double stranded 
FullCon promoter fragment was added.  10µl aliquots were taken at different time points 
after the addition of challenging DNA and bound to pre-washed filters (MF-membrane 
filters, Millipore) and immediately washed with 4ml 1x wash buffer (10mM Tris HCl pH 
8.0, 200mM NaCl).  Radioactive signal, corresponding to labeled promoter DNA 
fragment bound to RNAP, was quantified after exposure on a phosphoimaging cassette 
using ImageQuant. 
 
CarD: Ni-bead pulldown 
 10(his)-tagged Tth RNAP (2µM) was first incubated with CarD (10µM) or the 
CarD-RID (10µM) and σAΔN1.1 (5µM) for 10 minutes on ice in 1x pull-down buffer 
(20mM Tris HCl pH 8.0, 0.25M NaCl, 1mM DTT). The proteins were then added to pre-
washed and equilibrated Ni-NTA agarose beads (Qiangen) and incubated with gentle 
mixing for 1h at 22°C.  After binding, the slurry was centrifuged for 3 minutes at 4000xG 
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to separate the beads from the buffer.  Supernatent was carefully removed, and the beads 
were washed extensively (5 times 500µl, 10 minutes with gentle shaking per wash) with 
1x pull-down buffer containing 25mM imidazole.  After each wash, the slurry was 
centrifuged and supernatent removed.  Protein was eluted from the Ni-NTA resin with 
pull-down buffer containing 500mM Imidazole (in 50µl aliquots).  10µl aliquots were 
removed from each step (loading, washes and elution), added to 10µl 2x SDS loading 
buffer, and visualized on a 4-12% SDS-PAGE gel.  A negative control, using CarD 
(10µM), the CarD-RID (10µM) and σAΔN1.1 (5µM), none of which contain his-tags, was 
performed to evaluate non-specific binding to the Ni-NTA agarose resin.  
 
Construction of Pf α expression cassettes 
Full-length Pf α was amplified from Pf genomic DNA using a modified PCR 
protocol as described.  Primers for cloning into a modified pET vector, pRMC2, were 
used with an NheI site upstream of the start codon and EcoRI site downstream of the stop 
codon.  Sequences were verified by DNA sequencing 
 For expression of tagged α in Pf, I used the vector pHBIRH.  Pf α was amplified 
by PCR with an upstream primer containing a SpeI site and a downstream primer 
containing an in-frame NotI site.  The pA or PTP or mCherry tag was amplified by PCR 
with a primer containing a NotI site upstream of the first amino acid (containing an 
additional base to maintain the coding frame) and a SacI site downstream of the stop 
codon.  Both PCRs were digested with NotI and ligated for 1 hour at room temperature 
under standard conditions.  A second PCR was performed with the upstream α primer 
and the downstream tag primer to amplify a single linear DNA containing the α coding 
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region and the tag in a single reading frame.  This linear DNA fragment was then cloned 
into pHBIRH (with SpeI and SacI) by standard molecular techniques.  Sequences were 
verified by DNA sequencing. 
 
Culture and transfection of Pf parasites  
Pf C3 parasites were cultured and transfected by standard procedures (Deitsch et 
al., 2001; Epp et al., 2008).  Briefly, parasites were cultures at 5% haematocrit in RMPI 
1640 media with the addition of 0.5% Albumax II, 0.25% sodium bicarbonate and 
0.1mg/ml gentamicin to prevent bacterial contamination.  Cultures were grown at 37°C in 
90% nitrogen.   
Transfections were performed using loaded RBCs.  0.175ml of erythrocytes and 
50-75μg of plasmid DNA were added to 0.2cm electroporation cuvettes in cytomix. The 
DNA/erythrocyte mix was elecetroporated with 0.31kV and 960mFD.  Electroporation 
was performed once, followed by incubation for 24-48 hours and a second 
electroporation.  After 2-4 days, WR99210 was added to 40ng/ml to select for the 
presence of the transgene. 
 
RNA extraction and RT-PCR 
 RNA was extracted from Pf cells essentially as described.  Briefly, 20mls of Pf 
parasites at 5% parasitimia was centrifuged to collect RBCs.  After one wash in 1x PBS, 
cells were resuspended in 1ml PBS with the addition of 10% saponin to lyse RBCs.  
After centrifugation, parasites were washed two times in 1x PBS, after which 750μl of 
tri-reagent was added.  The aqueous phase was further purified by the Qiagen RNeasy 
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RNA purification kit.  RNA was eluted in 15μl and quantified by Nanodrop.  RNA was 
treated with DNaseI to remove all traces of genomic and plasmid DNA and cDNA was 
synthesized by reverse transcriptase (Invitrogen).  PCR from the cDNA was performed 
using Accuprime DNA polymerase and a 1:10 dilution of the cDNA.   
 
Western Blot  
 20mls of Pf parasites at 5% parasatimia were collected, centrifuged to collect 
RBCs and washed with PBS.  RBCs were lysed in 1ml PBS with the addition of 10% 
saponin.  Parasites were subsequently washed in 1ml PBS, centrifuged and flash frozen in 
liquid nitrogen.   
 20μl of 2x SDS load buffer was directly to the parasite pellet, and the samples 
were boiled for 30 minutes at 95°C.  Nup130, expressed in yeast, was used as a positive 
control and treated essentially as the parasite pellet.  Samples were electrophoresed on a 
4-12% SDS-PAGE gel and transferred to a membrane for blotting in 1x CAPS buffer in 
10% methanol.  Membranes were blotted using an anti-pA antibody (IgG; Cappel) and 
visualized with a peroxidase doupled secondary antibody (Amersham NA934).   
 
Rifampicin pull-outs 
Rifampicin coupled agarose beads were synthesized with increasingly long 
linkers by Arkady Mustaev.  Purified Eco RNAP was used for initial binding tests.  
Briefly, Eco RNAP (50μl at 0.5mg/ml) was loaded onto the beads in 1x pull-out buffer 
(10mM Tris HCl pH 8.0, 0.2mM NaCl, 1mM DTT).  After one hour with gentle mixing, 
the beads were collected by gentle centrifugation and the supernatant removed.  Beads 
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were washed 10 times with 500μl pull-out buffer and bound protein eluted from the beads 
by denaturation with 6M guanidinium.  Eluted fractions were precipitated with acetone 
and resuspended in 2x SDS load buffer.  Load, flow-through and wash (10μl aliquots) 
and elution fractions were visualized on a 4-12% SDS-PAGE gel by silver staining.   
RNAP was purified from Eco lysates as above.  50ml of Eco CC118 cells were 
collected at OD 600 of 0.6 and collected by centrifugation.  Cells were resuspended in 1x 
pull-out buffer and lysed by sonication.  Lysate was cleared by centrifugation at high 
speed and 200μl of lyaste was added to Rif-conjugated agarose beads.  Purification was 
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  A.1a:	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  downregulated	  by	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9754  118.291 21.109 -1.723 0007 
12785 trna synthesis 338.936 69.359 -1.587 ***serS 
78526 Fe transport 320.21 51.904 -1.820 
00074 
(sirA) 
99487  751.303 128.28 -1.768 sodM 
164124 
Pyrimidine 





decarboxylate 139.571 21.343 -1.878 
00153 
(0188) 




methyltransferase 382.718 86.026 -1.493 
00182 
(0220) 
222778  120.479 20.511 -1.770 0200 
271578  431.454 60.837 -1.959 
00253 
(280) 
297407  285.614 47.161 -1.801 
00282 
(306) 
341745  148.352 33.927 -1.475 
00328 
(0346) 
342463  129.186 24.217 -1.674 
00329 
(347) 
342787  168.878 31.855 -1.668 
00330 
(348) 
366132  187.023 41.175 -1.513 
00357 
(0373) 
402507  44.8496 7.0150 -1.855 
00399 
(set15) 
500137 NTP synthesis 742.144 89.702 -2.113 pdxS 





from acetyl coa 242.677 39.254 -1.822 
00532 
(550) 
547607  36.7493 7.0773 -1.647 00543.1  
551104  507.965 83.640 -1.804 sdrD 
690241  195.406 23.006 -2.139 0707 
691928 frutcose permease 316.081 52.638 -1.793 
00708 
(FruA) 
722747  1358.73 86.276 -2.757 
00738 
(SAV0727) 
776118  3048 443.72 -1.927 00794 
245
(gapR) 
801076 cold shock 5402.94 322.97 -2.817 cspC 




028697  acyl 





phosphate (required) 1297.41 192.49 -1.908 ***pgi 
890664  999.459 146.08 -1.923 
00919 
(0982) 
909471  411.913 67.071 -1.815 
00937 
(1000) 
940007  185.156 31.379 -1.775 
00963 
(1028) 
947204  111.982 25.901 -1.464 00973 
990820  853.732 147.18 -1.758 
01021 
(1075) 




mrna degredation and 
processing (required) 966.567 134.26 -1.974 
***01036(
1089) 
1006241  914.677 119.55 -2.035 
01037 
(def) 
1028809  702.261 97.723 -1.972 
01064 
(pycA) 
1033752 heme biosynthesis 527.373 69.373 -2.028 ctaB 
1034688  473.681 67.918 -1.942 
01067 
(1118) 
1051882 trna synthetase 281.582 53.940 -1.653 ***pheS 
1114346 uracil permease 372.335 32.925 -2.426 pyrP 
1115681 
pyrmadine 
biosynthesis 409.408 36.638 -2.414 pyrB 
1116580 
Pyrimidine 










biosynthesis 461.721 87.618 -1.662 
01172 
(pyrF) 




negative regulator of 
fatty acid biosynthesis 1206.48 210.10 -1.748 plsX 
1204422  571.444 71.310 -2.081 
01252 
(1275) 





(required) 2175.49 290.89 -2.012 
***01287 
(glnA) 
1249421  46.319 7.8498 -1.775 1297 





transporter 597.115 92.257 -1.868 1326 
1272662 NTP biosynthesis 304.507 41.202 -2.000 
guaC 
(sav1337) 
1273814  458.992 76.713 -1.789 01332 
246
(1338) 
1304208 Oxidative stress 874.423 115.66 -2.023 msrA1 
1426309 tRNA synthetase 888.695 146.32 -1.804 asnS 




malonyl co-a fatty 
acid biosynthesis 
(required) 525.605 68.133 -2.043 
***01624 
(accB) 
1659667  MreD 238.947 27.886 -2.148 
01759 
(1648) 
1798610 riboflavin biosynthesis 673.018 142.48 -1.553 ribH 
1799087 riboflavin biosynthesis 602.566 124.79 -1.575 
01887 
(ribA) 
1800279 riboflavin biosynthesis 647.036 107.00 -1.800 
01888 
(ribB) 




fructose 6 phosphate 
aldolase 817.344 170.19 -1.569 
01901 
(1781) 
1883879  1006.38 193.93 -1.647 
01979 
(1847) 
1991203 trna synthesitase 953.649 201.14 -1.556 gatC 





2152964  248.686 53.497 -1.537 
02319 
2084) 
2189428  261.971 54.169 -1.576 
02367 
(2126) 






putative 177.138 38.462 -1.527 
02447 
(2187) 
2272019  83.2365 16.023 -1.648 
02448 
(2188) 






family 1032.03 200.06 -1.641 sarR 
2370059 
ribosomal protein E 
(required) 394.45 42.534 -2.227 ***rpsE 
2370857  200.504 20.811 -2.265 2580.1 
2438501  146.33 33.948 -1.461 
02652 
(2370) 
2453507  181.402 38.899 -1.540 
02668 
(2385) 
2454270  825.607 75.899 -2.387 sarZ 
2454932 
protein 
oxidoreductase 533.963 113.27 -1.551 
02670 
(2387) 
2477970  129.194 23.611 -1.700 
02694 
(2409) 




2595325  94.3532 15.658 -1.796 
02816 
(2513) 
2619737  92.976 15.579 -1.786 
02845 
(5326) 
2620123 glycolosis 98.7279 11.306 -2.167 
02846 
ptsG 
2691654 Na/SO4 symporter 2120.95 361.13 -1.770 fda (2606) 
2801301 Cold shock protein 147.207 27.530 -1.677 
03030 
(2694) 
2813019 trna synthesis 6199.66 634.56 -2.279 cspB 
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  A.1b:	  Genes	  significantly	  upregulated	  by	  PhERI	  expression.	  	  Only	  genes	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  a	  P-­‐value	  <	  0.05	  are	  listed.	  
	  
Genome 











42680 trna modification 183.00 1346.6 2.00 39 
110292  6.90 31.31 1.51 106 
119491 
polysaccharide 
binding prot  4.25 22.63 1.67 114 
121648 nadp sugar binding 3.07 14.48 1.55 117 
125615 cell wall biosynthesis 4.00 18.92 1.55 120 
130861 cell wall biosynthesis 9.13 40.99 1.50 125 
133575 cell wall biosynthesis 15.50 66.86 1.46 128 
140421  20.74 147.88 1.96 134 
141657 ABC transporter 37.82 159.99 1.44 136 
190529  33.36 208.49 1.83 174 
303758 
pfkb carbohydrate 
kinase 2.41 16.74 1.94 291 
308682 
sialic acid 
synthethetase 3.14 17.61 1.72 nanA 
330822 
MepB (MFS family) 
transporter 34.68 152.72 1.48 316 
337879  4.60 24.69 1.68 325 
339970  7.63 38.28 1.61 327 
349924 
METHIONINE 
BIOSYNTHESIS 15.25 124.41 2.10 340 
365422  26.05 432.25 2.81 356 
366695  30.63 660.34 3.07 358 
564127 PROLINE TRANSPORT 110.78 589.76 1.67 556 
567449 
acetyl co-a 
transferase 24.70 157.40 1.85 558 
568931  33.70 187.21 1.71 560 
610261  6.33 122.99 2.97 619 
614349  9.42 64.79 1.93 624 
614928 translation 17.25 86.63 1.61 mnhB2 
619570 translation 15.67 95.92 1.81 mnhG2 
628913 
glycosyl transferase ie 
WecG / TagA  193.52 1213.98 1.84 640 
657303 
PHOSPHATE 
TRANSPORTER 562.03 4493.62 2.08 669 
657936 
PHOSPHATE 
TRANSPORTER 533.30 4734.35 2.18 670 
688883  226.10 1372.71 1.80 704 
716261 sulfate transporter 123.67 1232.61 2.30 731 
718985 Histidine biosynthesis 28.07 298.82 2.36 hisC 
720394  160.51 912.64 1.74 734 
816025  30.42 884.46 3.37 845 
855576  298.98 1401.18 1.54 892 
889973  196.80 1643.28 2.12 918 
249
901688 peptide transporter 4.00 17.65 1.49 929 
908437  5.42 25.51 1.55 936 
924132  45.07 435.87 2.27 950 
957785 Cystein protease 28.61 132.72 1.53 sspC 
960953 
Aspartate amino 
transferase 179.25 1737.92 2.27 989 
1025648  289.56 1585.69 1.70 1060 
1025817  288.33 1646.66 1.74 1061 
1081622 ARG BIOSYNTHESIS 7.08 70.45 2.30 1128 
1082646 Carbamate kinase 10.42 73.49 1.95 arcC1 
1083816 anion permease 16.52 71.89 1.47 1130 
1086146 mallic acid transporter 165.48 891.37 1.68 1133 
1087342  126.91 850.30 1.90 1134 
1162044  43.21 256.51 1.78 1213 
1186353 zinc metallo protease 346.89 2482.23 1.97 1239 
1187557 trna synthetase 580.53 4381.59 2.02 proS 
1276192  205.49 903.45 1.48 1336 
1329326 phosphate transporter 4.43 19.67 1.49 1386 
1332693  5.91 68.22 2.45 A01332 
1349110  6.26 49.50 2.07 1410 
1446046  674.41 5336.69 2.07 gpsA 
1447061  593.55 4578.22 2.04 engA 
1531152 ArgE, Arg biosynthesis 72.93 438.67 1.79 1606 
1596249 ROS scavenging 73.59 361.01 1.59 1686 
1635662  35.81 346.15 2.27 1729 
1635848  33.56 337.70 2.31 1730 
1692301 Co-A biosynthesis 202.54 957.01 1.55 1795 
1705673  6.24 40.28 1.87 1804 
1706497  10.18 61.67 1.80 1805 
1723310  105.23 498.33 1.56 1817 
1770560  76.57 813.58 2.36 1864 
1795367  8.52 101.50 2.48 1880 
1806781  1009.79 8086.02 2.08 1895 
1813963  3.74 27.20 1.99 1905 
1843315 Serine protease 7.15 32.86 1.53 splE 
1844133 Serine protease 4.94 25.96 1.66 splD 
1845029 Serine protease 4.11 44.18 2.37 splC 
1845806 Serine protease 3.09 29.60 2.26 splB 
1846653 Serine protease 2.76 19.67 1.96 splA 
1889484  125.92 915.47 1.98 1984 
1889998  8.95 45.97 1.64 1985 
1978642  18.50 179.01 2.27 2104 
1979280  221.48 1459.98 1.89 2106 
1980013  202.69 1335.89 1.89 2107 
1982200  16.68 295.79 2.88 2109 
2031740  71.08 472.18 1.89 hlb 
2202995  938.94 14904.3 2.76 2381 
2208189 nadp binding prop 9.36 94.24 2.31 2387 
250
2223263  14.04 68.34 1.58 2402 
2264436  4.57 24.59 1.68 2437 
2266096  44.58 1452.99 3.48 asp23 
2266668  14.04 489.08 3.55 2442 
2266920  19.98 513.40 3.25 2443 
2267631  3.47 72.07 3.03 2444 
2279891 Lactose metabolism 71.09 478.15 1.91 lacR 
2289533  3.54 33.20 2.24 2466 
2290322  33.92 142.67 1.44 2467 
2389508  296.07 1437.99 1.58 2600 
2391719  41.85 188.11 1.50 2603 
2420343  52.11 235.33 1.51 2632 
2425298  5.91 68.22 2.45 A02505 
2503504 glycerate kinase 85.32 512.81 1.79 2723 
2504706  201.33 1558.81 2.05 2724 
2516693 NADP binding 176.09 1067.86 1.80 2737 
2517700  52.52 797.26 2.72 2738 
2519027 drug transporter 392.01 3899.53 2.30 2740 
2525681 
amino acid 




NADP 6.40 29.76 1.54 2772 
2590644  28.17 208.43 2.00 2812 
2591199  34.47 190.78 1.71 2814 
2650766 Squalene synthase 7.71 34.11 1.49 crtN 
2652286 Squalene desaturase 5.28 30.00 1.74 crtM 
2653186  3.32 20.07 1.80 crtQ 
2654319 
Phytoene 
dehydrogenase 2.91 16.62 1.74 crtP 
2659919 acetyl transferase 18.93 138.41 1.99 2886 
2735411  46.69 299.58 1.86 2973 
2775173 
Polysaccharide 
polymerase (biofilm) 7.20 44.80 1.83 icaD 
2797472  315.36 1869.31 1.78 3024 
2798580 
Pyroglutamyl 
peptidase 30.13 177.12 1.77 pcp 
2800599  9.03 54.80 1.80 3028 
2816354  210.35 1261.91 1.79 mnmG 
2819017 translation 149.09 832.60 1.72 mnmE 
2820535 translation 146.23 801.59 1.70 rnpA 
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Genome 












1143162 translation 21944 19572 -0.17 0.871 rpmB 
1345916-
1346117 cold shock, putative 18639 18982 0.03 0.979 cspA 
520793-




biosynthesis 13995 10009 -0.48 0.624 acpP 
518656-
519079 translation 13826 19981 0.53 0.622 rplK 
529959-
530373 translation 13589 15650 0.20 0.849 rpsL 
1587819-
1587996 translation 13307 8910 -0.58 0.550 rpsU 
1201451-
1201721 translation 12420 12584 0.02 0.985 rpsO 
530438-
530909 translation 11783 12623 0.10 0.925 rpsG 
1600105-
1600357 translation 10753 6378 -0.75 0.439 rpsT 
1659192-
1659501 translation 10585 10572 0.00 0.999 rplU 
1734576-
1735179 translation 10422 10869 0.06 0.955 rpsD 
2182601-




hypothetical 9651 9374 -0.04 0.965 2853 
1161540-
1161891 translation 9390 8857 -0.08 0.933 rplS 
2821009-
2821147 translation 9131 6259 -0.54 0.546 rpmH 
360629-
360926 translation 8764 9270 0.08 0.935 rpsF 
2299326-
2299725 translation 8524 8664 0.02 0.982 rpsI 
360946-
361450 translation 8500 8593 0.02 0.988 349 
1658570-




hypothetical 8329 9101 0.13 0.897 1756 
529607-




hypothetical 7817 3588 -1.12 0.250 1977 
2299738-
2300176 translation 7664 8713 0.19 0.856 rplM 
2315349-
2316183 translation 7159 8692 0.28 0.794 rplB 
1180819-
1181588 translation 6897 9291 0.43 0.689 rpsB 






hypothetical 6209 3634 -0.77 0.451 2571 
1159734-
1160010 translation 6076 5102 -0.25 0.790 rpsP 
2316215-
2317114 translation 6054 6813 0.17 0.859 rplW 
	  
253
Table	  A.3a:	  Single	  Nucleotide	  Polymorphisms	  previously	  identified	  as	  unique	  












22181 --- C A --- intergenic  




binding protein, putative C A 16 V-F 00105 
392716 --- G A --- intergenic  
412762 --- . T --- intergenic  
412765 --- C G --- intergenic  
590402 
Conserved hypothetical 
protein G . Frameshift 00591 
653801 --- C T --- intergenic  
751285 SecA A T 449 E-V 00769 
827849 TauE, sulfite exporter A T 164 T-S 00860 
926213 hypothetical protein G C 235 P-A 00952 
939304 ComK C T 53 E-K 00961 
947899 hypothetical protein C . 232 P-X 00973 
1016979 putative ABC transporter G A 220 E-K 01048 
1020577 
Conserved Hypothetical 
protein G T 286 S-* 01053 
1042000 ribosomal protein L32 T . 34 G-X 01078 
1123048 
PyrE pyramadine 
biosynthesis G A 42 G-S 01 
1160513 rimM G A 106 A-T rimM 
1160531 rimM A G 112 K-E rimM 
1180886 
rpsB 30S ribosomal 
protein S2 G . 10 V-X 01232 
1283784 hypothetical protein C . 943 D-X 01342 
1358230 
Kdg alpha-ketogluterate 
decarboxylase C T 590 D-N 01418 
1562913 rhomboid family protein A T 337 *-K 01649 
1636255 hypothetical protein T . 100 Q-X 01732 
1683491 
infC translation initiation 
factor IF-3 T C 40 K-E 01786 
1733515 EzrA G T 73 T-N 01827 
2087725 GroEL A T 218 F-I Transcript 
2106539 
ABC transporter, 




carboxyvinyltransferase G C 124 T-R 02337 
2221850 hypothetical protein C A 244 S-Y 02401 
2244467 --- A G --- intergenic  
2244495 --- G A --- intergenic  
2244932 hypothetical protein C . 296 *-X 02417 
2244933 hypothetical protein T . 296 *-X 02417 
254
 
2318272 --- G A --- intergenic  
2318274 --- G T --- intergenic  
2318290 --- C A --- 
intergenic 02512 <--
> 02515 
2349916 --- G T --- intergenic  
2420618 
hypothetical protein;- 
hypothetical protein . T --- 02632;02633 
2447620 --- G A --- intergenic  
2592012 
hypothetical protein;- 
hypothetical protein A . --- 02813;02814 
2689048 hypothetical protein G T 353 V-L 02923 




subunit hisF, putative C . 247 G-X 03008 
649126 hypothetical protein G T 202 G-G 00661 
841103 hypothetical protein G T 39 G-G 00877 
841139 hypothetical protein G T 51 G-G 00877 
1653482 
tgt queuine tRNA-




carboxyvinyltransferase C A 117 G-G 02337 
2383630 hypothetical protein G T 68 G-G 02591 
2383660 hypothetical protein G T 78 G-G 02591 
2446246 
PTS system sucrose-
specific IIBC component C T 42 E-E 02662 
2446641 hypothetical protein T A 95 I-I 02663 
2678563 hypothetical protein T C 107 P-P 02911 
	  
	  













1009713 G C 
Pyruvate 
dehydrogenase G64A gGt/gCt 01041 
1137863 T C 
Phosphatase, 
putative I134T aTt/aCt 01186 
1653482 G A 
Queuine tRNA-
ribosyltransferase Syn atC/atT 01747 
1733515 G T EzrA T73N aCc/aAc 01827 
1967009 C T 
Conserved 
hypothetical (YfkB-
like) syn aaC/aaT 02090 




Table	  A.4a:	  Genes	  significantly	  upregulated	  in	  RN4220	  relative	  to	  NCTC8325-­‐4	  



















transporter 1.51517 44.2299 4.8674 0.000 00136 
424709-








transporter 3.87502 69.9488 4.1740 0.001 00926 
894010-








OppA, putative 8.17295 103.689 3.6652 0.002 00927 
1263418-




transporter 510.859 6489.18 3.6670 0.008 00636 
2722967-
2725601 clfB 130.692 1781.62 3.7689 0.009 clfB 
1338096-
1339086 asd (dap operon) 6.33142 68.3555 3.4324 0.009 01395 
547607-
550738 hypothetical 22.2434 233.87 3.3942 0.010 sdrC 
142411-
144144 
srpL ABC transporter, 












hypothetical  44.3692 332.065 2.9038 0.023 01115 
2484751-
2485438 hypothetical 238.492 1921.97 3.0105 0.024 gpmA 
73428-































hypothetical 15.999 98.0291 2.6152 0.038 00258 
2115681-
2116686 
ilvC, valine / 
isoleucine metabolism 2.37121 19.9625 3.0736 0.040 ilvC 
2581382-
2584524 hypothetical 11.1302 63.99 2.5233 0.048 fnbA 
2788278-












Table	  A.4b:	  Genes	  significantly	  downregulated	  in	  RN4220	  relative	  to	  NCTC8325-­‐




























phase metabolism 323.345 41.4389 -2.964 0.0010 02468 
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